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Diabetes mellitus is a global health problem, owing to the high prevalence and 
enormous associated economic burden. Insulin resistance is a critical condition to the 
development of type 2 diabetes (T2D). Adiponectin, a hormone secreted by the adipose 
cells, has attracted much attention for its insulin-sensitizing and anti-diabetic effects.  
 
The overall aim of this thesis was to have a better understanding of the roles of 
ethnicity, genetic variants and dietary factors in relation to adiponectin and insulin 
resistance by means of different analytical approaches.   
 
In Study I, using path analysis, we examined potential mediators including body fatness, 
adiponectin levels, and inflammation for the extent they mediate the ethnic differences 
in insulin resistance among Singaporean Chinese, Malays and Indians. General 
adiposity explained the difference in insulin resistance between Chinese and Malays, 
whereas abdominal fat distribution, inflammation, and unexplained factors contributed 
to excess insulin resistance in Asian Indians as compared with Chinese and Malays. 
 
In Study II, we carried out a genome-wide association study to identify genetic variants 
that influence adiponectin levels in East Asian populations. The top signal from CDH13 
explains a substantial part of variation in high-molecular-weight (HMW) adiponectin 
levels, but its effect on circulating HMW adiponectin levels did not appear to translate 
into effects on insulin-resistance related metabolic traits, suggesting that compensatory 
mechanisms exist that lead to greater ‘adiponectin sensitivity’. 
 
 
 In Study III, the question whether changes in adiponectin levels causally influence 
insulin sensitivity was addressed by a Mendelian randomization design in a cohort of 
Swedish men. Genetically determined adiponectin levels influence euglycemic clamp-
measured insulin sensitivity to the same degree as the observed epidemiological 
associations. Thus, the observed association between higher adiponectin levels and 
increased insulin sensitivity is likely to represent a causal relationship. 
 
In Study IV, we examined relations between serum selenium levels and measures of 
glucose and insulin metabolism, as well as risk of T2D longitudinally in Swedish men. 
There was no clear evidence of an effect of selenium status on various measures of 
insulin sensitivity or β-cell function. Selenium levels were also not associated with risk 
of T2D. These results do not support a role for selenium supplementation as a broad 
approach for the prevention of T2D. 
 
In conclusion, mediators of ethnic differences in insulin resistance differed markedly in 
the Singaporean populations. In East Asians, CDH13 strongly influences adiponectin 
levels and associates with a beneficial metabolic profile when controlling for circulating 
adiponectin. Inferred from genetics, the positive relationship between adiponectin and 
insulin sensitivity appears to be causal. There is no evidence of an effect of selenium 
intake on glucose and insulin metabolism or risk of T2D in the Swedish population.   
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 1 BACKGROUND 
 
1.1 Diabetes 
1.1.1 Prevalence of diabetes 
Diabetes mellitus is one of the most common non-communicable diseases in the world 
nowadays. It has three major types, namely type 1 diabetes, type 2 diabetes (T2D) and 
gestational diabetes. T2D used to be called non-insulin dependent diabetes and accounts 
for at least 90 percent of all diabetic cases. The global prevalence of diabetes by 
International Diabetes Federation (IDF) was estimated to be 8.3% in 2011 and this 
number is projected to reach 9.9% with a burden of 438 million individuals in 2030 [1].  
The economic cost incurred is heavy and 471 billion USD were spent due to diabetes in 
2012 [1], not to mention the indirect and intangible costs. 
 
A remarkable feature is that developing countries now experience more serious situation 
than developed countries, as 4 out of 5 people with diabetes live in low- and middle-
income countries. In addition, almost half of the global burden of diabetes now falls in 
Asia, mainly due to large population size in China and India. The estimated number for 
2011 was reported to be 92.4 million in China [2] and 62.4 million in India [3].  
 
Moreover, T2D is often undiagnosed and according to the IDF statistics, 50% of the 
people were unaware of their condition. Patients are usually only diagnosed due to 
serious macrovascular and microvascular complications which include cardiovascular 
diseases, kidney failure (diabetic nephropathy), neurological complications (diabetic 
neuropathy) and eye diseases (diabetic retinopathy).   
 
  1 
 1.1.2 Pathophysiology of the disease 
T2D is a disorder in glucose metabolism characterized by hyperglycemia. It results from 
a combination of defects in insulin secretion and insulin action and is hallmarked by 
resistance to effects of insulin in the liver, skeletal muscle and adipose tissues. As a 
result, the pancreatic β-cells increase the release of insulin to compensate for the 
reduced insulin action, until β-cell dysfunction occurs when the high demand cannot be 
met.  
 
The relationship between β-cell function and insulin sensitivity is nonlinear following a 
hyperbolic shape and β-cells adapt to changes in insulin sensitivity by improved 
functional responsiveness and an increase in volume/mass [4, 5]. The degree of 
abnormality of insulin release by the β-cells proved to be the primary determinant of 
differences in glucose tolerance between individuals. Moreover, β-cell function declines 
progressively and the risk could be pre-existing, or genetically determined [4, 6].  
 
Familial occurrences have been well known for diabetes [5]. The heritability of T2D 
was estimated to be 26% [7] and so far, known genetic variants explained only <10% of 
the estimated genetic contribution. Chronic over-nutrition and a failure to contain this 
fuel surfeit is the primary cause for the development of T2D [8]. Overweight and 
obesity are highly associated with risk of diabetes. However, many obese individuals 
manage to maintain normal glucose levels and do not develop diabetes in their entire 
life which implies the existence of interplay between genetics and environment. 
Moreover, early-life environment could regulate fatal and neonatal programming 
through epigenetic effects and hyperglycemic intrauterine environment is believed to 
contribute to the pathogenesis of T2D [9, 10].  
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 1.2 Insulin resistance 
1.2.1 Definition 
Insulin is secreted in the β-cells of the pancreatic islets of Langerhans in response to 
elevated blood glucose levels after a meal. The major tissues insulin targets to lower 
blood glucose levels include the liver, skeletal muscles and adipose tissue. Insulin 
suppresses gluconeogenesis in hepatic cells and promotes glucose uptake in the 
muscles and adipocytes. Insulin sensitivity measures the responsiveness of tissues to 
insulin action and conversely, insulin resistance refers to a condition where the body is 
less sensitive to the functions of insulin. As a result, high level of insulin is usually 
observed under insulin-resistant condition. 
 
1.2.2 Diagnostic tests 
The gold-standard method to measure insulin sensitivity is the glucose clamp, or more 
specifically, the hyperinsulinemic euglycemic clamp [11]. As the name suggests, in 
this test insulin is infused at a constant high rate to reach a hyperinsulinemic status. 
This stimulates glucose uptake in skeletal muscles and adipose tissue and suppressed 
glucose production in the liver. Glucose is infused during the entire process in order to 
keep glucose concentration at constant levels. At steady-state the glucose infusion rate 
is assumed to equal glucose disposal rate which measures tissue sensitivity to 
exogenous hyper insulin levels. However, this test requires sophisticated equipment 
and is time-consuming and labor-intensive, and is thus rarely used in large 
epidemiological studies. 
 
There are indirect measures of insulin sensitivity based on dynamic tests. One of such 
is the intravenous glucose tolerance test (IVGTT) and the most widely used method is 
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 the minimal model analysis of frequently sampled intravenous glucose tolerance test 
(FSIGT) [12]. FSIGT involves frequent blood samples for the measurement of glucose 
and insulin concentrations, and is slightly less laborious than the clamp method. There 
are also measures that are based on the oral glucose tolerance test (OGTT), a test 
widely used in clinical settings. Some OGTT-derived indices for the assessment of 
insulin sensitivity include the Matsuda index [13], the Stumvoll index [14], the Gutt 
index [15] and the Belfiore index [16].  
 
In large epidemiological studies, it is common to use simple fasting measures of blood 
glucose and insulin concentrations to estimate insulin sensitivity and β-cell function. 
The Homeostasis model assessment index of insulin resistance (HOMA-IR) [17] uses 
simple equation to compute a surrogate index of insulin resistance based on steady-
state basal glucose and insulin concentrations. However, it correlated more weakly 
with euglycemic clamp-measured insulin sensitivity, as compared with the OGTT-
derived indices [18].  
 
1.2.3 The role of obesity in insulin resistance and T2D 
Mammalian adipose tissues consist of white and brown adipose. The brown fat is 
involved in thermogenesis and in human it is mainly found in newborn infants. Instead, 
the white adipose tissue has an important role in maintaining whole-body glucose 
homeostasis as well as lipid metabolism and adipocyte dysfunction is closely linked to 
insulin resistance and T2D.  
 
Since the discovery of leptin in 1994 [19], the adipose tissue is increasingly 
recognized for its function as an endocrine organ. The white adipose tissue secretes 
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 numerous cytokines and hormones collectively known as adipocytokines, or 
adipokines [20]. Most of them, such as tumor necrosis factor-α (TNF-α), interleukin-6 
(IL-6), leptin, retinol-binding protein 4 (RBP4) are pro-inflammatory, while 
adiponectin (introduced in the next chapter) has a unique anti-inflammatory and 
insulin sensitizing property [20-22]. This is important because chronic low-grade 
inflammation has been implicated in obesity and insulin resistance. C-reactive protein 
(CRP) is an acute-phase protein that serves as an important marker of systemic 
inflammation and is also related to insulin resistance [23]. 
 
Hypertrophic adipocytes increase secretion of many adipokines including monocyte 
chemoattractant protein-1 (MCP-1), also known as chemokine (C-C motif) ligand 2 
(CCL2). MCP-1/CCL2 recruits additional macrophages which secretes large amount 
of TNF-α, resulting in an inflammatory state [24]. Increased lipolysis and decreased 
triglyceride storage lead to higher circulating levels of non-esterified fatty acids 
(NEFAs) and triglycerides. This causes ectopic lipid accumulation and impairs 
insulin-stimulated glucose uptake in skeletal muscle, which is believed to be a primary 
cause of insulin resistance [25]. Similarly, excess fatty acids in the liver decrease the 
responsiveness of the hepatic cells to insulin.  
 
High levels of NEFAs may be the most critical determinant of insulin sensitivity. One 
proposed mechanism [26] is that increased intracellular concentrations of fatty acid 
metabolites, such as fatty acyl-coenzyme A (fatty acyl-CoA), diacylglycerol (DAG), 
and ceramides lead to phosphorylation of insulin receptor substrates (IRS) at 
serine/threonine site, and this disrupts the insulin signaling pathway by deactivating 
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 the phosphatidylinositol 3–kinase (PI 3-kinase). As a result, downstream insulin 
signaling and glucose transport is compromised.  
 
Fat distribution is another important contributor of insulin resistance and abdominal 
obesity is closely associated with adverse metabolic consequences [27, 28]. Visceral 
adipose tissue is more lipolytic and less insulin-sensitive than the subcutaneous 
adipose tissue [29]. Together with the fact that the visceral fat depot is in closer 
proximity to the liver, portal NEFA levels are elevated in abdominal obesity. The 
expected results are increased hepatic glucose production and peripheral 
hyperglycemia [30].  
 
1.2.4 Ethnic differences 
Marked differences in insulin resistance exist between ethnic groups [31]. At the same 
degree of body fatness, whites have been consistently observed to have the lowest level 
of insulin resistance among major ethnic groups in the world [32-34].  
 
Focusing on Asia where the burden of T2D is the heaviest, Asians, and particularly 
Asian Indians, are more insulin resistant than whites for a given degree of adiposity 
[35]. For the same body mass index (BMI), Asian Indians tend to have a higher level of 
body fat than whites [36] and they were more insulin resistant than whites for the same 
level of total body fat [37, 38], likely contributed by their abdominal fat distribution [39-
41], differences in adipocyte cell size [38] and a higher ratio of total body fat to lean 
mass [37]. In addition, lower adiponectin levels [31, 32, 34, 42-44], higher CRP levels 
[44-46] as compared with whites independent of BMI, and dietary factors may 
contribute to the higher susceptibility of Asian Indians in developing T2D [47, 48]. 
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Several studies in the U.S. have also demonstrated greater insulin resistance in East 
Asians as compared with whites for a given BMI [33, 49, 50]. For example, Chinese-
American and Japanese-American women were more insulin resistant than white 
women after adjusting for waist circumference [49]. Asian Americans have also been 
shown to be more likely to develop T2D than whites after adjustment for BMI [51]. 
Lower adiponectin levels in East Asians than BMI-matched whites, as reported for 
Japanese men [52] and for Koreans men and women [53], may contribute to these 
ethnic differences in insulin resistance and T2D. In a Canadian study, Chinese had 
lower adiponectin levels than whites in both men and women after considering 
differences in waist circumference [31].  
 
There is also evidence for substantial differences in insulin resistance between ethnic 
groups in Asia. Asian Indians are more insulin resistant and glucose intolerant than 
Chinese and Malays [54], but reasons for these ethnic differences are not well 
understood. One of the major contributing factors could be adiposity and fat 
distribution, as Asian ethnic groups differ from each other in body composition [55]. 
However, this does not fully explain the ethnic difference in insulin resistance. In 
Singapore, for example, Malays have the highest levels of adiposity, but not the highest 
levels of insulin resistance [54]. Circulating adipokines and inflammatory markers may 
contribute to some of the differences in insulin resistance between Asian ethnic groups, 
but to what extend these factors mediate the relation between ethnicity and insulin 
resistance independently and inter-connectively remains largely inconclusive.  
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 1.2.5 Dietary antioxidants 
Oxidative stress manifests an imbalance between the production of reactive oxygen 
species (ROS) and antioxidant defenses [56]. Increased ROS levels and excessive 
oxidative stress trigger insulin resistance, impair glucose tolerance and β-cell function, 
and accelerate the development of T2D [57-59]. Some of the most recognized dietary 
antioxidants include vitamin C, vitamin E, selenium and carotenoids.  
 
A meta-analysis showed that the intake of antioxidants was associated with 13% 
reduction in the risk of T2D and this was mainly attributed to vitamin E and 
carotenoids [60]. Several longitudinal studies have found that dietary β-carotene (a 
subtype of carotenoids) and α-tocopherol (a subtype of tocopherol, or vitamin E) 
independently predicted risk of T2D [61-63], possibly mediated by an improvement in 
insulin sensitivity [63]. However, supplementation of β-carotene and α-tocopherol in 
randomized clinical trials (RCTs) revealed no benefit in the prevention of T2D and 
indicated that the relationship may not be causal [60].  
 
Flavonoids are compounds with anti-oxidant capacities. A recent large prospective 
study found an association between consumption of foods rich in anthocyanin (a sub-
class of flavonoids), especially berries and apples/pears, and a lower risk of T2D[64].   
 
In contrast to anti-oxidants, excess iron is believed to elicit toxic effects mainly related 
to oxidative stress, due to the generation of ROS during a redox cycle [65]. High body 
iron store, as reflected by serum ferritin levels, has been associated with increased risk 
of T2D and it was suggested that dietary iron caused insulin resistance through down-




Selenium is an essential trace mineral. It exists predominantly as selenocysteine and 
selenomethionine in foods, but the content varies greatly depending on the soil 
conditions. Selenocysteine (Se-Cys) is a cysteine analogue with a selenium-containing 
selenol group replacing the sulfur-containing thiol group. Proteins that include a 
selenocysteine amino acid are called selenoproteins. The most abundant selenoprotein 
in the plasma is selenoprotein P [68, 69]. Glutathione peroxidases (GPx) is a family of 
enzymes with peroxidase activity that detoxify peroxides and hydroperoxides. They 
are involved in antioxidant defense and protect against oxidative stress. GPx are also 
selenoproteins accounting for 10-30% of plasma selenium [68] and it contains 
selenium as selenocysteine in the catalytic site.   
 
Selenium has been suggested to have insulin-mimetic and anti-diabetic properties [70, 
71], but results from existing studies on its association with risk of T2D are inconclusive 
[71]. In cross-sectional studies, higher selenium status has been associated with both a 
lower and a higher prevalence of diabetes [72-74]. Most RCTs concluded no overall 
efficacy of selenium supplementation on risk of diabetes and glucose control [75-77]. 
Importantly, selenium supplementation in clinical trials is usually given in high doses 
and effects may thus not reflect effects of smaller variation in dietary selenium intakes. 
To date, little evidence is available from prospective cohort studies of selenium status in 
relation to glucose tolerance and risk of diabetes. In addition, there is a lack of studies 
studying selenium intake in relation to detailed measures of insulin processing, secretion 
and sensitivity. 
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 Selenium content in foods varies greatly depending on soil conditions and as a result, 
selenium intakes calculated using food composition databases are inaccurate. In 
contrast, serum/plasma selenium is a reliable biomarker for selenium status [78, 79]. 
The correlation between serum selenium and selenium intake has been shown to be 
reasonably high [80]. Besides, erythrocyte selenium and toenail selenium are good 
measures of long-term selenium intake.  
 
1.3 Adiponectin 
1.3.1 Structure and circulating forms 
Adiponectin is a 30-kDa protein secreted by the adipocytes. It is the most abundant 
adipokine in the circulation and its levels remain relatively constant [81, 82]. The 
protein is composed of four domains: an N-terminal signal peptide, a variable region, a 
collagenous domain, and a C-terminal globular domain. Adiponectin exists in full-
length as multimer complexes, and also as a globular fragment. The three major 
oligomeric forms include the low-molecular-weight (LMW) trimer, the middle-
molecular-weight (MMW) hexamer and the high-molecular-weight (HMW) 12-18mer 
[83]. The different isoforms could have distinct properties and exert diverse biological 
functions, although this is not completely understood yet. Therefore, multimer 
distribution, in addition to total adiponectin concentration, should also be considered in 
the interpretation of adiponectin levels and health outcomes [84]. 
 
1.3.2 Receptors and signaling pathways 
Three adiponectin receptors are known to date. Adiponectin receptor 1 (AdipoR1) and 
adiponectin receptor 2 (AdipoR2) are transmembrane receptors having an inverse 
topology as compared with the G protein-coupled receptors [85]. A third receptor, T-
10 
 cadherin, belongs to the cadherin family of proteins and has not been well-characterized 
for its function with adiponectin. It lacks an intracellular domain and is attached to the 
membrane by a glycosylphosphatidylinositol (GPI) anchor [86]. 
 
AdipoR1 binds to globular adiponectin with high affinity and AdipoR2 has intermediate 
affinity for both globular and full-length adiponectin [85]. Both receptors are 
abundantly expressed, although the relative abundance varies in tissues. T-cadherin is a 
receptor exclusively for hexameric and HMW adiponectin [86] and is expressed in the 
endothelial and smooth muscle cells [87].  
 
Adiponectin mainly signals through the adenosine monophosphate (AMP)-activated 
protein kinase (AMPK) and the peroxisome proliferator activated receptor-α (PPAR-α) 
signaling pathways [88, 89]. However, individual isoforms seem to have different 
biological activities and activate different signal transduction pathways. In skeletal 
muscle, trimeric adiponectin activates AMPK, whereas the hexamer and HMW form 
activate NF-kB pathway [90]. In the liver, AMPK are stimulated by full-length 
adiponectin only [88]. Therefore, it is possible that adiponectin controls its ligand 
signaling by different oligomerization states. Without an intracellular domain, T-
cadherin is thought to have no role in signal transduction, although it is capable of 
binding adiponectin.  
  
1.3.3 Functions in glucose and fatty acid metabolism 
Although adiponectin is primarily produced by the adipose tissue, as a paradox, blood 
levels of adiponectin are inversely associated with obesity [91]. In addition, a sexual 
dimorphism is observed where adiponectin levels are higher in women than in men, but 
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 this is not explained by fat mass [92] and could be partially accounted for by the 
inhibitory effect from testosterone [93, 94].  
 
It is also well-established that adiponectin levels are inversely associated with degree of 
insulin resistance [95, 96] and lower adiponectin is also associated with higher risk of 
T2D [97]. In concordance, hypoadiponectinemia is observed in insulin resistance-
related conditions such as metabolic syndrome, hypertension, dyslipidemia, and 
oxidative stress [98]. However, it remains a question whether the inverse relationship 
between adiponectin levels and degree of insulin resistance represents a causal 
relationship. 
 
In the liver, adiponectin lowers blood glucose levels by suppressing gluconeogensis and 
sensitizes hepatic cells to the effects of insulin by a reduction in lipid content [22, 99]. 
This is achieved by the inhibition of the expression of gluconeogenic enzymes and the 
phosphorylation of acetyl coenzyme A carboxylase (ACC). In skeletal muscle, it 
activates AMPK, thereby stimulating phosphorylation of ACC, fatty acid oxidation and 
glucose uptake [88, 100]. In particular, HMW adiponectin has been suggested to be the 
bioactive form having stronger associations with insulin sensitivity and suppression of 
hepatic glucose production than other forms of adiponectin [84, 101-103].  
 
In obese or obese T2D individuals, activation of AMPK signaling and fatty acid 
oxidation by globular adiponectin is reduced, not due to the expression of adiponectin 
receptors, but as a result of downstream signaling after receptor binding [104]. APPL1, 
an adaptor protein, has been suggested to be a key molecule in signal transduction 
linking adiponectin receptors and AMPK activation [105].  
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1.3.4 Heritability and genetic predisposition 
Genetic determinants account for a substantial proportion of the variation in plasma 
adiponectin, as estimated to be 30 -70% [106-108].  
 
Genome-wide scans based on LOD scores have identified signals on chromosome 5 and 
14 in Europeans [108], on chromosome 9 in Pima Indians [107], and on chromosome 15 
in East Asians [106]. The region flanking the adiponectin gene locus on chromosome 3 
was first reported to be responsible for the linkage to adiponectin levels in an Amish 
population through an initial linkage scan plus fine-mapping using single nucleotide 
polymorphisms (SNPs) [109]. However, linkage studies had limited accuracy in the 
ascertainment of the exact genomic location harboring the signal and more importantly, 
very few linkage studies (for any traits) have been replicated - probably due to the 
power being too low in all such studies. 
 
With the advancement of the Genome-wide association studies (GWAS) era, a 
substantial larger number of adiponectin-associated loci have been identified using the 
SNPs as markers. These include the adiponectin gene ADIPOQ [110-113], CDH13 
which exhibited as a prominent signal in Asians [114-117], ARL15 [110] and FER 
[113]. A recent multi-ethnic large GWAS meta-analysis identified 10 novel loci and this 
increased the known loci to 14 in total. Many of the newly identified loci, such as IRS1, 
PEPD, GPR109A, and ZNF664, have functional relevance with insulin resistance and 
T2D [118].  
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 The ADIPOQ gene is located on chromosome 3q27 and consists of 3 exons spanning 
17kb. Many common polymorphisms in the promoter, exon and introns, as well as rare 
non-synonymous mutations have been associated with obesity, glucose and insulin 
metabolism and T2D in diverse populations [119]. Variants in the adiponectin receptor 
genes ADIPOR1 and ADIPOR2 have also been found to associate with insulin 
resistance and T2D, but not always replicated across populations. Potential reasons that 
limit the reproducibility include undetected population structure, false-positive results, 
small sample sizes, between-study heterogeneity, imprecise measurement of phenotypes 
and gene-environment interactions [120].  
 
Another gene highly associated with adiponectin levels is CDH13 on chromosome 16 
and it contains 14 exons and spans 1.2 Mb. This gene encodes for T-cadherin which 
binds hexameric and HMW adiponectin in the vasculature and endothelial cells [86].  
Despite the strong association of CDH13 with adiponectin, follow-up studies for its 
roles in metabolic disorders are lacking. Polymorphisms in the CDH13 gene are not 
broadly studied and the mechanisms of T-cadherin in adiponectin signaling and insulin 
resistance are unclear at the moment. 
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 2 AIMS OF THE THESIS 
 
The overall aim of this thesis was to have a better understanding of the role of ethnicity, 
genetic variants and dietary factors as determinants of adiponectin levels and insulin 
resistance by means of different analytical approaches. The specific aims were: 
 
- To evaluate to what extent body fatness, adiponectin levels, C-reactive protein 
and their interconnections mediate the relation between ethnicity and insulin 
resistance by path analysis in an Asian context. (Study I) 
 
- To identify common genetic variants associated with adiponectin levels on a 
genome-wide scale and examine their associations with insulin resistance and 
related metabolic risk factors in East Asians. (Study II) 
 
- To elucidate the potential causal effect of adiponectin on insulin sensitivity 
measured by euglycemic insulin clamp in a cohort of Swedish men using a 
Mendelian randomization approach. (Study III) 
 
- To investigate prospectively the relationship between baseline selenium 
concentration as a surrogate of selenium dietary intake and measures of glucose 
metabolism and incidence of type 2 diabetes in Swedish men. (Study IV) 
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 3 METHODS 
3.1 Participants 
3.1.1 The Singapore Prospective Study Programme (SP2) 
Participants of SP2 previously participated in cross-sectional studies carried out from 
1982 to 1998, namely the Thyroid and Heart Study (1982-1984) [54], the National 
Health Survey (1992) [121], the National University of Singapore Heart Study (1993-
1995) [54], and the National Health Survey (1998) [122]. Each of these studies was 
based on a random sample of Singapore residents with the minority groups (Malays and 
Asian Indians) being over-sampled. From 2003 to 2007, all 10,747 participants from 
these studies were invited to participate in the SP2 study. Of these, 559 had deceased at 
the time of study, 6 emigrated, and 102 were excluded because of errors in their identity 
card numbers. Qualified participants were contacted and 7,774 completed the 
questionnaire. The remainder was invited to a health screening which 5,164 subjects 





Figure 1. Design of the Singapore Prospective Study Programme 
 
Written informed consent was obtained from all participants and ethics approval was 
obtained from the Singapore General Hospital and the National University Hospital 
Institutional Review Boards. 
 
3.1.2 The Uppsala Longitudinal Study of Adult Men (ULSAM) 
The Uppsala Longitudinal Study of Adult Men (ULSAM) was initiated between 
September 1970 and September 1973 with an invitation of all 50-year-old men living in 
Uppsala County, Sweden. Of the invited, 82% participated in the investigation. There 
are five follow-ups to date, at 60, 70, 77, 82 and 88 years of age. Figure 2 is an 
overview of the design of this cohort study and detailed information can be found at the 
cohort website (http://www.pubcare.uu.se/ULSAM/). The main sample used for this 
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 thesis work comes from the third investigation during 1991-1995 when the subjects 
were approximately 71 years old. A total of 1,221 men (73% of those invited, i.e. men 
still alive and residing in Uppsala County) participated and the examination included a 
medical questionnaire, blood pressure and anthropometric measurements, collection of 
blood samples, a 75-gram oral glucose tolerance test, and insulin sensitivity 
measurements.  
Figure 2. Overall design of the Uppsala Longitudinal Study of Adult Men. 
 
The ULSAM study was approved by the Ethics Committee of Uppsala University, and 
all participants provided written informed consent. 
 
3.2 Measurements 
3.2.1 SP2 (Study I and II) 
Height was measured using a wall mounted measuring tape and weight was measured 
using a digital scale. Waist circumference was measured midway between the lower rib 
margin and the iliac crest and hip circumference was measured at the widest point over 
the greater trochanters. BMI was computed as weight (kg) divided by height square 
18 
 (m2). Demographic data including ethnicity and lifestyle information such as smoking 
status and alcohol intake were assessed using standardized questionnaires. Total 
physical activity was measured using a locally validated questionnaire covering activity 
in four domains (household, occupational, leisure-time and transport). 
 
Fasting blood samples were analyzed for glucose using enzymatic methods (ADVIA 
2400, Siemens, Germany), for insulin using micro-particle enzyme immunoassay 
(Abbot AXSYM, Abbott Laboratories, Chicago, IL), for high-sensitivity CRP using an 
immuno-turbidimetric assay (Roche Diagnostics, Rotkreuz, Switzerland), and for total 
and HMW adiponectin using an enzyme linked immune-sorbent assay (Sekisui Medical 
Co Ltd, Japan). Insulin resistance was assessed by HOMA-IR calculated as: (fasting 
insulin in mIU/L x fasting glucose in mmol/L) / 22.5 [17]. The intra and inter batch 
coefficient of variations percent were as follows: glucose (2.5, 6.6), insulin (4.0, 4.5), 
total adiponectin (18.1, 15.9), HMW adiponectin (6.8, 18.3) and CRP (0.6–1.3, 2.3–
3.1). The larger intra-batch CV for total adiponectin relative to its inter-batch CV could 
be due to human error or long waiting time during the processing.    
 
3.2.2 ULSAM (Study III and IV) 
At baseline (50 years old) 
An IVGTT was performed where blood glucose and serum insulin levels were 
measured between 0 and 60 min after the intravenous glucose load. Proinsulin 
concentrations were analyzed using the two-site immunometric assay technique [123]. 
Glucose tolerance was evaluated by the K-value calculated as K=ln2·100/T1/2 where T1/2 
is the time in minutes required for the concentration to be reduced by half its value. 
Early serum insulin response was represented by the insulin peak and expressed as the 
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 mean value of the serum insulin concentrations determined at 4, 6 and 8 minutes. The 
insulin index was defined as the ratio between peak serum insulin response and fasting 
serum insulin concentration. Based on fasting glucose and insulin concentrations, the 
homeostasis model assessment index for insulin resistance and β-cell function (HOMA-
IR and HOMA-B) were calculated [17].  
 
T2D was ascertained by elevated fasting blood glucose (≥ 6.1 mmol/L, which equals 
plasma glucose ≥ 7.0 mmol/L) or use of anti-diabetic medicine. 
 
Selenium was determined in serum using the graphite-furnace atomic absorption 
spectrometric method [124]. Samples were diluted (1+9) with a solution containing 
nickel (to reduce the volatility of selenium) and nitric oxide (to keep samples free of 
precipitates) and measured by a standard additions method. 
 
Information about cigarette smoking status was based on data from a standardized 
interview. Current smokers were further classified according to the quantity of 
cigarettes smoked (<10 or >=10 cigarettes per day) based on information from the 
questionnaire. Leisure time physical activity was recorded in the questionnaire in four 
levels: sedentary, moderate, regular and athletic. Education level was also assessed on 
the questionnaire and was re-grouped into three categories: 7 years or 8 years was 
defined as low education; 12 years as medium education; and ≥3 years of college or 
completion of university graduate exam as high education.    
 
At 20-year follow-up (70 years old) 
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 Participants at the age 70 investigation underwent a 75-gram OGTT with measurement 
of plasma glucose and immunoreactive insulin. The intra-individual coefficient of 
variation (CV) for fasting plasma glucose was 3.2%. The insulinogenic index, 
calculated as [(insulin at 30 min) – (insulin at 0 min)]/ [(glucose at 30 min) – (glucose at 
0 min)], was used as a measure of glucose-stimulated insulin secretion indicative of β-
cell function [125]. Proinsulin levels were measured by the two-site immunometric 
assay technique [123].  
 
In vivo sensitivity to insulin was determined by the euglycemic insulin clamp, according 
to the procedure described by DeFronzo et al. (1979) [11], but with a higher insulin 
infusion rate per body surface area to better suppress liver glucose output (56 mU min-1 
(m2)-1 instead of 40 mU min-1 (m2)-1). After a primary dose in the initial 10 min, 
continuous infusion of insulin lasted for 110 min and hepatic glucose production was 
assumed to be entirely suppressed. Glucose disposal (M) was calculated as the total 
amount of glucose infused during the last 60 min (the steady state) of the clamp divided 
by kg body weight and minutes. The insulin sensitivity index (M/I ratio) was derived by 
dividing M by the steady-state mean insulin concentration (I). M/I thus represents the 
amount of glucose metabolized per unit of plasma insulin and was given in 100 × mg 
kg-1 min-1 mU-1 L.  
 
T2D was defined by elevated fasting glucose levels and/or use of anti-diabetic 
medicine. Elevated glucose levels were assessed as fasting plasma glucose ≥7.0 mmol/L 
at age 70 (the same criterion was used at age 60 and age 77).  
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 Serum adiponectin was measured in plasma samples frozen at -70 °C for 11 ± 2 years, 
without previous thaw-freeze cycles and using a validated in-house time-resolved 
immunofluorometric assay (TR-IFMA) with reagents from R&D Systems (Abingdon, 
UK). The intra- and inter-assay coefficient of variation averaged less than 5% and 10%, 
respectively, as described in detail previously [126].  
 
3.3 Genotyping 
3.3.1 SP2 (Study II) 
2,865 blood-derived DNA samples from the SP2 Chinese participants were genotyped 
using Illumina HumanHap 550, 610 Quad, and 1Mduov3 BeadChips 
(http://www.illumina.com). Quality control (QC) was performed on both the samples 
and the SNPs. In sample QC, sample missingness and heterozygosity were examined by 
a bivariate plot of the sample call rates and the proportion of heterozygous calls. 
Duplicated or related individuals were identified by identity-by-state computation.  
Ethnicity information was checked by principle component analysis (PCA) using Asian 
panels from the HapMap project and the Singapore Genome Variation Project [127]. 
Genotypes-inferred genders were compared against clinical data to identify discordant 
gender information. In SNP QC, monomorphic SNPs and SNPs with call rate < 0.95 or 
Hardy-Weinberg equilibrium (HWE) P-value < 1×10-6 were filtered out. These 
procedures have also been described in detail elsewhere [128]. 431 individuals did not 
pass the sample QC due to high rates of missingness, excessive heterozygosity, cryptic 
relatedness, discordant ethnicity and gender discrepancy. The number of post-QC SNPs 
was 504,625 for Illumina550, 542,298 for Illumina610 Quad, and 944, 241 for 
Illumina1Mduov3 chip. Imputation was done with IMPUTE 
(http://mathgen.stats.ox.ac.uk/impute/impute.html) on 22 autosomes using NCBI build 
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 36 HapMapII CHB and JPT data (release 22) as the reference panel. This resulted in a 
total number of SNPs between 2.1 and 2.5 millions on the three chips. Imputation 
results of SNPs that were actually genotyped were replaced with experimentally 
determined genotypes before the association tests were conducted.  
 
3.3.2 ULSAM (Study III) 
The ULSAM participants at age 70 have undergone prior genotyping on the Human 
CardioMetabo beadchip (Metabochip; http://www.illumina.com/support/array/ 
array_kits/ humancardio-metabo_beadchip_kit.ilmn), which is designed to interrogate 
200,000 markers of interest for cardiovascular and metabolic diseases. Of the 1,221 
individuals with genotype data, we removed those with genotyping call rate < 0.99 (n = 
5), failing sex check (n = 1), close relatedness (n = 36), or large heterozygosity (n = 7). 
Quality control also ensured that all SNPs had good call rate (> 0.99) and did not 
deviate from HWE (P > 1 × 10-6). In total, genotypes of 183,357 SNPs were available 
for 1,175 individuals.  
 
3.4 Statistical analysis 
3.4.1 Path analysis in Study I 
Path analysis is an extension of regression analysis that simultaneously performs a 
series of regression analyses in complex networks. It is suitable to elucidate complicated 
inter-relationships between exposure variables of interest, multiple potential mediators, 
and health outcomes [129, 130]. Compared with ordinary regression analysis, path 
analysis has the advantage that it allows examination of the potential causal processes 
underlying an observed relationship and to estimate the relative importance of 
alternative paths of influence in a complicated system [129]. Particularly, path analysis 
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 also allows a disentanglement of the direct and indirect effects which can provide more 
insights into the complicated relationships.   
 
In our study path analysis was carried out to evaluate mediators of pair-wise ethnic 
differences in insulin resistance. A hypothetical model was proposed based on previous 
biological knowledge of the relationships between ethnicity, insulin resistance, 
adipokines and inflammation (Figure 3). BMI and the BMI-adjusted waist 
circumference (waistR) were chosen based on previous analysis results to represent 
body fatness in the model, total adiponectin level to represent adipokines, and  
inflammation was represented by CRP levels. Covariates considered included age, 
alcohol, smoking and physical activity. One-way arrows represent causal effects and 
two-way arrows represent correlations between the variables. Endogenous variables 
which are variables having at least one incoming arrow were depicted with associated 
error terms. 
 
Figure 3. Full path diagram for the hypothetical model.  
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 We performed path analysis based on the full hypothesized model and paths with non-
significant path coefficients were removed to form a reduced model. Path analysis was 
performed again based on the reduced model. Model fit in comparison with the 
saturated and independent models was assessed based on the Bayesian Information 
Criterion (BIC).    
 
Amos 18.0 [131] was used to run the path analysis and Stata/SE 10.0 (Stata 
Corporation, College Station, Texas) for other analyses. All statistic tests were two-
sided and the level of significance was set at α=0.05. 
 
3.4.2 Genome-wide association analysis in Study II 
A genome-wide association study for total and HMW adiponectin was carried out on 
2,434 post-QC samples of the SP2 study. Adiponectin levels were natural log-
transformed and standardized to the z-scores. Additive genetic model adjusting for age 
and sex was used to test the associations and BMI was further adjusted for in a second 
model. The software used for the association study was SNPTEST v2.2.0 
(https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html). Samples 
genotyped on different chips were treated as separate studies and the results were meta-
analyzed under fixed-effect model weighted by inverse variance using METAL 
(http://www.sph.umich.edu/csg/abecasis/metal/). Sample size weighted meta-analysis 
was also performed and results were similar. Genomic control was applied to each study 
as well as the first-round meta-analysis results to correct for inflation.  
  
Genotypes for the top SNP from the meta-analysis, rs4783244 in the CDH13 gene, were 
successfully called for 2,429 individuals in the SP2 sample. Among them 39 had 
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 missing adiponectin levels and 4 had missing values for HOMA-IR. After further 
excluding those without age (n = 1), BMI (n = 2) and those taking diabetic medicine (n 
= 101), 2,282 individuals remained for the analysis.  
For the replication analysis, a total of 3,290 Japanese from the Nomura [132] and AAC 
studies [133] (1,226 with both total and HMW adiponectin levels) and 1,610 Koreans in 
the Yangpyeong Study [134] (total adiponectin levels only) with clinical data and 
genotypes for rs4783244 were included.  
 
Levels of adiponectin were measured using different kits in the studies involved, so 
standardization to mean of zero and variance of one was uniformly performed on 
adiponectin and other metabolic variables to facilitate cross-study comparisons and 
meta-analyses. Multiple linear regressions based on additive and general genetic models 
were used with different adiponectin forms and metabolic risk factors (log-transformed 
if necessary) as dependent variable and genotype, age and sex as independent variables. 
In addition, for metabolic traits, multivariable models that also included HMW 
adiponectin were evaluated. Bonferroni-corrected threshold α ≤ 5×10-8 was considered 
genome-wide significant and α ≤0.005 was used as a cutoff for the tests on rs4783244 
and 10 metabolic variables (calculated as 0.05/10).  All tests were 2-sided. 
 
3.4.3 Mendelian randomization in Study III 
Mendelian randomization (MR) is a method that uses genetic variants (instrumental 
variables, IVs) as robust proxies for an environmentally modifiable exposure to assess 
and quantify potential causal relationships with health outcomes [135, 136]. Because 
genotypes that influence the exposure are assigned at conception, they are unlikely to be 
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 related to confounders such as lifestyle, socioeconomic and environmental risk factors 
or reverse causation. 
Hypothetical model 
Figure 4 illustrates the key relationships in the study of the influence of adiponectin on 
insulin sensitivity using a MR design. Solid arrows represent causal influences that are 
expected and dotted arrows are causal influences that are assumed not to exist. Genetic 
variants from ADIPOQ gene are used as IVs based on three main assumptions: (1) The 
IVs are robustly associated with the exposure of interest, i.e. adiponectin levels; (2) the 
IVs are independent of confounders for the association between adiponectin and insulin 
sensitivity in observational studies; (3) the IVs are independent of the outcome insulin 
sensitivity given adiponectin levels and the confounders. Moreover, we hypothesize that 
part of the effect of adiponectin on insulin sensitivity is mediated by adiposity which is 
represented by BMI and waist circumference.  
 
Figure 4. Hypothetical model for the relationship between ADIPOQ, 
adiponectin and insulin sensitivity 
Selection of instrumental variables 
We searched the genomic region ± 50kb of the ADIPOQ gene and identified 16 SNPs 
that were present on the Metabochip. Pair-wise linkage disequilibriums (LDs) were then 
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 assessed and of the SNPs that were significantly associated with adiponectin, we 
selected rs17300539 and rs3774261 that were the top associated SNPs in their 
respective LD block as IVs. We also selected rs6444175 (r2 = 0.506 with rs3774261) 
and further generated an un-weighted allele score from rs17300539 and rs3774261 (r2 = 
0.137). Thus, we had three single SNPs and one allele score as IVs of serum adiponectin 
for subsequent MR analyses.  
 
Among the 1,221 participants, 199 were excluded for the following reasons: unavailable 
clamp data (n = 61), unavailable measurement of adiponectin (n = 15), or presence of 
T2D (n = 123). Of the remaining 1,022 participants, 942 participants with genotypes for 
ADIPOQ were eligible for the analysis.  
 
Adiponectin and insulin sensitivity index (M/I ratio) were natural log transformed and 
outliers (≥ 4SD from the mean) were truncated. The observed effects of adiponectin on 
M/I ratio, as well as effects of IVs on M/I ratio were obtained by linear regression under 
additive genetic models with adjustment for age. In further analyses, BMI and waistR 
were included as covariates into the model to evaluate effects independent of adiposity. 
Residual plots and cubic spline curves were plotted to visualize the degree of deviation 
from linearity. 
 
IV analysis was then performed using a two-stage least square (2SLS) approach with 
the Stata package ‘ivreg2’. In brief, the first stage was a conventional linear regression 
assessing the association between the SNPs and serum adiponectin. The predicted value 
of adiponectin from the model was saved and used as an independent variable in the 
second stage where the dependent variable was insulin sensitivity index (M/I ratio). This 
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 beta coefficient, or the IV estimate, reflects an unconfounded effect of genetically 
determined adiponectin level on insulin sensitivity. Endogeneity, or the difference 
between the IV estimate and the observed effect size, was examined by a Durbin-Wu-
Hausman Chi-square test implemented in the package. The percentage of change in 
insulin sensitivity with x% increase in adiponectin estimated by each instrument was 
calculated by ((1 + x%)β-1) × 100% where β is the corresponding IV estimate. To test 
the generalizability of our results, we performed secondary analyses including the 123 
individuals with T2D. In order to examine potential effect modification by adiposity, we 
conducted a BMI-stratified analysis by defining overweight using the median BMI level 
in our sample (BMI ≥ 25.7kg/m2).  
 
Data were analyzed using Stata/IC (version 12.1, StataCorp, College Station, TX). Two-
sided P-values < 0.05 were considered significant.  
 
3.4.4 Longitudinal analysis in Study IV 
Of the 2,322 participants at the age 50 examination, 393 individuals were excluded for 
the following reasons: serum selenium data not available (n = 274), presence of diabetes 
at baseline (n = 115) or missing glucose measurements (n = 8). In total, 1,925 non-
diabetic individuals formed the baseline study sample of the analysis in this study. After 
20 years of follow-up, among the 1,211 participants at age 70, 1,026 had baseline serum 
selenium and 936 non-diabetic individuals were included for the analyses on glucose 
metabolic measures.  
 
Selenium levels were analyzed both as categorical variables in tertiles and as continuous 
variable (presenting betas per 1-SD increment). Continuous outcome variables were 
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 natural log transformed to improve normality of the distribution and also presented as 
change in SD-unit. Observations beyond 4SD from the mean were defined as outliers 
and truncated. Logistic regression analysis was used to examine the association between 
baseline selenium levels and risk of T2D at follow-up. The relationship between 
selenium and glucose metabolism measures at baseline and after 20 years of follow up 
was examined by linear regression analysis. Two sets of models were used: model 1 
adjusted for age at baseline; model 2 further adjusted for potential confounders 
including BMI, cigarette smoking, leisure time physical activity, and education levels. 
P-values for trend were calculated by assigning the median value to each selenium 
tertile category and modeling it as continuous variable.  
 
In a sensitivity analysis, we evaluated the association of baseline selenium levels and 
incident diabetes risk using the follow-up data at age 60 and 77 and compared the 
estimates with those from the age 70 follow-up.  
 
Analyses were performed using Stata/IC (version 12.1, StataCorp, College Station, TX). 
Two-tailed P-values < 0.05 were considered significant. 
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 4 RESULTS & DISCUSSIONS 
4.1 Study I 
In this study we examined the mediating effects of body fatness, adiponectin and CRP 
on the differences of insulin resistance between three major ethnic groups in Singapore 
using path analysis. 
 
As shown in Table 1, the degree of insulin resistance as reflected by HOMA-IR was 
highest in Asian Indians, intermediate in Malays, and lowest in Chinese. CRP was 
higher in Asian Indians and Malays than in Chinese, and Indian women had particularly 
high levels of CRP. Total and HMW adiponectin were highest in Chinese and lowest in 
Asian Indians when women were compared, but these ethnic differences were less 
marked among men. BMI was lowest in the Chinese and was similar for Malays and 
Asian Indians. However, Asian Indians had a larger WHR and a larger waist 
circumference than Malays and Chinese. WHR was not significantly different between 
Chinese and Malay men. 
 
Table 1. Risk factors for insulin resistance by gender and ethnicity in Study I. 
 
Chinese Malay Asian Indian P-value 
Males 
   
N 1,201 363 269 
Age, years 49.0 (11.7)a 48.9 (11.1)a 50.2 (11.0)a 0.27 
HOMA-IR 1.22 (0.80-1.90)a 1.51 (0.93-2.24)b 1.90 (1.17-3.40)c <0.001 
CRP, mg/l 0.9 (0.5-1.9)a 1.4 (0.7-2.9)b 1.9 (0.8-3.9)b <0.001 
Total adiponectin, ug/ml 2.70 (1.98-3.71)a 2.62 (1.92-3.54)a,b 2.47 (1.83-3.39)b 0.10 
HMW adiponectin, ug/ml 0.82 (0.53-1.33)a 0.80 (0.48-1.22)a 0.74 (0.45-1.22)a 0.15 
BMI, kg/m2 23.4 (3.4)a 25.1 (4.0)b 25.1 (4.2)b <0.001 
Waist, cm 86.8 (9.7)a 89.3 (10.6)b 93.3 (11.6)c <0.001 
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 Hip, cm 98.4 (7.7)a 101.2 (9.3)b 101.9 (9.7)b <0.001 
WHR 0.88 (0.06)a 0.88 (0.06)a 0.91 (0.06)b <0.001 
WaistR, cm -0.1 (5.8)a -1.4 (6.1)b 2.5 (6.9)c <0.001 
HipR, cm -0.1 (5.6)a -0.1 (6.2)a 0.6 (6.5)a 0.23 






Cigarette smoking (%) 
Non-smoker 782 (65.1)a 169 (46.6)b 169 (62.8)a 
<0.001 
Ex-smoker 180 (15.0) 66 (18.2) 41 (15.2) 
Current smoker 239 (19.9) 128 (35.3) 59 (21.9) 
Alcohol drinking (%) 
Non-drinker 802 (66.8)a 352 (97.0)b 184 (68.4)a <0.001 
Females 
N  1,600  381 322
Age, years  48.3 (11.4)a 47.9 (11.0)a 49.7 (10.2)b  0.07 
HOMA-IR  1.14 (0.76-1.74)a 1.51 (1.05-2.50)b 2.00 (1.29-2.99)c  <0.001 
CRP, mg/l  0.8 (0.4-2.0)a 1.9 (0.8-4.6)b 3.6 (1.3-6.6)c  <0.001 
Total adiponectin, ug/ml  4.11 (2.93-5.86)a 3.63 (2.69-5.17)b 3.58 (2.55-4.75)b  <0.001 
HMW adiponectin, ug/ml 1.58 (0.95-2.55)a 1.31 (0.83-2.12)b 1.19 (0.81-1.92)b  <0.001 
BMI, kg/m2  22.3 (3.8)a 26.8 (5.2)b 26.5 (4.7)b  <0.001 
Waist, cm  76.5 (9.8)a 84.9 (11.3)b 87.0 (11.0)c  <0.001 
Hip, cm  95.2 (9.1)a 103.1 (11.0)b 104.3 (10.9)b  <0.001 
WHR  0.80 (0.06)a 0.82 (0.07)b 0.84 (0.07)c  <0.001 
WaistR, cm  -0.2 (5.8)a -0.9 (6.4)b 1.8 (6.7)c  <0.001 
HipR, cm  0.0 (5.8)a  -0.7 (5.8)b 1.1 (6.0)c  <0.001 







Non-smoker  1,518 (94.9)a 360 (94.5)a 317 (98.5)b  0.08 
Ex-smoker  38 (2.4)  9 (2.4) 2 (0.6)
Current smoker  44 (2.8)  12 (3.2) 3 (0.9)
Alcohol drinking (%) 
Non-drinker  1,383 (86.4)a 377 (99.0)b 306 (95.0)c  <0.001 
Drinker  217 (13.6) 4 (1.0) 16 (5.0)
a, b, c: Common superscript indicates no significant difference in the pair-wise comparison by Student’s 
t-test or Wilcoxon’s rank-sum test. Data are expressed as mean (SD) for continuous variables that are 
normally distributed, including age, BMI, waist, hip, WHR, waistR and hipR, and as median (inter-
quartile range) for continuous variables not normally distributed including HOMA-IR, CRP, total 
adiponectin, HMW adiponectin and physical activity. For categorical variables including cigarette 
smoking and alcohol consumption, values are presented by the numbers and percentages. 
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By linear regression, ethnic difference in insulin resistance between Malays and Chinese 
disappeared after adjusting for BMI and waist or only BMI. The difference in HOMA-
IR between Asian Indians and Chinese was also reduced after adjusting for BMI and 
waist, but remained statistically significant. Further adjustment for adiponectin and CRP 
levels explained slightly more of the ethnic difference in HOMA-IR (Table 2).  
 
Table 2. Associations between ethnicity and the HOMA-index of insulin resistance based on 
linear regression analysis with and without adjustment for potential intermediates. 
 
 Male Female 
Model 1 Model 2 Model 3  Model 1 Model 2 Model 3 
Chinese Ref. Ref.  Ref.  Ref. Ref. Ref. 
Malay  0.17 -0.01 -0.01  0.28 -0.05 -0.02 
Asian Indian  0.48 0.25 0.23  0.50 0.17 0.15 
BMI, kg/m2  0.58 0.48   0.56 0.42 
WaistR, cm  0.13 0.10   0.13 0.10 
Adiponectin, ug/ml   -0.19    -0.21 
CRP, mg/l   0.11    0.13 
R2 0.06 0.38 0.42  0.12 0.38 0.44 
Results were based on linear regression analysis with continuous independent variables and HOMA-IR 
expressed per 1 SD increment except of ethnicity variables. Adiponectin and CRP were log-transformed. 
Model 1, unadjusted; Model 2, adjusted for BMI and waistR; Model 3, further adjusted for adiponectin 
and CRP. Italic values indicate statistically non-significant at α=0.05 level. 
 
Malay-Chinese comparison 
The effect of ethnicity on insulin resistance when Malays were compared with Chinese 
could be fully explained by the considered mediators as indicated by the non-significant 
direct path between ethnicity and HOMA-IR (Figure 5A and 5B).  
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Figure 5A, 5B. Path coefficients in the reduced models for Malay-Chinese comparison of 
differences in insulin resistance in men (A) and women (B). 
 
Ethnic Malays represent millions of people from different Southeast Asian Island 
populations including Malaysians, Filipinos and Indonesians who are experiencing a 
rapid increase in chronic disease burden [137]. Studies have demonstrated that overall 
ethnic Chinese from East Asia and Malays from Southeast Asia were genetically closer 
than either of them with Asian Indians [138]. More specifically, although culturally 
distinct, Malays in Singapore had a greater genetic similarity with Chinese than Asian 
Indians [127, 138]. Greater general adiposity of Malays as compared with Chinese 
explained their greater insulin resistance in our study and targeting excess weight gain 




BMI alone accounted for a substantial proportion of the observed difference in insulin 
resistance between Asian Indians and Chinese. In addition, CRP, but not adiponectin, 
also contributed independently to the greater insulin resistance in Asian Indians as 
compared with Chinese. A smaller proportion was attributable to effects of adiposity 
34 
 through adiponectin and CRP and effects of CRP independent of BMI (Figure 5C and 
5D). 
Figure 5C, 5D. Path coefficients in the reduced models for Indian-Chinese comparison of 
differences in insulin resistance in men (C) and women (D). 
 
Two previous studies [31, 37] found higher insulin resistance in Asian Indians than in 
Chinese, which is consistent with our results. One of them [37] suggested that the 
differences in total body fat mass could explain the higher insulin resistance in Asian 
Indians as compared with Chinese. In our study the difference in insulin resistance 
between Asian Indians and Chinese partly remained after adjusting for BMI and waist 
circumference. This discrepancy in results might be due to the use of anthropometry 
instead of direct body fat measurements in our study or the relative small sample size in 
the previous study. 
 
Indian-Malay comparison 
The difference in insulin resistance between Asian Indians and Malays was not 
mediated by BMI (Figure 5E and 5F) and this was in agreement with the similar BMI 
of Asian Indians and Malays. Instead, abdominal adiposity contributed to the greater 
insulin resistance in Asian Indian men and women as compared with their Malay 
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 counterparts. A substantial independent contribution of adiponectin and CRP to Indian-
Malay differences in insulin resistance was observed in women, but not in men. 
 
 
Figure 5E, 5F. Path coefficients in the reduced models for Indian-Malay comparison of 
differences in insulin resistance in men (E) and women (F). 
 
The comparison between Asian Indians and Malays highlighted the role of abdominal 
fat distribution in the contribution to insulin resistance and the effects of abdominal 
adiposity also appeared to mediate through adiponectin levels. In line with this finding, 
results from previous studies in Asian populations suggest that intra-abdominal fat may 
reduce adiponectin levels to a greater extent than subcutaneous fat [139-141] although 




 4.2 Study II 
In this study, we conducted a GWAS of total and HMW adiponectin in a Chinese 
population living in Singapore. With an extension to other East Asian populations 
including 3,290 Japanese and 1,610 Koreans, we also examined a genetic variant in 
CDH13 in relation to insulin resistance and associated metabolic traits. 
 
Among the populations involved in this study, Singaporeans were generally younger 
than Japanese and Korean participants, whereas Koreans had a higher BMI, higher 
triglyceride levels, higher HOMA-IR, and lower HDL-cholesterol (HDL-C) levels than 
the other populations (Table 3). The substantial differences in adiponectin levels 
between study populations may be partly due to differences in laboratory methods and 
have been addressed by standardization of adiponectin levels in the data analysis. As 
expected, blood adiponectin levels were inversely correlated with insulin resistance 
(measured by HOMA-IR or fasting insulin), fasting glucose, triglycerides and CRP and 
directly correlated with HDL-C in our study populations.  
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 Table 3. Characteristics of the study populations in Study II. 
 Singaporean Chinese Japanese Koreans 
N 2,282 3,290 1,610 
Age, years 47.6 (10.9) 63.4 (11.6) 61.0 (10.5) 
Males , % 1,055 (46.2) 1,365 (41.5) 667 (41.4) 
BMI, kg/m2 22.8 (3.6) 23.3 (3.2) 24.6 (3.3) 
Total adiponectin*, ug/ml 3.27 (2.28 – 4.78) 9.10 (6.40 – 13.40) 7.15 (4.74 – 10.57) 
HMW adiponectin, ug/ml 1.14 (0.65 – 1.93) 4.40 (2.70 – 7.20) --- 
HMW/total adiponectin ratio 0.35 (0.27 – 0.43) 0.41 (0.35 – 0.47) --- 
HOMA-IR 1.16 (0.77 – 1.79) 1.21 (0.80 – 1.89) 2.20 (1.63 – 2.98) 
HOMA-B, % 100.0 (67.6 – 147.0) 56.7 (38.1 – 83.6) 102.1 (71.2 – 135.7) 
Fasting glucose, mmol/L 4.7 (4.4 – 5.0) 5.3 (5.0 – 5.7) 5.3 (5.0 – 5.8) 
Fasting insulin, mU/L 5.6 (3.8 – 8.4) 5.1 (3.4 – 7.7) 9.2 (6.9 – 11.8) 
LDL-C, mmol/L 3.10 (2.58 – 3.67) 3.18 (2.62 – 3.72) 3.11 (2.56 – 3.65) 
HDL-C, mmol/L 1.43 (1.21 – 1.69) 1.63 (1.34 – 1.94) 1.15 (1.00 – 1.33) 
Total cholesterol, mmol/L 5.15 (4.58 – 5.78) 5.40 (4.80 – 6.00) 5.12 (4.50 – 5.72) 
Triglycerides, mmol/L 1.08 (0.76 – 1.60) 1.05 (0.78 – 1.48) 1.45 (1.06 – 2.09) 
CRP, mg/L 0.8 (0.4 – 1.9) 0.5 (0.3 – 1.0) 0.9 (0.5 – 1.8) 
Data are represented as: mean (SD) for age and BMI; median (IQR) for all the other metabolic variables; n 




In the GWAS in Singapore Chinese, signals reaching genome-wide significance (5 ×10-
8) mapped exclusively to the CDH13 and ADIPOQ gene (Figure 6A) and the Quantile-
Quantile plot suggested no systemic bias (Figure 6B). Power calculation showed that 
with a sample of 2,434 independent individuals, we had > 73% power to detect a variant 
that explains at least 1.5% of the variance in adiponectin levels in a GWAS setting (with 
multiple-testing adjustment), and > 94% power to detect such a variant that explains 2% 




 Table 4. Power for a genome-wide association study on adiponectin in SP2. 
 
Variance explained Power Calculated main genetic effect 
0.010 0.307 1.543 
0.015 0.730 1.889 
0.020 0.941 2.182 
0.025 0.992 2.440 
0.030 0.999 2.673 
0.035 0.999 2.887 
0.040 0.999 3.086 
 
The strongest signal in CDH13 was rs4783244 located in the intron region. With regard 
to other previously reported loci, associations with total and HMW adiponectin levels 
reached genome-wide significance for ADIPOQ (rs10937273) and we observed 
nominally significant associations for GPR109A (rs601339), CMIP (rs2925979) and 
PEPD (rs731839). We focused on the top hit CDH13 SNP rs4783244 in this study.  
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Figure 6. Manhattan plot (A) and Quantile-Quantile plot (B) for the whole-genome association 
with HMW adiponectin in Singapore Chinese.  
 
Association of the CDH13 variant with different adiponectin forms 
In the combined data from Singapore Chinese, Japanese and Korean cohorts,  total 
adiponectin levels significantly decreased by 0.34 SD on the log scale for each 
additional T allele rs4783244 in CDH13 (95% CI: -0.38 to -0.30, Table 5). This 
CDH13 variant was even more strongly associated with HMW adiponectin levels and 
the HMW-to-total adiponectin ratio based on the Singaporean Chinese and Japanese 
data. Adjustment for BMI did not substantially affect these effect estimates and similar 
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 results were obtained for the general genetic model. The CDH13 rs4783244 variant 
explained more than 4% of variation in total adiponectin (Singapore: 4.5%, Korea: 
5.5%, Japan: 4.1%) and more than 6% of variation in HMW adiponectin levels 
(Singapore: 8.3%, Japan: 6.5%). 
 
Table 5. Association between rs4783244 in CDH13 and different forms of adiponectin. 
 N β (95% CI) P-value 
Total adiponectin 
Singaporean Chinese 2,282 -0.32 (-0.37, -0.26) 2.7 × 10-27 
Japanese 1,266 -0.34 (-0.42, -0.27) 4.2 × 10-19 
Koreans 1,610 -0.37 (-0.44, -0.30) 2.4 × 10-25 
Meta-analysis 5,158 -0.34 (-0.38, -0.30) 2.0 × 10-70 
HMW adiponectin 
Singaporean Chinese 2,282 -0.43 (-0.48, -0.37) 1.7 × 10-51 
Japanese 3,290 -0.38 (-0.42, -0.34) 3.3 × 10-64 
Meta-analysis 5,572 -0.40 (-0.43, -0.36) 1.1 × 10-117 
HMW-to-total adiponectin ratio 
Singaporean Chinese 2,282 -0.48 (-0.54, -0.43) 9.7 × 10-62 
Japanese 1,266 -0.36 (-0.44, -0.29) 1.7 × 10-19 
Meta-analysis 3,548 -0.44 (-0.49, -0.40) 3.2 × 10-83 
Results are age and sex adjusted. Total and HMW adiponectin were natural log transformed 
and all the adiponectin forms were standardized to the z-scores. An additive genetic model is 
assumed and each β represents the effect of one copy of the T allele on the respective form of 
adiponectin.  
 
Association of the CDH13 variant with metabolic traits 
At a Bonferroni-corrected threshold of P ≤ 0.005, no significant association between 
rs4783244 in CDH13 and metabolic risk factors was observed in Singaporean Chinese 
or in Japanese (Model 1). Because CDH13 is known to code for a receptor for HMW 
adiponectin, we reassessed these associations after adjustment for HMW adiponectin 
levels (Model 2). In a meta-analysis of the Singaporean Chinese and Japanese samples, 
the minor allele T in rs4783244 was significantly associated with lower BMI (β = -0.15, 
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 95% CI: -0.19 to -0.11, P = 3.5×10-14), lower HOMA-IR (β = -0.16, 95% CI: -0.20 to -
0.12, P = 9.2×10-16), higher HDL-C (β = 0.16, 95% CI: 0.12 to 0.19, P = 2.1×10-17) and 
lower triglycerides (β = -0.16, 95% CI: -0.19 to -0.12, P = 1.3×10-16) when HMW 
adiponectin levels were adjusted for. After further adjusting for BMI, associations were 
weaker, but remained significant (Figure 7). In Singaporean Chinese, adjustment for the 
top four principle components had minimal impact on the effect estimates and this 
eliminated concerns over population admixture in this population. The associations 
were significant but also weaker when we adjusted for total adiponectin instead of 
HMW adiponectin. In a sensitivity analysis, there was minimal difference in effect 
estimates between fixed- and random-effect meta-analysis and the estimates retained 
genome-wide significant with random-effect analysis. 
 
Figure 7. Effect estimates of rs4783244 in CDH13 on selected metabolic traits across studies; 
age, sex and HMW adiponectin adjusted.  
 
Results from previous studies also provided little support for an association between 
variants at the CDH13 locus and metabolic traits. In Filipino women, no significant 
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 associations with metabolic risk factors were detected for rs3865188 in CDH13 (LD 
with rs4783244, r2 = 0.85) except for a nominal association (P = 0.042) with waist 
circumference [116]. Similarly, a Swedish study reported that rs11646213, a SNP 
upstream of CDH13, in minimal LD with rs4783244 (r2 = 0.08), was not associated with 
metabolic risk factors [144]. In a Taiwanese study, the significant associations between 
rs4783244 and waist circumference, glucose and triglyceride levels did not remain after 
adjustment for BMI, although the adiponectin-lowering T allele was paradoxically still 
associated with a reduced risk for diabetes, the metabolic syndrome and stroke [117]. 
 
Recently, Japanese researchers reported an association between another CDH13 SNP 
(rs12051272) and BMI, fasting insulin, fasting glucose, HOMA-IR, and fasting 
triglycerides only after controlling for adiponectin levels [115]. This SNP is in close 
proximity and moderate LD (r2 = 0.66) with rs4783244, which we studied. Together 
with our findings, current evidence suggests a complex relationship between variants at 
the CDH13 locus and metabolic traits that is only evident after controlling for their 
effects on blood adiponectin levels. 
 
Hypothetical mechanism 
The association between the variants at CDH13 and plasma HMW adiponectin may be 
explained by the function of the T-cadherin receptor that it encodes. T-cadherin is a 
receptor for hexameric and HMW adiponectin that is expressed in the vasculature [145], 
cardiac myocytes [146] and epithelial cells in the lung [147]. We believe that the T 
allele at rs4783244 is associated with increased binding of HMW adiponectin to the T-
cadherin receptor resulting in the sequestration of HMW adiponectin in these tissues, 
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 thus removing it from the blood. Consistent with this explanation, ablation of the T-
cadherin receptor increased plasma adiponectin levels in mice [145-147].  
 
To explain the paradoxical observation that the T allele at rs4783244 that is associated 
with lower blood levels of HMW adiponectin is associated with a more favorable 
metabolic profile than would be expected based on HMW adiponectin levels, we 
hypothesize that the rs4783224 variant at the CDH13 locus or other variants that it tags 
may have an indirect effect on an individual’s sensitivity to circulating adiponectin. In 
this hypothesis, the chronically low levels of plasma adiponectin associated with the T 
allele may result in up-regulation of adiponectin receptors AdipoR1/R2. Consistent with 
this proposed mechanism, chronic elevation of plasma adiponectin led to down 
regulation of AdipoR2 in adipose tissue in mice [148]. Furthermore, the expression of 
AdipoR1/R2 was up-regulated in insulin-resistant women with the polycystic ovary 
syndrome [149], who would be expected to have low blood adiponectin levels. The 
greater expression of adiponectin receptors could counter-balance the low adiponectin 
levels resulting in the lack of association between rs4783244 and the metabolic profile 
in unadjusted analyses. However, when the blood adiponectin levels are controlled for, 
then the greater ‘adiponectin sensitivity’ results in an association between the T allele 
and a more favorable metabolic profile.  
 
Despite the strong association of rs4783244 with HMW adiponectin, how this intronic 
SNP could have an impact on HMW adiponectin levels remains to be resolved. For this, 
we explored the genetic region 500 kb around rs4783244 by a conditional analysis in 
collaboration with additional cohorts from Asia [150]. Conditioning on rs4783244, the 
associations of all the nearby SNPs (~1900) with adiponectin were substantially 
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 attenuated and none of them remained genome-wide significant (top signal: 
rs12448339, P-value = 2.3 × 10-4). The conditional analysis suggested that signals 
within this 1Mb flanking region could be explained by rs4783244. Whether a causal 
variant that this SNP tags is located further away, for example, in the promoter region 
and alters the binding affinity of T-cadherin to HMW adiponectin, could be studied as a 
next step, possibly with sequencing and experimental efforts. 
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 4.3 Study III 
In this study, we examined the causal effect of increased adiponectin levels on improved 
insulin sensitivity in humans using a Mendelian randomization approach with ADIPOQ 
SNPs as instruments in a population-based cohort study of 71-year-old men in Sweden.  
Association between the instruments and serum adiponectin 
Table 6 shows the 16 ADIPOQ SNPs available on the Metabochip and their 
associations with adiponectin levels in the ULSAM cohort. Based on LD structure, they 
were assigned to 11 different blocks. Seven SNPs belonging to two different LD blocks 
showed highly significant associations with serum adiponectin (all P ≤ 4.8 × 10-7). The 
three SNPs chosen as instrumental variables, namely rs17300539, rs3774261 and 
rs6444175 were all strongly associated with adiponectin levels. As expected, the allele 
score generated from rs17300539 and rs3774261 was even more strongly associated 
with adiponectin level as compared with each of the single ADIPOQ SNPs. The 
instruments explained 3.5 to 6.0% (rs17300539: 4.3%, rs3774261: 3.8%, rs6444175: 




 Table 6. ADIPOQ SNPs available on the Metabochip and their associations with serum 
adiponectin. 
 




Alleles* EAF HWE  
P-value 
Association with adiponectin,  
age adjusted 
     Beta (95% CI) P-value 
rs3917086        (1) 188007420 A/C 0.03 0.621 0.02 (-0.08, 0.12) 0.668 
rs864265          (2) 188036986 T/G 0.15 0.015 -0.06 (-0.10, -0.01) 0.020 
rs822387          (3) 188038731 C/T 0.07 0.660 0.16 (0.10, 0.22) 4.8 × 10-7 
rs17300539‡    (3) 188042154 A/G 0.07 0.189 0.21 (0.14, 0.27) 1.1 × 10-10 
rs16861209      (3) 188045808 A/C 0.07 0.088 0.21 (0.15, 0.28) 1.5 × 10-10 
rs16861210      (3) 188049192 A/G 0.08 0.550 0.19 (0.13, 0.25) 1.1 × 10-9 
rs16861194      (4) 188042119 G/A 0.09 0.855 -0.05 (-0.11, 0.01) 0.106 
rs822396          (5) 188049571 G/A 0.17 0.475 0.01 (-0.03, 0.06) 0.562 
rs3774261‡      (6) 188054253 A/G 0.38 0.950 0.11 (0.07, 0.14) 1.3 × 10-9 
rs6773957        (6) 188056399 A/G 0.38 0.950 0.11 (0.07, 0.14) 1.4 × 10-9 
rs6444175‡      (6) 188062438 A/G 0.29 0.438 0.11 (0.08, 0.15) 5.3 × 10-9 
rs3774262        (7) 188054508 A/G 0.09 0.185 0.03 (-0.03, 0.09) 0.327 
rs9853541        (8) 188095161 A/G 0.38 0.121 0.00 (-0.04, 0.04) 0.927 
rs11708293      (9) 188096021 G/A 0.04 1.000 -0.04 (-0.13, 0.04) 0.322 
rs11716002    (10) 188096058 G/A 0.24 0.105 0.01 (-0.03, 0.05) 0.616 
rs17301514    (11) 188096103 A/G 0.13 1.000 0.01 (-0.04, 0.06) 0.757 
Allele score§     0.40 (0.30, 0.51) 1.2 × 10-13 
EAF, Effect allele frequency. SNPs were first sorted based on physical position in the ADIPOQ gene and 
then aggregated by LD group indicated by the number in the bracket. All the SNPs had call rate >0.96. 
*The first allele is the effect allele. ‡SNPs selected for instrumental variable analysis. §The allele score 
was created using genotypes for rs17300539 and rs3774261 (R2 = 0.137).  
 
The three SNPs selected as IVs have been repeatedly reported for their association with 
adiponectin in individuals of European descent [110, 111, 151-154]. This confirms that 
the SNPs we selected are robust instruments for adiponectin levels in European 
populations. 
 
As discussed in Study II, the CDH13 gene exhibits strong association with adiponectin 
levels. However, genetic variants in CDH13 are not ideal candidates to be used as IVs 
in Study III. This is because one of the core assumptions for the Mendelian 
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 randomization design is the absence of pleiotropic effects of the IVs, i.e., not having 
multiple phenotypic effects. Unlike the clear function of ADIPOQ gene to code for 
adiponectin, the protein T-cadherin, which CDH13 codes for, has been reported for 
diverse functions and the mechanisms are not well understood yet [155]. Pleiotropy can 
distort the results of Mendelian randomization studies under certain circumferences, by 
establishing an association with the outcome not through the exposure of interest. 
Therefore, we did not consider the use of CDH13 variants as IVs in Study III. 
 
Association between the instruments and insulin sensitivity 
All the instrumental variables including the three ADIPOQ SNPs and the allele score 
were significantly associated with insulin sensitivity represented by the M/I ratio (P ≤ 
0.022 for all SNPs and P = 8.0 × 10-4 for the allele score). Adjustment for adiposity 
represented by BMI and waistR weakened these associations, but some of the 
instruments remained significantly associated with the M/I ratio (rs6444175, P = 0.011; 
allele score, P = 0.042).  
 
Studies of the relationship between ADIPOQ and insulin sensitivity in candidate gene 
studies have been less consistent [156]. The 3q27 region in which the ADIPOQ gene is 
located was reported for its linkage signal with seven metabolic traits, and was 
suggested for an association with obesity and insulin sensitivity [157]. However, 
individual ADIPOQ SNPs, including some of the IVs in our study, did not show an 
association with parameters for glucose and insulin metabolism [110, 112, 154]. 
However, in a recent large study, Dastani et al. demonstrated that several individual 
SNPs which were significant in their GWAS of adiponectin levels, including a few 
ADIPOQ SNPs, were associated with T2D and related traits. Furthermore, they found a 
48 
 multi-SNP genotypic risk score based on the identified hits to be strongly associated 
with metabolic traits related to insulin resistance [118]. Therefore, even though 
ADIPOQ has been established as major determinant of adiponectin levels, its 
associations with measures of insulin sensitivity have not been consistent which may 
have been due to lack of statistical power to detect this indirect effect. Of note, prior 
studies have not assessed associations of ADIPOQ variants and insulin sensitivity 
measured with intravenous methods in a larger study sample.  
 
Instrumental variable analysis of the effect of adiponectin on insulin sensitivity  
To examine the potential causal effect of adiponectin on insulin sensitivity in an IV 
analysis, we assessed the first-stage F-statistic in which an empirical value >10 indicates 
sufficient strength of the genetic variant as a proxy of the exposure. The large F-
statistics ensured that the SNPs chosen were strong instruments for adiponectin levels 
(Table 7).  
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 Table 7. Instrumental variable estimated and observed association between adiponectin and 
insulin sensitivity. 
 











rs17300539 42.6 0.47 (0.10, 0.84) 0.014 
0.50  
(0.42, 0.58) 
1.2 × 10-33 
0.878 
rs3774261 37.6 0.68 (0.28, 1.08) 9.1 × 10-4 0.364 
rs6444175 34.7 0.81 (0.38, 1.23) 2.1 × 10-4 0.136 
Allele 
score* 
56.7 0.60 (0.27, 0.93) 3.3 × 10-4 0.528 
Age, BMI and waistR adjusted 
rs17300539 38.5 0.27 (-0.08, 0.61) 0.131 
0.28  
(0.21, 0.34) 
1.3 × 10-14 
0.955 
rs3774261 29.3 0.39 (-0.01, 0.78) 0.055 0.572 
rs6444175 28.1 0.55 (0.13, 0.96) 0.010 0.178 
Allele score 46.7 0.34 (0.03, 0.65) 0.034 0.677 
*The allele score was created using genotypes for rs17300539 and rs3774261 (R2 = 0.137). †Endogeneity 
was assessed by Durbin-Wu-Hausman test and reflects whether the difference between the IV estimate and 
the observational estimate was statistically significant. 
 
The IV-estimated effect size of adiponectin levels on insulin sensitivity was highly 
significant and consistent for all instruments. In addition, endogeneity tests suggested 
there was no statistical difference between the IV estimate and the observational 
estimate (Table 7). This was consistent for each of the individual SNP instruments and 
also the allele score, demonstrating that genetically determined adiponectin levels affect 
insulin sensitivity to the same degree as expected based on the observed association. In 
our secondary analyses including individuals with T2D, the results were similar to those 
from our main analyses. 
 
For some of the IVs, we still observed an association between the IV-estimated 
adiponectin and insulin sensitivity after adjustment for BMI and waistR (Table 7), 
although the effect sizes were substantially attenuated. This suggests that at least part of 
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 the causal beneficial effect of adiponectin levels on insulin sensitivity was mediated by 
lower adiposity as measured by BMI and waist circumference. BMI-stratified analysis 
suggested that the association between increased adiponectin levels and higher insulin 
sensitivity was stronger in the group with higher BMI, for which the observed causal 
relationship between adiponectin and insulin sensitivity also persisted. However, in the 
group with lower BMI, we did not have enough power to robustly confirm or refute an 
association due to limited sample size.  
 
The role of adiposity is important to dissect the causal relationship between adiponectin 
and insulin sensitivity, as will be discussed in Future perspectives.   
 
Estimated impact of adiponectin on insulin sensitivity 
Based on the IV estimates in the age-adjusted  model (ranged between 0.47 and 0.81), 
we estimated the relationship between percent change in adiponectin levels and 
corresponding percent change in insulin sensitivity. For example, a 10% increase in 
serum adiponectin level would lead to an improvement of insulin sensitivity ranging 
between 4.6% and 8.0%. Similarly, excluding the mediation through obesity, the 
percent increase in insulin sensitivity associated with a 10% elevation in adiponectin 
level was estimated to be between 2.6% to 5.3%. However, due to the large confidence 
intervals for the IV estimates, these numbers should be interpreted with caution.  
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 4.4 Study IV 
In this study, we examined relations between serum selenium levels and measures of 
glucose and insulin metabolism, as well as risk of diabetes after 20 years of follow-up in 
1,925 participants from the ULSAM cohort. 
 
The mean concentration of serum selenium in our study population was 75.6 μg/L. At 
baseline, serum selenium was not significantly associated with fasting glucose levels or 
glucose tolerance represented by the K-value from the IVGTT. Higher serum selenium 
levels were associated with a lower insulin peak during the IVGTT indicating lower 
early insulin response. This association persisted after adjustment for potential 
confounders (selenium as continuous variable, standardized β = -0.08; 95% CI: -0.14 to 
-0.03, P for trend = 0.026). However, this is likely a chance finding due to the multiple 
tests we performed and does not have an obvious biological meaning. Selenium was not 
substantially associated with HOMA measures of insulin resistance or insulin secretion.  
 
At follow-up after 20 years, we observed no clear associations with any glucometabolic 
traits as well as adiponectin levels (Table 8).  
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 Table 8. Association of baseline serum selenium (at age 50) with adiponectin 
levels at the age-70 follow-up. 
 
 Model 1 Model 2 
N 927 927 
Low Se tertile 1 1 
Middle Se tertile 0.12 (-0.04, 0.28) 0.13 (-0.02, 0.29) 
High Se tertile 0.03 (-0.13, 0.19) 0.03 (-0.12, 0.19) 
Continuous Se 0.02 (-0.05, 0.09) 0.03 (-0.04, 0.09) 
P for trend 0.451 0.842 
Results are beta (95% CI). For categorical selenium, the coefficients represent SD 
difference on the natural log scale in adiponectin as compared with the low tertile 
(reference). For continuous selenium variables, the regression coefficients represent 
SD change in adiponectin per SD change in selenium levels on the natural log scale. 
Model 1: adjusted for age; Model 2: adjusted for age, BMI, cigarette smoking, leisure 
time physical activity, and education at the baseline examination. 
 
Among 1,024 individuals with baseline selenium levels and follow-up data, 88 
developed diabetes. Selenium levels were not substantially associated with a higher risk 
of diabetes during follow-up in either age-adjusted or multivariable models (Table 9). 
Analysis with selenium as a continuous variable also revealed no association of baseline 
selenium levels with incident risk of diabetes.  
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 Table 9. Association of baseline serum selenium (at age 50) with diabetes risk during follow-up 
at age 60, age 70 and age 77 years. 
 




High Se tertile Continuous Se 








53/1,486 15/501 15/489 23/496   
Model 1 1,539 1 0.99 (0.48, 2.05) 1.51 (0.78, 2.92) 1.15 (0.87, 1.52) 0.201 






88/936 24/302 33/314 31/320   
Model 1 1,024 1 1.31 (0.76, 2.27) 1.21 (0.69, 2.10) 1.04 (0.82, 1.31) 0.544 
Model 2 1,024 1 1.31 (0.73, 2.36) 1.25 (0.68, 2.27) 1.06 (0.83, 1.38) 0.497 




91/565 27/179 34/182 30/204   
Model 1 656 1 1.23 (0.71, 2.14) 0.97 (0.55, 1.70) 0.97 (0.76, 1.25) 0.876 
Model 2 656 1 1.16 (0.65, 2.08) 0.97 (0.54, 1.75) 0.96 (0.74, 1.25) 0.880 
Logistic regression was used and results as OR (95% CI). The low Se tertile is the reference category. Model 1: 
adjusted for age; Model 2: adjusted for age at baseline, BMI, cigarette smoking, leisure time physical activity, 
and education at the baseline examination. 
 
In sensitivity analyses, 53 individuals free of diabetes at baseline developed diabetes by 
the age 60 follow-up. A total of 91 incident diabetes cases were identified in the age 77 
examination after 27 years of follow-up since baseline at age 50. The odds ratio 
estimates based on continuous selenium levels were similar to those observed at age 70 
with no evidence for an association of selenium levels with incident diabetes (Table 9).  
 
Two large RCTs to address the effect of selenium on future risk for disease have been 
conducted to date, including the Selenium and Vitamin E Cancer Prevention Trial 
(SELECT) [76] and the Nutritional Prevention of Cancer (NPC) trial [77]. Results from 
these two trials suggested a lack of beneficial effect of selenium supplementation on 
T2D and the NPC trial reported that the risk significantly increased with greater baseline 
selenium levels defined by tertiles [77]. To be noted, both trials were conducted in the 
United States where selenium supplementation is common.  
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Comparison and interpretation of the findings for the effects of selenium in different 
studies is not straightforward. Firstly, baseline selenium levels are greatly different 
across populations, due to factors such as soil selenium content, dietary patterns, 
selenium supplements used and genetics [158, 159]. For example, selenium intakes are 
considerably lower in Europe than in USA and Canada [158]. In Sweden, the estimated 
intake is 31 to 38 μg per day [159] while in USA the daily intake ranged from 60 to 220 
μg [158]. Serum or plasma selenium concentrations also vary substantially by country 
[158, 160]. In our cohort, serum selenium averaged 76 μg /L, which is even lower than 
most participants of low baseline selenium levels in SELECT and NPC trial [76, 77]. It 
is possible that selenoenzyme activities have already reached a maximum in the trials 
[161], whereas in most of the ULSAM participants it did not.  
 
Secondly, selenium supplementation in the clinical trials used high doses and the 
resulting circulating selenium levels were substantially higher than would result from 
dietary intake only. This is even more pronounced if the baseline levels were already 
different. Selenium is a trace element with a relatively narrow range between deficiency 
and toxicity [162, 163]. Protective effects of selenium on diabetes and glucose 
metabolism, if these exist, may only be found at optimal levels that enhance 
selenoprotein activities. A loss of benefit or even adverse effects could occur outside the 
optimal range. In a prospective study of similar design and baseline selenium levels to 
our study, no significant association was detected between selenium and hyperglycemia 
[164]. Therefore, the role of selenium in the development of diabetes and 
hyperglycemia remains to be elucidated.  
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 Insulin resistance can be induced by ROS [165] and several selenoproteins have an 
antioxidant property [166]. Thus, selenium could exert a protective effect on insulin 
sensitivity by alleviating oxidative stress. However, experimental evidence has been 
conflicting. On the one hand, selenoproteins such as GPx1 and selenoprotein P have 
been shown to interfere with insulin signaling and contribute to the development of 
insulin resistance [71, 167-169]. Mice overexpressing GPx1developed diabetic 
phenotypes, including hyperglycemia, increased insulin production and insulin levels, 
and elevated β-cell mass [170, 171]. On the other hand, selenium-containing 
micronutrients such as sodium selenate can serve as an insulin-mimetic [70]. Sodium 
selenate has been demonstrated to improve peripheral insulin sensitivity measured by 
the euglycemic clamp in rats [172] and increased the expression of PPAR-γ, a 
transcription factor that sensitizes the body to insulin, in diabetic db/db mice [173]. One 
human trial found that adding selenium to a hypocaloric diet led to a borderline 
significant reduction of fasting insulin and HOMA-IR in 84 centrally-obese women 
[174]. 
 
Adiponectin is an adipocyte-secreted hormone and plays an important role in glucose 
metabolism, especially in the regulation of insulin sensitivity [96, 97, 175, 176]. 
Selenium treatment  decreased adiponectin levels possibly by suppressing adiponectin 
production in Otsuka Long-Evans Tokushima Fatty (OLETF) rats [177]. A few studies 
have examined the effects on adiponectin levels when selenoprotein P, a major class of 
selenoproteins [68], was knocked out/down in mice, but results from different studies 
have been inconsistent [178, 179]. A human study involving 36 patients with diabetes 
reported an inverse association of selenoprotein P with circulating adiponectin, but not 
with the quantitative insulin sensitivity index [178]. In a recent randomized trial from 
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 UK where selenium status is comparable to Sweden, baseline plasma selenium was 
inversely associated with adiponectin concentrations, but selenium supplementation of 
six months at doses 100, 200 and 300 μg/day had no effect on adiponectin levels [180]. 
Results of our study did not support an association between baseline selenium levels 
and adiponectin levels after 20 years of follow-up, but further research is needed to 
clarify the inconsistency of results across studies.  
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 4.5 Strengths and limitations 
4.5.1 Strengths 
A major strength of the SP2 study is the inclusion of a multi-ethnic sample consisting of 
Chinese, Malays and Asian Indians, which well represents the populations in East and 
South East Asia. Their susceptibility to (central) obesity, insulin resistance, as discussed 
in Study I, makes it an important research focus to study Asians for the etiology and 
prevention of T2D. In addition, HMW adiponectin was measured together with total 
adiponectin levels in all the participants with blood samples. This is valuable because 
HMW adiponectin has been shown to be the form of highest bioactivity and a stronger 
association with various metabolic traits [84, 101-103]. 
The strengths of the ULSAM study include the longitudinal design and the long follow-
up period. Moreover, the study was undertaken in a homogeneous, age-standardized 
sample from Uppsala in Sweden, and therefore population stratification which could, 
for example, violate assumptions of Mendelian randomization in Study III is unlikely. 
Moreover, the ULSAM cohort has detailed measurements of many metabolic variables 
related to insulin and glucose metabolism. Importantly, it is the largest single-center, 
population-based cohort in the world with insulin sensitivity measured by the 
euglycemic insulin clamp technique. Compared with indirect measurements and 
surrogate indices, this method directly measures whole body glucose disposal at a given 
level of insulinemia under steady-state conditions and is therefore regarded as the gold 
standard for measuring insulin resistance [181]. This partially compensated for the 
relatively modest sample size of the ULSAM study when analyzing insulin sensitivity 
as the main outcome in Study III and Study IV.  
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 4.5.2 Limitations 
To date, the SP2 study only contains cross-sectional data and this does not allow us to 
study the temporal relationship between exposure and outcome. This study also suffered 
from a moderate response rate (~60%). In 1998, non-participants were contacted and 
they were similar to the participants for the collected information including 
demographic, socio-economic status, diabetes and hypertension status. However, it is 
not known whether they differ from the participants in other aspects.   
 
The ULSAM study was based on elderly men of Northern European descent and hence, 
the generalizability to women, other age groups and other ethnicities is unknown. In 
addition, there was substantial loss to follow-up in the two most recent investigations, 
although this thesis only used studies with participation rate above 60%.   
 
In both SP2 and ULSAM studies, adiponectin was only measured once due to cost, 
research interest and other reasons. It would be desirable to have repeated measurements 
of adiponectin in future cohort studies, so as to discern changes over time and evaluate 
its temporal relationship with metabolic outcome of interest. Besides, in both studies, 
adiposity was assessed by anthropometry instead of direct techniques which are more 
accurate but were not feasible in our relatively large study. It would be ideal to measure 
adiposity in different depots and differentiate visceral abdominal fat from subcutaneous 
fat. As another limitation, in ULSAM dietary intake was not assessed at baseline. Due 
to this, in study IV we cannot rule out the possibility of confounding by unmeasured 
dietary factors or other unmeasured or imperfectly measured confounders.  
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 Underlying assumptions 
We proposed the path model in Study I based on previous research findings, but the 
studied risk factors might not be in the causal pathway towards insulin resistance or 
T2D. In addition, other adipokines and inflammatory markers may also contribute to 
ethnic differences in insulin resistance [182], but were not considered in our study.  
 
In Study II, we started with a GWAS to search for genetic variants associated with 
adiponectin levels. As is for all GWAS, this is based on the ‘common disease common 
variants’ assumption. We did identify CDH13 and a few other loci strongly associated 
with total and HMW adiponectin, but rarer variants (minor allele frequency [MAF] < 
1%) are unlikely to be captured by the GWAS approach due to a lack of statistical 
power.  
  
The choice of the instrumental variables and the fulfillment of the assumptions of the 
Mendelian randomization are critical in Study III. ADIPOQ is the most established gene 
influencing adiponectin levels and genetic variation in ADIPOQ affects adiponectin 
production without affecting insulin sensitivity in other known ways. Therefore, by 
focusing on ADIPOQ, concerns over the strength and potential pleiotropic effects of the 
instrument could largely be eliminated. 
 
For study IV, our longitudinal assessment of selenium as an exposure in relation to 
glucometabolic profiles and diabetes risk was based on serum selenium measured at 
baseline, which assumes that this single measurement reflects dietary selenium intake 
over the long follow-up years. Even though serum selenium is a good indicator of long-
term dietary selenium intake, it is still desirable to have repeated sampling to minimize 
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 the possibility of residual confounding due to substantial changes in individual intake of 
this element.  
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 5 CONCLUSIONS 
 
I. Mediators of ethnic differences in insulin resistance differed markedly 
depending on the ethnic groups compared. General adiposity explained the 
difference in insulin resistance between Chinese and Malays, whereas 
abdominal fat distribution, inflammation, and unexplained factors 
contributed to excess insulin resistance in Asian Indians as compared with 
Chinese and Malays. Interventions targeting excess weight gain can reduce 
ethnic disparities in insulin resistance among Asian Indians, Chinese and 
Malays.  
II. A genetic variant in CDH13 explains a substantial part of variation in 
HMW adiponectin levels in East Asian populations. However, this effect 
of CDH13 on circulating HMW adiponectin levels did not appear to 
translate into effects on insulin-resistance related metabolic traits, 
suggesting that compensatory mechanisms exist that lead to greater 
‘adiponectin sensitivity’. 
III. Genetically determined adiponectin levels influence insulin sensitivity to 
the same degree as the observed epidemiological associations. The 
observed association between higher adiponectin levels and increased 
insulin sensitivity is likely to represent a causal relationship. 
IV. No effect of selenium intake on insulin sensitivity, insulin secretion, or risk 
of type 2 diabetes was identifiable in older Swedish men. Taken together 
with prior studies including randomized clinical trials, the body of 
evidence argues against a role for selenium supplementation as a broad 
approach to prevent diabetes in the older population. 
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 6 FUTURE PERSPECTIVES 
6.1 Clinical utility of adiponectin as a biomarker 
Clinical trials usually involve substantial investment of resources. Validated 
biomarkers, when used in clinical studies, can help detect the efficacy of the drug 
early (for example, in stage I or stage II) that would otherwise only be known at late 
stages and thus reduce unnecessary cost. In addition, a good predictive biomarker 
could aid in the selection of patients to treat [183].  
 
Thiazolidinediones (TZDs) are synthetic ligands of PPAR-γ that have been widely 
used to treat diabetes [184] and many studies have shown that adiponectin levels 
increased in response to TZD treatment [21, 185]. Thus adiponectin could be viewed 
as a promising biomarker of PPAR–γ activation.  
 
Despite the robust inverse association of adiponectin with insulin resistance and T2D, 
current research largely focuses on pathogenesis of this protein and studies on the 
clinical utility of adiponectin in predicting the risk of T2D are still lacking. Because 
adiponectin correlates well with established metabolic risk factors of T2D [91, 96], it 
remains to be assessed in a formal statistical approach whether adiponectin improves 
risk prediction in addition to existing predictors in a cost-effective manner.   
 
Adiponectin has also been studied as a biomarker for gestational diabetes (GDM). 
Since the placenta does not produce adiponectin, plasma adiponectin which solely 
comes from the adipose tissue is an independent marker of maternal adipose 
homeostasis [186]. In a study involving 445 pregnant women, decreased maternal 
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 adiponectin levels positively correlated with GDM diagnosed in the second trimester 
and was proposed to be a potential early marker of susceptibility to GDM [187].  
 
In view of adiponectin’s anti-diabetic property, interestingly and paradoxically, 
elevated adiponectin levels have been associated with increased risk of all-cause and 
cardiovascular mortality for individuals at-risk, for example, elderly people [188], 
those with renal diseases [189], and heart failure [190, 191]. It is possible that 
adiponectin levels increase in response to vascular stress as a compensatory effect or 
due to adiponectin resistance, but further studies are needed to better understand this. 
Therefore, the effect of adiponectin on cardiovascular diseases should be interpreted 
with caution at the moment.  
 
6.2 Further characterization of the causality between adiponectin and insulin 
sensitivity 
Our results in Study III support the hypothesis that adiponectin levels are causally 
related to the degree of insulin sensitivity in humans. However, the role of adiposity in 
the relationship between adiponectin and insulin sensitivity is debatable. The degree of 
adiposity is associated with both adiponectin levels and insulin sensitivity [91, 175, 192] 
and thus could confound the adiponectin-insulin sensitivity relationship. What we 
observed in Study III was attenuated associations of the SNPs and insulin sensitivity 
with adjustment for adiposity, which does not support a role of adiposity as a 
confounder, but instead implies it as a partial mediator for the relationship between 
adiponectin and insulin sensitivity. Previous studies also suggested that adiponectin 
influenced insulin sensitivity independent of adiposity [22, 96]. As proposed by 
Kadowaki and et al., obesity caused by environmental risk factors could interact with 
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 genetic factors leading to reduced adiponectin levels, which in turn plays a role in the 
development of insulin resistance, T2D and metabolic disease [98]. Due to limited 
statistical power, we were not able to fully explore the role of adiposity in the causal 
effect of adiponectin on insulin sensitivity, but suggested it as a partial mediator which 
might work by antagonizing the secretion of pro-inflammatory cytokines through 
reduced adiposity.  
 
Therefore, in order to establish causality, further studies on the inter-relationship 
between adiposity, adiponectin and insulin sensitivity are warranted. 
 
6.3 Adiponectin as a therapeutic target in diabetes treatment 
Experimental studies have provided convincing evidence for an effect of adiponectin 
on insulin sensitivity when adiponectin levels are altered in transgenic and 
adiponectin-deficient models [193, 194]. In a recent study using adiponectin knockout 
mice, high-fat diet and adiponectin supplementation were associated with changes in 
lipid, carbohydrate and amino acid metabolomic profiles in skeletal muscle. 
Conversely, the replenishment of adiponectin reversed euglycemic clamp-measured 
insulin sensitivity by a certain degree [195].  
 
One of the logical strategies for the treatment of insulin resistance and T2D is to 
increase adiponectin levels. Direct administration of adiponectin is difficult, but 
therapeutic agent that target adiponectin signaling could achieve this. For example, the 
anti-diabetic drug TZDs, are known to ameliorate insulin resistance partly by 
increasing adiponectin levels through transcriptional activation [98]. In addition, 
lifestyle and surgical interventions with weight loss have also led to a significant 
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 increase of adiponectin concentration [196, 197]. Motivated by our results in Study III, 
if a causal relationship exists between adiponectin and insulin sensitivity, dietary 
factors that affect adiponectin levels would be of interest, as already shown for coffee 
[198] and alcohol [199] in RCTs. Another viable strategy to enhance insulin 
sensitivity is to up-regulate adiponectin receptors and this includes an approach to 
develop receptor agonists that can mimic adiponectin actions. Some studies have 
reported proteins or short-peptides that could function as adiponectin receptor agonist 
[200, 201] and further research in this area is promising.  
 
Compared with currently used anti-diabetic drugs, novel drugs that may enhance the 
effect of adiponectin possess several potential advantages [22]. For example, in 
addition to its anti-diabetic and lipid-lowering effects, adiponectin also has an anti-
inflammatory property which potentially prevents atherogenesis, although this still 
need to be supported by further evidence given the association between adiponectin 
and cardiovascular disease death. Moreover, anti-diabetic drugs commonly incur 
weight gain and adiponectin seems to avoid this. However, our findings on CDH13 in 
Study II may be a cautionary tale for drug development that not all ways to increase 
adiponectin are beneficial, especially when it concerns the vascular systems. 
 
Future research on the therapeutic potentials of adiponectin could also focus on the 
changes of metabolic profiles in relation to the presence/alteration of adiponectin, 
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Can body fat distribution, adiponectin levels and inﬂammation
explain differences in insulin resistance between ethnic Chinese,
Malays and Asian Indians?
H Gao1,2, A Salim1, J Lee1, ES Tai1,3,4 and RM van Dam1,3,5
OBJECTIVE: Diabetes in Asia constitutes approximately half of the global burden. Although insulin resistance and incidence of
type 2 diabetes differ substantially between ethnic groups within Asia, the reasons for these differences are poorly understood.
We evaluated to what extent body fatness, adiponectin levels and inﬂammation mediate the relationship between ethnicity
and insulin resistance in an Asian setting.
DESIGN: Cross-sectional population-based study.
SUBJECTS: In total, 4136 adult Chinese, Malays and Asian Indians residing in Singapore.
MEASUREMENTS: Insulin resistance was assessed using homeostasis model assessment (HOMA-IR) and systemic inﬂammation
by C-reactive protein (CRP). Data were analyzed using path analysis.
RESULTS: HOMA-IR was highest in Asian Indians, intermediate in Malays and lowest in Chinese (Po0.001). The difference in
HOMA-IR between Malays and Chinese disappeared after adjusting for body mass index (BMI). For the comparison of Asian
Indians with Chinese, the association between ethnicity and HOMA-IR was mediated by BMI (men: 32.9%; women: 48.5%),
BMI-adjusted waist circumference (men: 6.1%; women: 3.5%), and CRP (men: 5.1%; women: 5.6%), and unidentiﬁed factors
(men: 47.2%; women: 26.5%). Part of the mediating effects of body fatness was indirect through effects of body fatness on
CRP and adiponectin concentrations.
CONCLUSION: Mediators of ethnic differences in insulin resistance differed markedly depending on the ethnic groups
compared. General adiposity explained the difference in insulin resistance between Chinese and Malays, whereas abdominal fat
distribution, inﬂammation and unexplained factors contributed to excess insulin resistance in Asian Indians as compared with
Chinese and Malays. These ﬁndings suggest that interventions targeting excess weight gain can reduce ethnic disparities in
insulin resistance among Asian Indians, Chinese and Malays.
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INTRODUCTION
Diabetes in Asia currently constitutes approximately half of the
global burden and the diabetes prevalence in Asia is expected to
increase rapidly to 4200 million people by 2030 (Western Paciﬁc
and South-East Asia regions combined).1 At the same time, ethnic
disparities in diabetes prevalence exist between ethnic groups in
Asia. For example, Asian Indians in Singapore have a substantially
higher prevalence of diabetes mellitus (15.9%) than Malays
(11.4%) and Chinese (6.4%).2
Insulin resistance is closely associated with type 2 diabetes
mellitus (T2DM) and marked differences in insulin resistance have
been observed between ethnic groups.3 Asians, and particularly
Asian Indians, have been shown to be more insulin resistant for a
given degree of adiposity as compared with whites.4 Substantial
differences in insulin resistance may also exist between ethnic
groups in Asia, with Asian Indians having worse insulin resistance
and glucose tolerance than Chinese and Malays.5 However, the
reasons for these ethnic differences are poorly understood.
Obesity is a well-established risk factor for insulin resistance and
T2DM and abdominal fat in particular is closely related to insulin
resistance.6 Asian ethnic groups differ from each other in body
composition7 and this may contribute to ethnic differences in
insulin resistance. However, this does not fully explain the ethnic
difference in insulin resistance. In Singapore, for example, Malays
have the highest levels of adiposity, but not the highest levels of
insulin resistance.5
Adipokines, which are cytokines secreted by adipose tissue, and
inﬂammation are key contributors to insulin resistance.8 Adipo-
nectin is an adipokine for which circulating levels decrease with
increasing adiposity and are consistently inversely associated
with insulin resistance and risk of T2DM.9 C-reactive protein (CRP)
is an acute-phase protein that serves as an important marker
of systemic inﬂammation and is related to insulin resistance.10
Asian Indians have been shown to have lower adiponectin
levels4,9 and higher CRP levels11,12 as compared with whites.
However, so far no study has evaluated whether adiponectin or
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CRP can explain differences in insulin resistance between ethnic
groups in Asia.
The objective of this study is to use path analysis to evaluate to
what extent body fatness, adiponectin levels, CRP and their
interconnections mediate the relation between ethnicity and
insulin resistance in an Asian context.
SUBJECTS AND METHODS
Study population
We conducted a cross-sectional analysis based on data from the Singapore
Prospective Study Project (SP2). Participants of SP2 previously participated
in cross-sectional studies carried out from 1982 to 1998, namely the
Thyroid and Heart Study (1982--1984),5 the National Health Survey
(1992),13 the National University of Singapore Heart Study (1993--1995)5
and the National Health Survey (1998).14 Each of these studies was based
on a random sample of Singapore residents with the minority groups
(Malays and Asian Indians) being over-sampled. From 2003 to 2007, all
10 747 participants from these studies were invited to participate in this
study. Of these, 559 subjects had deceased at the time of study,
6 emigrated and 102 were excluded because of errors in their identity
card numbers. Qualiﬁed subjects were contacted to administer a
questionnaire at their homes and 30 of the 7774 contactable participants
refused to participate. The remainder was invited to a health screening,
which 5164 subjects attended. For the current analysis, we excluded
13 subjects with missing anthropometric data, 664 subjects who had a
history of diabetes mellitus, cancer or cardiovascular diseases (including
coronary heart disease, stroke, and transient ischemic attack) and 2 women
who were pregnant. Of the remaining 4485 participants, blood samples
were available for 4461 subjects of whom we excluded 296 because of
missing data for homeostatic model assessment-insulin resistance (HOMA-
IR), CRP, or adiponectin concentrations. In addition, we excluded 1 subject
without gender information, 2 subjects whose ethnicity was not Chinese,
Malay or Indian, and 26 subjects missing smoking or alcohol information.
As a result, we included 4136 subjects in the data analysis (online
Supplementary Figure 1).
Ethics approval was obtained from the Singapore General Hospital and
the National University Hospital Institutional Review Boards.
Data collection
Height was measured using a wall mounted measuring tape and weight
was measured using a digital scale. Waist circumference was measured
midway between the lower rib margin and the iliac crest and hip
circumference was measured at the widest point over the greater
trochanters. Body mass index (BMI) was computed as weight (kg) divided
by height square (m2). Demographic data including ethnicity and lifestyle
information such as smoking status and alcohol intake were assessed using
standardized questionnaires. Total physical activity was measured using a
locally validated questionnaire covering activity in four domains (house-
hold, occupational, leisure-time and transport).
Fasting blood samples were analyzed for glucose using enzymatic
methods (ADVIA 2400, Siemens, Germany), for insulin using micro-particle
enzyme immunoassay (Abbot AXSYM, Abbott Laboratories, Chicago, IL,
USA), for high-sensitivity CRP using an immuno-turbidimetric assay (Roche
Diagnostics, Rotkreuz, Switzerland) and for total and high molecular
weight adiponectin using an enzyme-linked immunosorbent assay (Sekisui
Medical Co. Ltd, Tokyo, Japan). Insulin resistance was assessed by HOMA-IR
calculated as: (fasting insulin in mIUl--1 fasting glucose in mmoll--1)/22.5.15
The intra and inter batch coefﬁcient of variations percent were as follows:
glucose (2.5, 6.6), insulin (4.0, 4.5), total adiponectin (18.1, 15.9), high
molecular weight adiponectin (6.8, 18.3) and CRP (0.6--1.3, 2.3--3.1).
Statistical analysis
Outliers were deﬁned as observations beyond the mean±4 s.d. and were
truncated to the cutoff values. For normally distributed variables, one-way
analysis of variance was used to examine differences in characteristics
according to ethnicity and pair-wise differences were examined using
Student’s t-tests. For non-normally distributed variables, the Kruskal--Wallis
equality-of-populations rank test was used to examine differences
according to ethnicity and pair-wise differences were examined using
two-sample Wilcoxon rank-sum (Mann--Whitney) tests. Chi-square tests
were used to compare proportions of categorical variables.
To reﬂect body fat distribution independent of overall body fatness, we
calculated BMI-adjusted waist and hip circumferences using the residual
method. BMI-adjusted waist circumference (waistR) was derived by
regressing waist circumference on BMI and saving the residuals as a new
variable. BMI-adjusted hip circumference (hipR) was derived in a similar way.
Pearson’s correlation coefﬁcients with age adjustment were calculated
for selected anthropometric variables and metabolic risk factors. Multiple
linear regression analysis was used to assess the associations between
ethnicity and insulin resistance and the extent to which this association
could be explained by anthropometric variables and CRP and adiponectin
concentrations.
Path analysis is an extension of regression analysis that simultaneously
performs a series of regression analyses in complex networks. It is suitable
to elucidate complicated inter-relationships between exposure variables of
interest, multiple potential mediators and health outcomes.16,17 In our
study, path analysis was carried out to evaluate mediators of pair-wise
ethnic differences in insulin resistance. A hypothetical model was
proposed based on previous biological knowledge of the relationships
between ethnicity, insulin resistance, adipokines and inﬂammation. We
performed path analysis based on the full hypothesized model and paths
with nonsigniﬁcant path coefﬁcients were removed to form a reduced
model. Path analysis was performed again based on the reduced model. By
multiplying the path coefﬁcients, effect sizes (total, direct and indirect)
were calculated and were also presented as percentages of the total effect
of ethnicity on insulin resistance. Model ﬁt in comparison with the
saturated and independent models was assessed based on the Bayesian
Information Criterion.
Amos 18.0(ref. 18) was used to run the path analysis and STATA/SE 10.0
(Stata Corporation, College Station, TX, USA) for other analyses. All statistic
tests were two-sided and the level of signiﬁcance was set at a¼ 0.05.
RESULTS
Risk factors for insulin resistance according to ethnicity
Table 1 shows the characteristics of the study population
according to ethnicity. The degree of insulin resistance as reﬂected
by HOMA-IR was highest in Asian Indians, intermediate in Malays
and lowest in Chinese. CRP was higher in Asian Indians and Malays
than in Chinese, and Indian women had particularly high levels
of CRP. Total and high molecular weight adiponectin were
highest in Chinese and lowest in Asian Indians when women
were compared, but these ethnic differences were less marked
among men.
BMI was lowest in the Chinese and was similar for Malays and
Asian Indians. However, Asian Indians had a larger waist-to-hip ratio
(WHR) and a larger waist circumference than Malays and Chinese.
WHR was not signiﬁcantly different between Chinese and Malay
men. Chinese had the lowest physical activity level for both men
and women. Malay men were more likely to be cigarette smokers
than Indian or Chinese men, but were less likely to consume alcohol.
Few women smoked cigarettes or consumed alcohol.
Correlations between anthropometric and metabolic risk factors
Age-adjusted correlation coefﬁcients for the key variables in this
study are shown in Table 2. Adiponectin, CRP and HOMA-IR all had
a higher correlation with BMI and waist circumference as
compared with WHR. Waist circumference, but not hip circumfer-
ence, remained substantially correlated with adiponectin, CRP and
HOMA-IR after adjustment for BMI. We therefore focused on BMI
and BMI-adjusted waist circumference for subsequent analyses.
Furthermore, we used total adiponectin instead of high molecular
weight-adiponectin for further analysis because the two were
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highly correlated (r¼ 0.89 in men and 0.93 in women) and total
adiponectin had a higher correlation with HOMA-IR.
Association between ethnicity and insulin resistance
We examined the association between ethnicity and insulin
resistance and potential mediators using linear regression analysis
(Table 3). Ethnic difference in insulin resistance between Malays
and Chinese disappeared after adjusting for BMI and waist or only
BMI (result not shown). The difference in HOMA-IR between Asian
Indians and Chinese was also reduced after adjusting for BMI and
waist, but remained statistically signiﬁcant. Further adjustment for
adiponectin and CRP levels explained slightly more of the ethnic
difference in HOMA-IR.
Path analysis of the mediating factors for ethnic differences
in insulin resistance
The hypothetical model (online Supplementary Figure 2A) was
based on prior knowledge of the inter-relationships between the
variables in this study. The ethnic differences in insulin resistance
could be direct as represented by the arrow pointing directly from
ethnicity to insulin resistance. Alternatively, the differences could
be indirect, mediated by body fatness alone or through
adiponectin or CRP. The indirect effect could also bypass
body fatness, indicating mediation through adiponectin or CRP
independent of body fatness. In a simpliﬁed model (online
Supplementary Figure 2B) only key variables are shown.
Figure 1 shows the results of path analysis carried out for each
pair of ethnic groups and separately for men and women. We
created reduced models by removing nonsigniﬁcant paths, which
are represented by the dotted arrows in the ﬁgure. Based on
Bayesian Information Criterion, each of the reduced models had a
better model ﬁt as compared with respective saturated model.
The effect of ethnicity on insulin resistance when Malays were
compared with Chinese could be fully explained by the
considered mediators as indicated by the nonsigniﬁcant direct
path between ethnicity and HOMA-IR (Figures 1a and b). In
addition to body fatness, CRP, but not adiponectin, also
contributed independently to the greater insulin resistance in
Asian Indians as compared with Chinese (Figures 1c and d).
For example, in women, the mediating role of CRP was
represented by the path from ethnicity to CRP with a path
coefﬁcient 0.15 and the path from CRP to HOMA-IR with a path
coefﬁcient 0.11. Multiplying 0.15 and 0.11 gave the indirect effect
of ethnicity on HOMA-IR through CRP. In agreement with the
similar BMI of Asian Indians and Malays, the nonsigniﬁcant path
between ethnicity and BMI suggested that the difference in insulin
resistance between Asian Indians and Malays was not mediated by
BMI (Figures 1e and f). Instead, abdominal adiposity contributed to
the greater insulin resistance in Asian Indian men and women as
compared with their Malay counterparts. In women, but not in
men, independent effects of adiponectin and CRP also contrib-
uted to this ethnic difference in insulin resistance.
Table 4 shows the effect sizes of ethnicity on insulin resistance
including the direct effect, indirect effect through potential
mediators, and the total effect, which is the sum of the direct
and indirect effects. The higher degree of insulin resistance in
Malays as compared with Chinese was fully mediated by BMI, with
BMI alone accounting for 85.2% of the total effect in men, 81.8% in
women and the rest mediated further through adiponectin and
CRP. Interestingly, when Malay men were compared with Chinese
men, BMI-adjusted waist had a negative effect, suggesting a
difference in fat distribution had a beneﬁcial effect on insulin
resistance in Malays. Similarly, the negative independent effect of





















BMI, kgm--2 0.84 0.83 0.30 0.04 0.00 0.34 0.34 0.56 0.58
Waist, cm 0.81 0.82 0.54 0.51 0.22 0.35 0.35 0.53 0.56
Hip, cm 0.72 0.82 0.01 0.20 0.56 0.26 0.26 0.48 0.48
WHR 0.51 0.67 0.13 0.52 0.47 0.26 0.24 0.26 0.30
WaistR, cm 0.01 0.59 0.40 0.43 0.41 0.11 0.11 0.09 0.12
HipR, cm 0.01 0.32 0.69 0.35 0.57 0.04 0.03 0.03 0.01
Total adiponectin, mgml--1 0.32 0.31 0.20 0.30 0.09 0.05 0.93 0.36 0.42
HMW adiponectin, mgml--1 0.27 0.27 0.17 0.25 0.08 0.04 0.89 0.35 0.39
CRP, mg l--1 0.37 0.36 0.28 0.28 0.11 0.02 0.24 0.18 0.47
HOMA-IR 0.59 0.56 0.43 0.44 0.15 0.00 0.37 0.31 0.35
Abbreviations: BMI, body mass index; CRP, C-reactive protein Hip, hip circumference; HipR, hip circumference residual (adjusted for BMI); HMW adiponectin,
high-molecular-weight adiponectin; HOMA-IR, homeostatic model assessment-insulin resistance; Waist, waist circumference; WaistR, waist circumference
residual (adjusted for BMI); WHR, waist-to-hip ratio. Correlation coefficients with a magnitude 40.04 had a P-value o0.05 for both males and females. The
values of total adiponectin, HMW-adiponectin, CRP and HOMA-IR were log-transformed. Correlation coefficients for male participants are shown in the lower
half of the table, and that for female participants are in the upper half.
Table 3. Associations between ethnicity and the HOMA-index of
insulin resistance based on linear regression analysis with and without
adjustment for potential intermediates
Male Female
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3
Chinese Ref. Ref. Ref. Ref. Ref. Ref.
Malay 0.17 0.01 0.01 0.28 0.05 0.02
Asian Indian 0.48 0.25 0.23 0.50 0.17 0.15
BMI, kgm--2 0.58 0.48 0.56 0.42




CRP, mg l--1 0.11 0.13
R2 0.06 0.38 0.42 0.12 0.38 0.44
Abbreviations: BMI, body mass index; CRP, C-reactive protein; HOMA,
homeostatic model assessment; WaistR, waist circumference residual
(adjusted for BMI). Results were based on linear regression analysis
with continuous independent variables and HOMA-IR expressed per 1 s.d.
increment except for ethnicity variables. The values of adiponectin and
CRP were log-transformed. Model 1, unadjusted; Model 2, adjusted for BMI
and waistR; Model 3, further adjusted for adiponectin and CRP. Italic values
indicate statistically nonsignificant at a¼ 0.05 level.
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adiponectin in women suggests that after adjusting for body
fatness, Malay women experienced a beneﬁcial effect of higher
adiponectin levels on insulin sensitivity as compared with Chinese
women. In contrast, the difference in insulin resistance between
Asian Indians and Chinese was only partly explained by BMI alone
(32.9% in men and 48.5% in women). Differences in abdominal
Figure 1. Path coefficients in the reduced models for pair-wise ethnic comparisons of differences in insulin resistance. Path coefficients
generated by path analysis were labeled on each path. Nonsignificant paths that had been removed were represented by dotted arrows.
Covariates including age, alcohol, smoking and physical activity were not shown. The values of adiponectin, CRP and HOMA-IR were log-
transformed. (a) Malay men compared with Chinese men. (b) Malay women compared with Chinese women. (c) Indian men compared with
Chinese men. (d) Indian women compared with Chinese women. (e) Malay men compared with Indian men. (f ) Malay women compared with
Indian women. WaistR, waist circumference residual (adjusted for BMI).
Table 4. Contribution of potential mediating factors on the effects of ethnicity on the HOMA index of insulin resistance based on the reduced path
analysis model
Malays versus Chinesea Asian Indians versus Chinesea Asian Indians versus Malaysa

























Total effect 0.113 0.185 0.254 0.283 0.217 0.197
Direct effect 0.000 0.0 0.000 0.0 0.120 47.2 0.075 26.5 0.173 79.7 0.115 58.4
Indirect effect through 0.113 100.0 0.185 100.0 0.133 52.4 0.208 73.5 0.044 20.3 0.082 41.6
BMI alone 0.096 85.2 0.151 81.8 0.084 32.9 0.137 48.5 0.000 0.0 0.000 0.0
WaistR alone 0.008 6.7b 0.000 0.0 0.015 6.1 0.010 3.5 0.035 16.2 0.018 8.9
Adiponectin alone 0.000 0.0 0.020 10.6 0.000 0.0 0.000 0.0 0.000 0.0 0.025 12.8
BMI through adiponectin 0.012 10.9 0.028 15.3 0.010 4.0 0.023 8.2 0.000 0.0 0.000 0.0
WaistR through adiponectin 0.002 1.4 0.000 0.0 0.002 0.8 0.003 1.0 0.006 2.6 0.007 3.4
CRP alone 0.008 6.9 0.000 0.0 0.013 5.1 0.016 5.6 0.000 0.0 0.029 14.8
BMI through CRP 0.006 5.4 0.025 13.7 0.007 2.7 0.017 6.2 0.000 0.0 0.000 0.0
WaistR through CRP 0.001 0.7 0.000 0.0 0.002 0.8 0.001 0.4 0.003 1.6 0.003 1.7
Abbreviations: BMI, body mass index; CRP, C-reactive protein; WaistR, waist circumference residual (adjusted for BMI). aThe ethnic group mentioned second in
each pair-wise comparison is used as the reference group. bThe minus sign is in accordance with the sign of the effect and indicates the effect is in the
opposite direction.
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adiposity, as reﬂected by BMI-adjusted waist, explained more of
this ethnic difference (6.1% in men and 3.5% in women). It
appeared that adiponectin’s mediating role was not independent
from BMI and abdominal adiposity. Comparing Asian Indians with
Malays, abdominal adiposity instead of general adiposity con-
tributed to the greater insulin resistance in Asian Indians as
compared with their Malay counterparts, with the BMI-adjusted
waist alone accounting for 16.2% of the total effect in men and
8.9% in women. Substantial independent mediating effects by
adiponectin (12.8%) and CRP (14.8%) were observed in women,
but not in men.
DISCUSSION
Our study examined the mediating effects of body fatness,
adiponectin and CRP in the differences of insulin resistance
between three major ethnic groups in Singapore. Asian Indians
were most insulin resistant, Malays had intermediate levels, and
Chinese were the least insulin resistant. The role of mediators
differed by ethnic comparison. The difference in insulin resistance
between Malays and Chinese appeared to be fully mediated by
the greater general body fatness of the Malays. In contrast, fat
distribution, inﬂammation and unidentiﬁed factors also contrib-
uted to excess insulin resistance in Asian Indians as compared
with Chinese and Malays.
BMI alone accounted for a substantial proportion of the
observed difference in insulin resistance between Asian Indians
and Chinese. A smaller proportion was attributable to effects of
adiposity through adiponectin and CRP and effects of CRP
independent of BMI. The difference in insulin resistance between
Asian Indians and Malays was partly accounted for by abdominal
fat distribution but not by BMI. A substantial independent
contribution of adiponectin and CRP to Indian-Malay differences
in insulin resistance was observed in women, but not in men.
Effects of abdominal adiposity on adiponectin levels also
appeared to contribute to the difference in insulin resistance
between Indians and Malays. This observation reﬂects the
association between abdominal fat distribution, measured as
BMI-adjusted waist circumference, and lower adiponectin levels in
our study. In line with this ﬁnding, results from previous studies in
Asian populations suggest that intra-abdominal fat may reduce
adiponectin levels to a greater extent than subcutaneous fat,19--21
although other studies did not support this.22,23
Previous studies on ethnic differences in insulin resistance
mainly compared various ethnic groups with whites who have
consistently been observed to have the lowest level of insulin
resistance among major ethnic groups for a given degree of
adiposity.24--26 Among the few studies that included multiple
Asian ethnic groups, two Canadian studies3,27 found higher insulin
resistance in Asian Indians than in Chinese, which is consistent
with our results. The results of one of these studies27 suggested
that the differences in total body fat mass could explain the higher
insulin resistance in Asian Indians as compared with Chinese. In our
study, the difference in insulin resistance between Asian Indians
and Chinese partly remained after adjusting for BMI and waist
circumference. This discrepancy in results might be due to the use
of anthropometry instead of direct body fat measurements in our
study or the relative small sample size in the previous study.
Insulin resistance in Asian Indians has been extensively studied,
because this group is known to be highly susceptible to
developing T2DM.24,28--31 Several studies have shown greater
insulin resistance in Asian Indians as compared with whites for a
given BMI.26,32 For the same BMI, Asian Indians tend to have a
higher level of body fatness than whites.33 However, several
studies using direct measurements of body fatness showed that
Asian Indians were more insulin resistant than whites for the same
level of total body fat.27,31 Having an abdominal fat distribution
appears to contribute to the greater insulin resistance in Asian
Indian.6,34,35 In a study in the United Kingdom, Asian Indians had a
larger WHR and were also more insulin resistant at every level of
WHR as compared with whites.28 Differences in adipocyte cell
size31 and a higher ratio of total body fat to lean mass27 have also
been suggested to contribute to greater insulin resistance in Asian
Indians. Furthermore, Asian Indians have been shown to have a
lower adiponectin levels3,24,26,29,30,36 and higher CRP levels30,32,37
as compared with whites independent of BMI. In addition, dietary
factors may contribute to the higher susceptibility of Asian Indians
to developing type 2 diabetes. For example, it has been suggested
that poor maternal vitamin B12 status during pregnancy, which is
common in Indian populations, contributes to a higher risk of type
2 diabetes in the offspring.38,39
Several studies in the United States have also demonstrated
greater insulin resistance in East Asians as compared with whites
for a given BMI.25,40,41 For example, Chinese-American and
Japanese-American women were more insulin resistant than
white women after adjusting for waist circumference in a large
cross-sectional study.40 Asian Americans have also been shown to
be more likely to develop T2DM than whites after adjustment for
BMI.42 Lower adiponectin levels in East Asians may contribute to
these ethnic differences in insulin resistance and T2DM. Lower
adiponectin levels have been reported in Japanese men as
compared with white American men despite lower levels of
adiposity43 and in Korean men and women as compared with
BMI-matched whites.44 In a Canadian study, Chinese had lower
adiponectin levels than whites in both men and women after
adjusting for waist circumference.3
In our study, we found a higher degree of insulin resistance and
unfavorable metabolic proﬁles in Malays as compared with
Chinese, whereas Malays were less insulin resistant as compared
with Asian Indians. Ethnic Malays represent millions of people
from different Southeast Asian Island populations including
Malaysians, Filipinos and Indonesians who are experiencing a
rapid increase in chronic disease burden.45 Studies have demon-
strated that overall ethnic Chinese from East Asia and Malays from
Southeast Asia were genetically closer than Asian Indians.46 More
speciﬁcally, although culturally distinct, Malays in Singapore had a
greater genetic similarity with Chinese than Asian Indians.46,47
Greater general adiposity of Malays as compared with Chinese
explained their greater insulin resistance in our study and
targeting excess weight gain in Malays should have high priority
in public health efforts for chronic disease prevention.45
Compared with ordinary regression analysis, path analysis has
the advantage that it allows examination of the potential
causal processes underlying an observed relationship and to
estimate the relative importance of alternative paths of inﬂuence
in a complicated system.16 Particularly, path analysis also
allows a disentanglement of the direct and indirect effects,
which can provide more insights into the complicated relation-
ships.
Our study had several limitations that need to be considered.
First, adiposity was assessed by anthropometry instead of direct
techniques, which are more accurate but were not feasible in our
relatively large study. Therefore, we were not able to measure
adiposity in different depots and differentiate visceral abdominal
fat from subcutaneous fat. Second, insulin resistance was
measured by HOMA-IR, which is a reliable indicator,46 but still a
proxy as compared with the ‘gold standard’, the hyperinsulinemic
euglycemic clamp. Third, the hypothetical model was proposed
based on previous research ﬁndings, but the studied risk factors
might not be in the causal pathway toward insulin resistance
or type 2 diabetes. The cross-sectional study design did not allow
us to establish temporal relationships. Finally, other adipokines
and inﬂammatory markers such as retinol binding protein-4,
interleukin-6, leptin and resistin may contribute to ethnic
differences in insulin resistance and were not measured in our
study.47
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In summary, our results suggest that the higher degree of
insulin resistance in Malays compared with Chinese was due to
general adiposity. When Asian Indians were compared with
Chinese, greater general adiposity, abdominal fat distribution,
and higher CRP independent of adiposity appeared to contribute
to the greater insulin resistance in Asian Indians. These ﬁndings
indicate that determinants of differences in insulin resistance
between Asian ethnic groups differ markedly according to speciﬁc
ethnic groups that are compared. A large proportion of the
difference in insulin resistance between Asian Indians and Chinese
and Asian Indians and Malays remained unexplained. Thus, more
research is needed to identify additional contributors to the
greater insulin resistance including genetic and epigenetic
factors48 in Asian Indians who are at high risk for T2DM. However,
our results do suggest that interventions that reduce generalized
and abdominal adiposity and to a lesser extent those that reduce
generalized inﬂammation and increase adiponectin, can address
ethnic disparities in insulin resistance among Chinese, Malays
and Asian Indians.
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Supplementary Figure 1. Flow chart of the subjects included in the Singapore 
Prospective Study Program, 2004–2007. a Height, weight, waist circumference, hip 
circumference. b Pre-existing diabetes, cancer, cardiovascular disease (coronary heart 
disease, stroke and transient ischemic attack). c Homeostatic model assessment-insulin 
resistance, C-reactive protein, total adiponectin, high-molecular-weight adiponectin. 
  
Supplementary Figure 2. Diagrams for the model used in path analysis of the mediating 
factors for the relation between ethnicity and insulin resistance. A) Complete path 
diagram for the hypothetical model. Body mass index (BMI) and the BMI-adjusted waist 
circumference (waistR) were chosen based on previous analysis results to represent body 
fatness in the model, total adiponectin level was used to represent adipokines, and  
inflammation was represented by C-reactive protein level. Covariates considered 
included age, alcohol, smoking and physical activity. One-way arrows represent causal 
effects and two-way arrows represent correlations between the variables. Endogenous 
variables which are variables having at least one incoming arrow were depicted with 
associated error terms. B) Simplified path diagram where only key variables in this study 
was shown.  
   
STUDY II 
Genetic Variation in CDH13 Is Associated With Lower
Plasma Adiponectin Levels but Greater Adiponectin
Sensitivity in East Asian Populations
He Gao,1,2,3 Yu-Mi Kim,4 Peng Chen,1 Michiya Igase,5 Ryuichi Kawamoto,6 Mi Kyung Kim,7
Katsuhiko Kohara,5 Jeannette Lee,1 Tetsuro Miki,5 Rick Twee-Hee Ong,1 Hiroshi Onuma,8
Haruhiko Osawa,8 Xueling Sim,9,10 Yik Ying Teo,1,2,11 Yasuharu Tabara,12 E Shyong Tai,1,13,14
and Rob M. van Dam1,2,13
Variants in the CDH13 gene have been identiﬁed as determinants
of blood levels of adiponectin, an insulin-sensitizing adipokine.
However, their association with other metabolic risk factors
remains unclear. We examined variants at CDH13 in relation to
total and high-molecular-weight (HMW) adiponectin using data
from a genome-wide association study performed in 2,434 Singa-
porean Chinese with replication in up to 3,290 Japanese and 1,610
Koreans. The top signal rs4783244 in CDH13 showed strong asso-
ciations with total adiponectin (standardized b [b] = 20.34, 95%
CI 20.38 to 20.30, P = 2.0 3 10270), HMW adiponectin (b =
20.40, 95% CI 20.43 to 20.36, P = 1.1 3 102117), and the
HMW-to-total adiponectin ratio (b = 20.44, 95% CI 20.49 to
20.40, P = 3.2 3 10283). In the replication study, this single
nucleotide polymorphism explained 4.1% of total and 6.5% of
HMW adiponectin levels. No association was observed between
rs4783244 and metabolic traits associated with insulin resistance
before adjustment for HMW adiponectin levels. After adjustment
for HMW adiponectin levels, the minor allele was associated with
lower BMI (b = 20.15, 95% CI 20.19 to 20.11, P = 3.5 3 10214),
homeostasis model assessment-insulin resistance index (b =
20.16, 95% CI 20.20 to 20.12, P = 9.2 3 10216), and triglycerides
(b = 20.16, 95% CI 20.19 to 20.12, P = 1.3 3 10216) and with
higher HDL (b = 0.16, 95% CI 0.12 to 0.19, P = 2.1 3 10217).
CDH13 variants strongly inﬂuence plasma total and HMW adi-
ponectin levels in East Asian populations but appear to alter
adiponectin sensitivity, resulting in better metabolic health than
expected based on circulating adiponectin levels. Diabetes
62:4277–4283, 2013
Adiponectin is a protein abundantly secreted byadipose tissue with anti-inﬂammatory (1) andinsulin-sensitizing properties (2). Blood levels ofadiponectin are inversely associated with obe-
sity (3), insulin resistance (4), and risk of type 2 diabetes
(5). Genetic determinants account for a substantial pro-
portion of the variation in plasma adiponectin (6), and
genome-wide association studies (GWAS) have identiﬁed
several loci associated with plasma adiponectin (7–10).
Adiponectin exists in several forms in the blood. High-
molecular-weight (HMW) adiponectin has shown stronger
associations with insulin sensitivity and suppression of
hepatic glucose production than other forms of adipo-
nectin (11). Few existing GWAS have included both total
and HMW adiponectin and compared the associations.
This may be pertinent because CDH13 has been identiﬁed
to code for T-cadherin, a speciﬁc receptor for hexameric
and HMW adiponectin (12). In addition, the effects of
variants at the CDH13 locus on insulin resistance and
other metabolic risk factors remain unclear.
We therefore conducted a GWAS of total and HMW
adiponectin in a Singaporean Chinese population. With an
extension to other East Asian populations, we also ex-
amined the effects of CDH13 variants in relation to insulin
resistance and associated metabolic traits.
RESEARCH DESIGN AND METHODS
Study populations. Participants from several studies conducted in East
Asians were used for the analyses presented here. These included 2,282 Chi-
nese living in Singapore from the Singapore Prospective Study Program (SP2)
(13), 3,290 Japanese from the Nomura study (14) and the Ehime University
Hospital Antiaging Center (AAC) study (15), and 1,610 Koreans from the
Yangpyeong Cohort Study (16). Detailed descriptions of these studies are in-
cluded in the Supplementary Data.
Laboratory analyses and genotyping. Fasting blood samples were obtained
in all studies, and concentrations of total adiponectin, HMW adiponectin, and
metabolic variables were measured with acceptable coefﬁcients of variation.
Details of the methods used are included in the Supplementary Data. Insulin
resistance and b-cell function were calculated using homeostasis model
assessment-insulin resistance (HOMA-IR) and HOMA–b-cell function (HOMA-B)
indices.
Genotyping in SP2 was done on three different arrays (Illumina HumanHap
550, 610 Quad, and 1Mduov3 BeadChips; http://www.illumina.com). Details
on genotyping and quality control measures are included in the Supplemen-
tary Data. For replication, blood-derived genomic DNA of a Japanese and
Korean sample was used. The CDH13 single nucleotide polymorphism (SNP)
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rs4783244 was analyzed by a TaqMan probe assay (Applied Biosystems Co.,
Ltd., Foster City, CA) using commercially available primers and probes pur-
chased from the Assay-on-Demand system (C_10076301_10).
Statistical analysis. We standardized adiponectin and other metabolic vari-
ables to mean of 0 and variance of 1 to facilitate cross-study comparisons.
Multiple linear regression analysis, based on additive and general genetic
models, was used with different adiponectin forms and metabolic risk factors
(log-transformed if necessary) as the dependent variable, and genotype, age,
and sex were used as independent variables. In addition, for metabolic traits,
multivariable models that also included HMW adiponectin (or total adipo-
nectin) and BMI were evaluated. Results across studies were combined by
a ﬁxed-effect meta-analysis. Population structure in Singaporean Chinese was
assessed by principal component analysis. A Bonferroni-corrected threshold
a # 5 3 1028 was considered genome-wide signiﬁcant, and a # 0.005 was
used as a cutoff for the tests on rs4783244 and 10 metabolic variables (cal-
culated as 0.05/10). All tests were two-sided.
RESULTS
Characteristics of the participants in each study are sum-
marized in Table 1. Singaporeans were generally younger
than Japanese and Korean participants, whereas Koreans
had a higher BMI, higher triglyceride levels, higher HOMA-
IR, and lower HDL levels than the other populations. The
substantial differences in adiponectin levels among study
populations may be partly due to differences in laboratory
methods and have been addressed by standardization of
adiponectin levels in the data analysis. As expected, blood
adiponectin levels were inversely correlated with insulin
resistance (measured by HOMA-IR or fasting insulin),
fasting glucose, triglycerides, and C-reactive protein and
directly correlated with HDL in our study populations
(Supplementary Table 1).
In the GWAS in Singaporean Chinese, signals reaching
genome-wide signiﬁcance (5 31028) mapped exclusively
to the CDH13 and ADIPOQ gene (Supplementary Figs. 1
and 2). Associations for selected SNPs from these two
genes and SNPs from other genes previously reported to
be associated with adiponectin levels are listed in Sup-
plementary Table 2. The strongest signal in CDH13 was
rs4783244, located in the intron region. With regard to
other previously reported loci, associations with total and
HMW adiponectin levels reached genome-wide signiﬁcance
for ADIPOQ (rs10937273), and we observed nominally
signiﬁcant associations for GPR109A (rs601339), CMIP
(rs2925979), and PEPD (rs731839) (Supplementary Table 2).
The principal components were not correlated with total or
HMW adiponectin levels (Supplementary Fig. 3 and Supple-
mentary Table 3). For subsequent analyses, we focused on
the top hit CDH13 SNP rs4783244.
In the combined data from Singaporean Chinese, Japa-
nese, and Korean cohorts, total adiponectin levels signiﬁ-
cantly decreased by 0.34 SD on the log scale for each
additional T allele rs4783244 in CDH13 (95% CI 20.38 to
20.30, P = 2.0 3 10270; Table 2). This CDH13 variant was
even more strongly associated with HMW adiponectin
levels (standardized b [b] = 20.40, 95% CI 20.43 to 20.36,
P = 1.1 3 102117) and the HMW-to-total adiponectin ratio
(b = 20.44, 95% CI 20.49 to 20.40, P = 3.2 3 10283) based
on the Singaporean Chinese and Japanese data. Adjust-
ment for BMI did not substantially affect these effect
estimates, and similar results were obtained for the gen-
eral genetic model (Supplementary Table 4). The CDH13
rs4783244 variant explained more than 4% of variation in
total adiponectin (Singapore: 4.5%, Korea: 5.5%, Japan:
4.1%) and more than 6% of variation in HMW adiponectin
levels (Singapore: 8.3%, Japan: 6.5%).
At a Bonferroni-corrected threshold of P # 0.005, no
signiﬁcant association between rs4783244 in CDH13 and
metabolic risk factors was observed in Singaporean Chi-
nese or in Japanese (model 1; Table 3). Because CDH13 is
known to code for a receptor for HMW adiponectin, we
reassessed these associations after adjustment for HMW
adiponectin levels (model 2; Table 3). In a meta-analysis of
the Singaporean Chinese and Japanese samples, the minor
allele T in rs4783244 was signiﬁcantly associated with
lower BMI (b = 20.15, 95% CI 20.19 to 20.11, P = 3.5 3
10214), lower HOMA-IR (b =20.16, 95% CI20.20 to20.12,
P = 9.2 3 10216), higher HDL (b = 0.16, 95% CI 0.12
to 0.19, P = 2.1 3 10217), and lower triglycerides (b =
20.16, 95% CI 20.19 to 20.12, P = 1.3 3 10216) after ad-
justment for HMW adiponectin levels (Fig. 1A). After fur-
ther adjusting for BMI, associations were weaker but
remained signiﬁcant for HOMA-IR (b = 20.09, 95% CI 20.12
to 20.05, P = 5.4 3 1027), HDL (b = 0.12, 95% CI 0.09 to
TABLE 1
Characteristics of the study populations
Singaporean Chinese Japanese Koreans
n = 2,282 n = 3,290 n = 1,610
Age (years) 47.6 (10.9) 63.4 (11.6) 61.0 (10.5)
Males, n (%) 1,055 (46.2) 1,365 (41.5) 667 (41.4)
BMI (kg/m2) 22.8 (3.6) 23.3 (3.2) 24.6 (3.3)
Total adiponectin (mg/mL)* 3.27 (2.28–4.78) 9.10 (6.40–13.40) 7.15 (4.74–10.57)
HMW adiponectin (mg/mL) 1.14 (0.65–1.93) 4.40 (2.70–7.20) —
HMW-to-total adiponectin ratio 0.35 (0.27–0.43) 0.41 (0.35–0.47) —
HOMA-IR 1.16 (0.77–1.79) 1.21 (0.80–1.89) 2.20 (1.63–2.98)
HOMA-B (%) 100.0 (67.6–147.0) 56.7 (38.1–83.6) 102.1 (71.2–135.7)
Fasting glucose (mmol/L) 4.7 (4.4–5.0) 5.3 (5.0–5.7) 5.3 (5.0–5.8)
Fasting insulin (mU/L) 5.6 (3.8–8.4) 5.1 (3.4–7.7) 9.2 (6.9–11.8)
Cholesterol (mmol/L)
LDL 3.10 (2.58–3.67) 3.18 (2.62–3.72) 3.11 (2.56–3.65)
HDL 1.43 (1.21–1.69) 1.63 (1.34–1.94) 1.15 (1.00–1.33)
Total 5.15 (4.58–5.78) 5.40 (4.80–6.00) 5.12 (4.50–5.72)
Triglycerides (mmol/L) 1.08 (0.76–1.60) 1.05 (0.78–1.48) 1.45 (1.06–2.09)
C-reactive protein (mg/L) 0.8 (0.4–1.9) 0.5 (0.3–1.0) 0.9 (0.5–1.8)
Data are represented as mean (SD) for age and BMI and as median (interquartile range) for all of the other metabolic variables. *Total
adiponectin levels were only available for a subset of the Japanese sample (n = 1,266).
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0.16, P = 5.4 3 10212), and triglycerides (b = 20.12, 95% CI
20.16 to 20.09, P = 2.2 3 10211; Fig. 1B). These associa-
tions were not driven by population admixture in Singa-
porean Chinese (Supplementary Table 5) and were
signiﬁcant but weaker when we adjusted for total adipo-
nectin instead of HMW adiponectin (results not shown). A
sensitivity analysis found minimal difference in effect
estimates between ﬁxed- and random-effect meta-analysis,
and the estimates retained genome-wide signiﬁcant with
random-effect analysis.
DISCUSSION
Our study replicates previously reported associations of
variants at the CDH13, ADIPOQ, GPR109A, CMIP, and
PEPD loci with blood adiponectin levels (10). Further-
more, we found that rs4783244 at the CDH13 locus, which
encodes a receptor for hexameric and HMW adiponectin,
was more strongly associated with HMW adiponectin than
total adiponectin, explaining more than 6% of the variation
in HMW adiponectin levels in East Asians.
However, rs4783244 at the CDH13 locus was not asso-
ciated with other metabolic traits, which would be expected
based on its association with adiponectin levels, if circu-
lating adiponectin causally inﬂuences insulin resistance.
Results from previous studies also provided little sup-
port for an association between variants at the CDH13
locus and metabolic traits. In Filipino women, no signiﬁ-
cant associations with metabolic risk factors were detected
for rs3865188 in CDH13 (linkage disequilibrium [LD] with
rs4783244, r2 = 0.85) except for a nominal association (P =
0.042) with waist circumference (9). A Swedish study
similarly reported that rs11646213, a SNP upstream of
CDH13 in minimal LD with rs4783244 (r2 = 0.08), was not
associated with metabolic risk factors (17). In a Taiwanese
study, the signiﬁcant associations between rs4783244
and waist circumference, glucose, and triglyceride levels
did not remain after adjustment for BMI, although the
adiponectin-lowering T allele was paradoxically still
associated with a reduced risk for diabetes, the metabolic
syndrome, and stroke (18).
After adjustment for total and HMW adiponectin levels,
the CDH13 allele associated with lower blood adiponectin
levels was associated with a better metabolic proﬁle, in-
cluding lower BMI, lower insulin resistance based on fasting
insulin measures, lower triglyceride levels, and higher HDL
levels. Japanese researchers recently reported an association
between another CDH13 SNP (rs12051272) and BMI, fasting
insulin, fasting glucose, HOMA-IR, and fasting triglycerides
only after controlling for adiponectin levels (19). This SNP is
close to and in moderate LD (r2 = 0.66) with rs4783244,
which we studied. Together, the data suggest a complex re-
lationship among variants at the CDH13 locus and metabolic
traits that is only evident after controlling for their effects on
blood adiponectin levels.
The association between the variants at CDH13 and
plasma HMW adiponectin may be explained by the func-
tion of the T-cadherin receptor that it encodes. T-cadherin
is a receptor for hexameric and HMW adiponectin that is
expressed in the vasculature (20), cardiac myocytes (21),
and epithelial cells in the lung (22). We believe that the
T allele at rs4783244 is associated with increased binding
of HMW adiponectin to the T-cadherin receptor, resulting
in the sequestration of HMW adiponectin in these tissues
and thus removing it from the blood. Consistent with this
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FIG. 1. Effect estimates of rs4783244 in CDH13 on selected metabolic traits across studies adjusted for age, sex, and HMW adiponectin (A) and
adjusted for age, sex, HMW adiponectin, and BMI (B). HMW adiponectin and levels of HOMA-IR, HDL, and triglycerides were natural log-trans-
formed. HMW adiponectin and all the dependent variables in the regression models were standardized to the z-scores. b represents the SD change
in the outcome variable per SD change in the explanatory variable, on the natural log scale if applicable. The solid squares denote the mean
difference, the horizontal lines represent the 95% CIs, and the diamond denotes the weighted mean differences.
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plasma adiponectin levels in mice (20–22). However, this
does not explain the paradoxical observation that the
T allele at rs4783244, which is associated with lower blood
levels of HMW adiponectin, is associated with a more fa-
vorable metabolic proﬁle than would be expected based
on HMW adiponectin levels.
We hypothesize that the rs4783224 variant at the CDH13
locus may have an indirect effect on an individual’s sen-
sitivity to circulating adiponectin. In this hypothesis, the
chronically low levels of plasma adiponectin associated
with the T allele may result in upregulation of adiponectin
receptors AdipoR1/R2. Consistent with this proposed
mechanism, chronic elevation of plasma adiponectin led to
downregulation of AdipoR2 in adipose tissue in mice (23).
Furthermore, the expression of AdipoR1/R2 was upregu-
lated in insulin-resistant women with polycystic ovary
syndrome (24), who would be expected to have low blood
adiponectin levels. The greater expression of adiponectin
receptors could counterbalance the low adiponectin lev-
els, resulting in the lack of association between rs4783244
and the metabolic proﬁle in unadjusted analyses. However,
when the blood adiponectin levels are controlled for, then
the greater “adiponectin sensitivity” results in an associa-
tion between the T allele and a more favorable metabolic
proﬁle. Alternatively, effects of CDH13 on T-cadherin ex-
pression and receptor function may directly affect insulin
sensitivity. A recent study identiﬁed the role of T-cadherin
in regulating insulin action in the endothelium such that
upregulation of T-cadherin promoted endothelial insulin
resistance (25).
Strengths of our study include the relatively large sam-
ple size in a homogeneous Chinese population, replication
in independent Japanese and Korean populations, and
availability of HMW adiponectin and other metabolic var-
iables in addition to total adiponectin. As a limitation, we
are unable to elucidate the underlying biological pathways
behind our epidemiological observations.
In summary, our study showed that a genetic variant in
CDH13 explains a substantial part of variation in HMW
adiponectin levels in East Asian populations. However,
this effect of CDH13 on circulating HMW adiponectin
levels did not appear to translate into effects on metabolic
traits related to insulin resistance, suggesting that compen-
satory mechanisms exist that lead to greater “adiponectin
sensitivity.” Further mechanistic studies on the complex in-
teraction between CDH13, blood adiponectin levels, and
metabolic traits are needed to better understand the physi-
ologic signiﬁcance of these observations.
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Study populations 
 
The Singapore Prospective Study Programme (SP2) was a follow-up of participants from four previous 
cross-sectional studies that all included a random sample of Singapore residents with over-sampling of 
ethnic minority groups [1-3]. From 2003 to 2007, all 10,747 participants from these studies were invited 
to participate in the current study. Clinical data from health examination was available for 5,139 
participants, among whom only individuals of Chinese ethnicity (n = 2,483) were genotyped. Written 
informed consent was obtained from all participants and ethics approval was obtained from the 
Singapore General Hospital and the National University Hospital Institutional Review Boards. 
 
We sought for replication of the results from the SP2 study in Japanese and Korean study populations. 
The Japanese sample was a combination of two population-based cohorts. The Nomura cohort was 
based on a community (Nomura town) of 11,000 inhabitants in Ehime Prefecture, a largely rural area 
located in western Japan [4]. Participants were recruited through a community-based annual medical 
check-up in 2002 and the study population consisted of 2,895 middle-aged and elderly residents. The 
other Japanese cohort was composed of participants in the medical check-up program at the Ehime 
University Hospital Anti-aging Center (AAC) [5]. These cross-sectional investigations were carried out 
as part of the longitudinal Shimanami Health Promoting Program (J-SHIPP) study [6]. The Japanese 
studies were approved by the ethics committee of Ehime University Graduate School of Medicine. All 
study participants provided informed consent.  
 
The Korean replication sample consisted of the community-based Yangpyeong Cohort Study [7]. Five 
out of 12 districts of the Yangpyeong county were selected and 1,841 residents over 40 years old were 
recruited from 2005 to 2006. Written informed consent was obtained from all participants. The 




In the SP2 study, fasting blood samples were analyzed for glucose using enzymatic methods (ADVIA 
2400, Siemens, Germany), for insulin using micro-particle enzyme immunoassay (Abbot AXSYM, 
Abbott Laboratories, Chicago, IL), and for total and HMW adiponectin using an enzyme linked 
immune-sorbent assay (Sekisui Medical Co Ltd, Tokyo, Japan). The intra- and inter-batch coefficient of 
variations percent were as follows: glucose (2.5, 6.6), insulin (4.0, 4.5), total adiponectin (18.1, 15.9), 
HMW adiponectin (6.8, 18.3). 
 
In the replication samples, the plasma concentration of total adiponectin was determined using a latex 
enhanced imunoturbidimetric assay (Mitsubishi Chemical Medience, Tokyo, Japan) and HMW 
adiponectin using an ELISA system (Fujirebio Inc., Tokyo, Japan) in the Japanese studies [6]. The intra- 
and inter-assay coefficients of variation of the HMW adiponectin assay were 4.4% and 9.7%, 
respectively. In the Yangpyeong Study, total adiponectin was determined by Radioimmunoassay 
(Gamma Counter, PacKard, USA) using Human adiponectin RIA Kit (LINCO Research, Inc., USA). 
The intra- and inter-assay coefficients of variation at adiponectin concentration in the range of 1.5 to 7.5 
ug/mL were 6.9 to 9.3% and 1.8 to 6.2%, respectively.  
 
Genotyping and quality control 
2,865 blood-derived DNA samples from the SP2 Chinese participants were genotyped using Illumina 
HumanHap 550, 610 Quad, and 1Mduov3 BeadChips.  (http://www.illumina.com). The data went 
through quality control (QC) procedures which were described in detail elsewhere [8]. SNPs with call 
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rate < 0.95, minor allele frequency < 0.01 or Hardy-Weinberg equilibrium P-value < 1×10-6 were 
filtered out. 431 individuals did not pass the QC due to high rates of missingness, excessive 
heterozygosity, cryptic relatedness, discordant ethnicity and gender discrepancy. Imputation was done 
with IMPUTE (http://mathgen.stats.ox.ac.uk/impute/ impute.html) on 22 autosomes using NCBI build 
36 HapMapII CHB and JPT data (release 22) as the reference panel. Imputation results of SNPs that 
were actually genotyped were replaced with experimentally determined genotypes before the association 




A genome-wide association study for total and HMW adiponectin was carried out on 2,434 post-QC 
samples of the SP2 study. Adiponectin levels were natural log-transformed and standardized to z-scores. 
Additive genetic models adjusting for age and sex were used to test the associations and BMI was 
further adjusted for in a second model. The software used for the association study was SNPTEST 
v2.2.0 (https://mathgen.stats.ox.ac.uk/genetics_software/ snptest/snptest.html). Samples genotyped on 
different chips were treated as separate studies and the results were meta-analyzed under fixed-effect 
model weighted by inverse variance using METAL (http://www.sph.umich.edu/csg/abecasis/metal/). 
Sample size weighted meta-analysis was also performed and results were similar. Genomic control was 
applied to each study as well as the first-round meta-analysis results (λ=1.003 and 1.007 for total and 
HMW adiponectin) to correct for inflation and no obvious population stratification was detected.    
Genotypes for the top SNP from the meta-analysis, rs4783244 in the CDH13 gene, were successfully 
called for 2,429 individuals in the SP2 sample. After exclusion of participants with missing values for 
adiponectin (n=39), HOMA-IR (n=4), age (n=1), and BMI (n=2) and those taking anti-diabetic 
medications (n=101), 2,282 individuals remained for the analysis.  
 
A total of 3,290 Japanese from the Nomura and AAC studies (1,226 with both total and HMW 
adiponectin levels) and 1,610 Koreans in the Yangpyeong Study (total adiponectin levels only) had 
clinical and genotyping data for rs4783244 available and were included in the replication analysis. For 
the Nomura and AAC studies, potential cohort effect was accounted for by adjustment for cohort as a 
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Supplementary Table 1. Associations between adiponectin levels and metabolic traits in Singaporean Chinese, Japanese and Korean 
study populations.  
 
 Singaporean Chinese  Japanese  Korean 










 β (95% CI) P-
value 
β (95% CI) P-
value 
β (95% CI) P-value β (95% CI) P-value β (95% CI) P-value 
HOMA-IR           














1.6E-84 -0.63 (-0.72, 
-0.54) 
8.0E-39 














1.1E-39 -0.53 (-0.63, 
-0.43) 
7.6E-24 
HOMA-B           














2.8E-20 -0.14 (-0.23, 
-0.05) 
3.7E-03 



















          
Model 1 0.04 (-
0.00,0.08) 
0.065 0.02 (-0.01, 
0.05) 
0.176 0.01 (-0.01, 
0.03) 
0.411 0.05 (0.04, 
0.07) 
9.1E-10 0.10 (0.00, 
0.19) 
0.044 
Model 2 0.04 (-
0.01,0.08) 
0.090 0.02 (-0.01, 
0.05) 
0.238 0.02 (0.00, 
0.04) 
0.108 0.06 (0.04, 
0.08) 





          














1.2E-44 -1.24 (-1.54, 
-0.95) 
3.3E-16 
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3.8E-17 0.05 (-0.07, 
0.18) 
0.408 
Model 2 -0.06 (-0.13, 
0.01) 
0.115 -0.02 (-0.06, 
0.03) 
0.466 -1.32 (-3.36, 
0.71) 
0.203 -3.98 (-5.24, 
-2.72) 





          














4.5E-72 1.18 (0.99, 
1.37) 
1.2E-31 



















          
Model 1 -0.02 (-0.03, -
0.00) 
0.014 -0.01 (-0.02, 
0.00) 
0.080 1.43 (-0.67, 
3.53) 
0.181 -3.77 (-5.10, 
-2.44) 
3.1E-08 -0.38 (-0.62, 
-0.13) 
2.4E-03 
Model 2 -0.01 (-0.02, 
0.01) 
0.496 -0.00 (-0.01, 
0.01) 
0.861 2.41 (0.20, 
4.63) 
0.033 -2.98 (-4.36, 
-1.59) 
2.6E-05 -0.22 (-0.46, 
0.01) 
0.066 
Triglycerides           














1.1E-79 -0.58 (-0.66, 
-0.50) 
7.9E-41 














2.6E-53 -0.51 (-0.60, 
-0.43) 
2.3E-31 
CRP           














1.7E-37 -0.12 (-0.16, 
-0.07) 
1.9E-07 
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HMW adiponectin, High molecular weight adiponectin; HOMA-IR, Homeostasis model assessment-insulin resistance; HOMA-B, 
Homeostasis model assessment-β cell function; LDL-C, Low-density lipoprotein cholesterol; HDL-C, High-density lipoprotein cholesterol; 
CRP, C-reactive protein. 
* HOMA-IR adjusted HOMA-B 
Model 1 adjusted for age and sex; Model 2 adjusted for age, sex and BMI. Total and HMW adiponectin were natural log transformed and 
standardized in all the studies. All the metabolic traits were natural log transformed for normality except for LDL cholesterol in 
Singaporean Chinese, LDL, HDL and total cholesterol in Japanese. β represents SD change in the outcome variable per SD change in the 
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Supplementary Table 2 . Association between SNPs in reported loci and plasma adiponectin from a genome-wide association study in 
Singaporean Chinese. 
 
       Total adiponectin HMW adiponectin 
SNP Chromosome Position 
Nearest 
Gene Allele* EAF N β SE P-value β SE P-value 
rs4783244† 16 81219769 CDH13 T/G 0.342 2,387 -0.328 0.027 2.1× 10-33 -0.446 0.028 6.9 × 10-58 
rs8062260 16 81215591 CDH13 A/G 0.273 2,391 -0.386 0.032 5.6 × 10-33 -0.537 0.033 4.2 × 10-59 
rs3865188 16 81208218 CDH13 A/T 0.675 2,392 0.326 0.028 4.3 × 10-32 0.447 0.028 1.7 × 10-56 
rs12922394 16 81229828 CDH13 T/C 0.223 2,391 -0.177 0.031 1.0 × 10-8 -0.253 0.032 1.0 × 10-15 
rs10937273† 3 188032389 ADIPOQ A/G 0.424 2,392 0.150 0.026 6.4 × 10-9 0.157 0.026 2.2 × 10-9 
rs1648707† 3 188034405 ADIPOQ A/C 0.553 2,391 0.122 0.026 2.4 × 10-6 0.137 0.026 2.1 × 10-7 
rs6810075 3 
188031259 ADIPOQ T/C 0.575 2,391 0.125 0.027 
2.5 × 10-6 
0.127 0.027 
2.3 × 10-6 
rs3001032 1 217794402 LYPLAL1 T/C 0.775 2,390 -0.027 0.030 0.379 -0.052 0.031 0.089 
rs925735 2 226887874 IRS1 C/G 0.076 2,392 0.045 0.048 0.350 0.015 0.049 0.765 
rs1108842† 3 52695120 GNL3 A/C 0.577 2,391 0.013 0.025 0.618 -0.002 0.026 0.938 
rs4311394† 5 53336419 ARL15 G/A 0.554 2,390 0.029 0.025 0.258 0.047 0.026 0.070 
rs10447248 5 107943635 FER A/G 0.685 2,390 0.049 0.028 0.082 0.023 0.028 0.417 
rs998584 6 43865874 VEGFA A/C 0.581 2,387 -0.001 0.027 0.962 0.025 0.028 0.370 
rs592423 6 139882386 --- A/C 0.720 2,391 -0.011 0.029 0.695 -0.020 0.029 0.496 
rs2980879 8 126550657 TRIB1 A/T 0.309 2,392 0.003 0.028 0.922 -0.018 0.028 0.530 
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rs7955516 12 20389303 PDE3A A/C 0.895 2,392 -0.089 0.043 0.037 -0.080 0.043 0.063 
rs601339 12 121740696 GPR109A A/G 0.519 2,392 -0.097 0.025 1.3 × 10-4 -0.081 0.026 1.6 × 10-3 
rs7133378 12 122975455 DNAH10 A/G 0.113 2,391 0.077 0.046 0.089 0.066 0.046 0.154 
rs2925979† 16 80092291 CMIP T/C 0.426 2,390 -0.084 0.026 1.0 × 10-3 -0.075 0.026 4.1 × 10-3 
rs731839 19 38590905 PEPD A/G 0.445 2,392 0.064 0.026 0.012 0.058 0.026 0.026 
EAF, effect allele frequency; HMW adiponectin, high molecular weight adiponectin.  
SNPs presented here include the top hits for ADIPOQ and CDH13 in our study as well as previously implicated loci associated with 
adiponectin level. Results are based on the additive genetic model adjusting for age, gender and BMI.  
* Effect allele, followed by other allele. †The SNP is genotyped on all the three arrays used for this study.  
 
Supplementary Table 3. Correlations between the first four principal components (PCs) and adiponectin levels in Singaporean Chinese.  
 
 Total adiponectin HMW adiponectin 
PC1 0.004 (0.87) 0.005 (0.80) 
PC2 -0.025 (0.24) -0.032 (0.13) 
PC3 0.025 (0.23) 0.045 (0.03) 
PC4 -0.004 (0.84) -0.013 (0.54) 
The numbers are correlation coefficient followed by P-value of significance in the bracket. 
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Supplementary Table 4. Associations between rs4783244 genotypes and different forms of adiponectin under general genetic model. 
 
Population Genotype Total adiponectin HMW adiponectin HMW-to-total adiponectin ratio 

























































































































1.8 × 10-55 
Results are based on linear regression with rs4783244 as independent variable, adjusted for age and sex. Total and HMW adiponectin were natural log 
transformed and all the adiponectin forms were standardized to the z-scores. rs4783244 genotypes refer to GG, GT and TT with GG as the reference. A 
general genetic model is assumed and each β represents the effect of the alternative genotype on the specific form of adiponectin as compared with the 
reference genotype.  
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Supplementary Table 5. Association between rs4783244 in CDH13 and glucometabolic traits after 
adjusting for the top four principal components in Singaporean Chinese.  
 
Metabolic trait  Model 1 Model 2 Model 3 
BMI β (95% CI) -0.04 (-0.10, 0.02) -0.21 (-0.27, -0.14) --- 
P-value 0.178 3.8 × 10-11 --- 
HOMA-IR β (95% CI) -0.06 (-0.12, 0.00) -0.23 (-0.29, -0.16) -0.12 (-0.18, -0.07) 
P-value 0.065 5.9 ×10-13   6.6 × 10-6 
HDL-C β (95% CI) 0.01 (-0.05, 0.06) 0.18 (0.13, 0.24) 0.14 (0.08, 0.19) 
P-value 0.847 1.2 × 10-10 7.0 × 10-7 
Triglycerides β (95% CI) -0.02 (-0.08, 0.04) -0.19 (-0.25, -0.14) -0.15 (-0.20, -0.09) 
P-value 0.449 3.1 × 10-11 3.3 × 10-7 
Model 1: adjusted for age and sex; Model 2: adjusted for the covariates in Model 1 plus HMW 
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Supplementary Figure 1. Whole genome association with total plasma adiponectin in Singapore 
Prospective Study Programme (SP2). (A) Manhattan plot with significance level set at 5 × 10-8 as 
indicated by the gray horizontal line.  (B) Quantile-quantile plot of the observed and expected P-values 
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Supplementary Figure 2. Whole genome association with HMW adiponectin in Singapore 
Prospective Study Programme (SP2). (A) Manhattan plot with significance level set at 5 × 10-8 as 
indicated by the gray horizontal line.  (B) Quantile-quantile plot of the observed and expected P-values 
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Supplementary Figure 3. Plot of principal components (PCs) to identify population structure in the 
Singaporean Chinese population. (a), the first and the second PCs; (b), the second and the third PCs; (c), the third 
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Evidence of a Causal Relationship Between Adiponectin
Levels and Insulin Sensitivity
A Mendelian Randomization Study
He Gao,1,2,3 Tove Fall,1 Rob M. van Dam,2,3 Allan Flyvbjerg,4 Björn Zethelius,5 Erik Ingelsson,1 and
Sara Hägg1
The adipocyte-secreted protein adiponectin is associated with
insulin sensitivity in observational studies. We aimed to evaluate
whether this relationship is causal using a Mendelian randomi-
zation approach. In a sample of Swedish men aged 71 years (n =
942) from the Uppsala Longitudinal Study of Adult Men (ULSAM),
insulin sensitivity (M/I ratio) was measured by the euglycemic
insulin clamp. We used three genetic variants in the ADIPOQ
locus as instrumental variables (IVs) to estimate the potential
causal effect of adiponectin on insulin sensitivity and compared
these with results from conventional linear regression. The three
ADIPOQ variants, rs17300539, rs3774261, and rs6444175, were
strongly associated with serum adiponectin levels (all P #
5.3 3 1029) and were also signiﬁcantly associated with M/I ratio
in the expected direction (all P # 0.022). IV analysis conﬁrmed
that genetically determined adiponectin increased insulin sensi-
tivity (b = 0.47–0.81, all P # 0.014) comparable with observa-
tional estimates (b = 0.50, all Pdifference $ 0.136). Adjustment
for BMI and waist circumference partly explained the association
of both genetically determined and observed adiponectin levels
with insulin sensitivity. The observed association between higher
adiponectin levels and increased insulin sensitivity is likely to
represent a causal relationship partly mediated by reduced adi-
posity. Diabetes 62:1338–1344, 2013
Adiponectin is the most abundantly secretedprotein by white adipose tissue. Unlike mostother adipokines, it has a well-known inverserelationship with adiposity and risk of type 2
diabetes (1–3). Insulin resistance is a major link between
excessive adiposity and the development of type 2 dia-
betes, and murine studies have demonstrated that adipo-
nectin exerts an insulin-sensitizing effect (4–6). Although
adiponectin is also inversely associated with insulin
resistance in human populations (7–9), it remains unclear
whether this represents a causal relationship (10).
Mendelian randomization is a method that uses genetic
variants [instrumental variables (IVs)] as robust proxies
for an environmentally modiﬁable exposure to assess and
quantify potential causal relationships with health out-
comes (11,12). Because genotypes that inﬂuence adipo-
nectin levels are assigned at conception, they are unlikely
to be related to confounders such as lifestyle, socioeco-
nomic and environmental risk factors, or reverse causa-
tion. Given sufﬁcient power and carefully selected genetic
variants that have robust association with adiponectin
levels, a Mendelian randomization study has the potential
to help disentangle adiponectin as cause or consequence
of insulin sensitivity. Thus far, there is to our knowledge
no such existing study.
Genome-wide linkage scan and association studies have
revealed a few loci that affect the circulating level of adi-
ponectin (13). Among them, ADIPOQ, which encodes for
the adiponectin protein, is by far the most established lo-
cus, with many studies demonstrating its robust and strong
association with adiponectin levels (7,14–16). With no
known pleiotropic effect, ADIPOQ variants presumably
fulﬁll the key assumptions of a Mendelian randomization
design (Fig. 1), and therefore they are good candidate
instruments for a Mendelian randomization study with
adiponectin as the exposure variable.
The aim of our study was to use single nucleotide poly-
morphisms (SNPs) in ADIPOQ that are reliably associated
with serum adiponectin levels as IVs to elucidate the po-
tential causal effect of adiponectin on insulin sensitivity
measured by euglycemic insulin clamp in nondiabetic men
in a population-based cohort.
RESEARCH DESIGN AND METHODS
Study sample. The Uppsala Longitudinal Study of Adult Men (ULSAM) was
initiated between September 1970 and September 1973 with an invitation to all
men aged 50 years living in Uppsala County, Sweden. The sample used for this
study comes from the third investigation, during 1991–1995, when the subjects
were aged ~71 years. A total of 1,221 men (73% of those invited, i.e., men still
alive and residing in Uppsala County) participated, and the examination in-
cluded a medical questionnaire, blood pressure and anthropometric mea-
surements, collection of blood samples, a 75-g oral glucose tolerance test, and
insulin sensitivity measurements. Detailed information can be found at the
cohort website (http://www.pubcare.uu.se/ulsam/).
Of the 1,221 participants, 199 were excluded for the following reasons:
unavailable clamp data (n = 61), unavailable measurement of adiponectin (n =
15), or presence of type 2 diabetes [deﬁned as fasting glucose .7.0 mmol/L
(.126 mg/dL) or use of antidiabetes medication (n = 123)]. Of the remaining
1,022 participants, genotypes were available for 943 participants, and after
exclusion of 1 person with missing genotypes in .1 of the 16 ADIPOQ SNPs,
942 participants were eligible for the ﬁnal analysis. The study was approved by
the ethics committee of Uppsala University, and all participants provided
written informed consent.
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Adiponectin and insulin sensitivity measurements. Serum adiponectin
was measured in plasma samples frozen at 270°C for 11 6 2 years without
previous thaw-freeze cycles and using a validated in-house time-resolved
immunoﬂuorometric assay with reagents from R&D Systems (Abingdon, U.K.).
The intra- and interassay coefﬁcient of variation averaged ,5 and 10%, re-
spectively, as previously described in detail (17).
In vivo sensitivity to insulin was determined by the euglycemic insulin
clamp, according to the procedure described by DeFronzo et al. (1979) (18),
but with a higher insulin infusion rate per body surface area to better suppress
liver glucose output [56 instead of 40 mU $ min21 (m2)21]. After a primary
dose in the initial 10 min, continuous infusion of insulin lasted for 110 min and
hepatic glucose production was assumed to be entirely suppressed. Glucose
disposal (M) was calculated as the total amount of glucose infused during the
last 60 min (the steady state) of the clamp divided by kilograms body weight
and minutes. The insulin sensitivity index (M/I ratio) was derived by dividing
M by the steady-state mean insulin concentration (I). M/I thus represents the
amount of glucose metabolized per unit of plasma insulin and was given as
100 3 mg $ kg21 $ min21 $ mU21 $ L.
Genotypes and IVs. The ULSAM cohort has undergone prior genotyping on
the Human CardioMetabo beadchip (19), which is designed to interrogate
200,000 markers of interest for cardiovascular and metabolic diseases. Of the
1,221 individuals who underwent genotyping, we removed those with a geno-
typing call rate ,0.99 (n = 5), failing sex check (n = 1), close relatedness (n =
36), or large heterozygosity (n = 7). Quality control also ensured that all SNPs
had good call rate (.0.99) and did not deviate from Hardy-Weinberg equilibrium
(P . 1 3 1026). In total, genotypes of 183,357 SNPs were available for 1,175
individuals, of whom 942 were eligible for the current study (see above).
We searched the genomic region 650 kb of the ADIPOQ gene based on
Human Genome build 36 and identiﬁed 16 SNPs that were present on the
Metabochip. Their associations with serum adiponectin in the ULSAM cohort
were examined by linear regression under an additive genetic model adjusting
for age. Pairwise linkage disequilibriums (LDs) were then assessed with in-
formation from the HapMap2 release 22 CEU panel, and SNPs in moderate LD
(r2 . 0.5) were assigned to the same LD block. Of the SNPs that were sig-
niﬁcantly associated with adiponectin, we selected rs17300539 and rs3774261,
which were the top associated SNPs in their respective LD block as IVs. Since
rs6444175 only showed intermediate LD (r2 = 0.506) with rs3774261, this
variant was evaluated as an instrument in separate analyses (but not in the
genotype score). We excluded rs864265 (P = 0.02) for further analyses, which
was from another LD block, because its association with adiponectin has not
been consistent in previous studies. Moreover, a Filipino study found the as-
sociation between this SNP and adiponectin to be mediated by R221S, a rare
variant affecting immunoassay binding afﬁnity with artiﬁcially low adiponectin
levels as a consequence (20).
To maximize the power of our study, we further generated an allele score
from rs17300539 and rs3774261 (r2 = 0.137) by adding up the number of effect
alleles and dividing the sum by the total copies of alleles, resulting in a range
from 0 to 1. Thus, we had three single SNPs and one allele score as IVs of
serum adiponectin for subsequent Mendelian randomization analyses.
Statistical analysis. Adiponectin and insulin sensitivity index (M/I ratio) were
natural log transformed to achieve normality. Values with a distance of .4 SD
from the mean were truncated to 64 SD, respectively, to avoid effects of
outliers on the effect estimates (did not occur for insulin sensitivity or adi-
ponectin; four, ﬁve, and three values were truncated for age, BMI, and waist,
respectively).
The observed effects of adiponectin onM/I ratio, as well as effects of IVs on
M/I ratio, were obtained by linear regression under additive genetic models
with adjustment for age. In further analyses, BMI and waist residual, which is
the BMI-adjusted waist circumference, were included as covariates into the
model to evaluate effects independent of adiposity. To test the linearity of the
relationship between adiponectin and insulin sensitivity, we examined the
residual plots after the multivariate linear regression. Furthermore, cubic
spline curves were plotted to visualize the degree of deviation from linearity.
IV analysis was then performed using a two-stage least squares approach
with the STATA package ivreg2. In brief, the ﬁrst stage was a conventional
linear regression assessing the association between the SNPs and serum adi-
ponectin. The predicted value of adiponectin from the model was saved and
used as an independent variable in the second stage, where the dependent
variable was insulin sensitivity index (M/I ratio). This b coefﬁcient, or the IV
estimate, reﬂects an unconfounded effect of genetically determined adipo-
nectin level on insulin sensitivity. Endogeneity, or the difference between the
IV estimate and the observed effect size, was examined by a Durbin-Wu-
Hausman x2 test implemented in the package. The percentage of change in
insulin sensitivity with x% increase in adiponectin estimated by each in-
strument was calculated as follows: [(1 + x%)b 2 1] 3 100%, where b is the
corresponding IV estimate. To test the generalizability of our results, we
performed secondary analyses including the 123 individuals with type 2 di-
abetes. In order to examine potential effect modiﬁcation by adiposity, we
conducted a BMI-stratiﬁed analysis by deﬁning overweight using the median
BMI level in our sample (BMI $25.7 kg/m2).
Data were analyzed using Stata/IC (version 12.1; StataCorp, College Station,
TX). Two-sided P values ,0.05 were considered signiﬁcant.
RESULTS
Characteristics of the study participants are summarized in
Table 1.
Association between the instruments and serum
adiponectin. Table 2 shows the 16 ADIPOQ SNPs avail-
able on the Metabochip and their associations with adi-
ponectin levels in the ULSAM cohort. Based on LD
structure, they were assigned to 11 different blocks. Ex-
cluding rs864265, seven SNPs belonging to two different
LD blocks showed highly signiﬁcant associations with se-
rum adiponectin (all P # 4.8 3 1027). The three SNPs
chosen as IVs, namely, rs17300539, rs3774261, and
rs6444175, were all strongly associated with adiponectin
levels (P = 1.1 3 10210, 1.3 3 1029, and 5.3 3 1029, re-
spectively). As expected, the allele score generated from
rs17300539 and rs3774261 was even more strongly asso-
ciated with adiponectin level (P = 1.2 3 10213) compared
with each of the single ADIPOQ SNPs. The instruments
explained between 3.5 and 6.0% (rs17300539, 4.3%;
rs3774261, 3.8%; and rs6444175, 3.5%; all three SNPs
combined: 6.0%) of the total variance in adiponectin levels.
Association between the instruments and insulin
sensitivity. All of the IVs including the three ADIPOQ
SNPs and the allele score were signiﬁcantly associated
with insulin sensitivity represented by the M/I ratio (P #
0.022 for all SNPs and P = 8.0 3 1024 for the allele score)
(Supplementary Table 1). Adjustment for adiposity repre-
sented by BMI and waist residual weakened these associ-
ations, but some of the instruments remained signiﬁcantly
associated with the M/I ratio (rs6444175, P = 0.011; allele
score, P = 0.042).
IV analysis of the effect of adiponectin on insulin
sensitivity. To examine the potential causal effect of
adiponectin on insulin sensitivity in an IV analysis, we
assessed the ﬁrst-stage F statistic in which an empirical
value .10 indicates sufﬁcient strength of the genetic
FIG. 1. Hypothetical model for the relationship between ADIPOQ,
adiponectin, and insulin sensitivity. This paradigm illustrates the key
relationships in the study of the inﬂuence of adiponectin on insulin
sensitivity using a Mendelian randomization design. Solid arrows rep-
resent causal inﬂuences that are expected, and dotted arrows are
causal inﬂuences that are assumed not to exist. Genetic variants from
the ADIPOQ gene are used as IVs based on three main assumptions: 1)
The IVs are robustly associated with the exposure of interest, i.e.,
adiponectin levels; 2) the IVs are independent of confounders for the
association between adiponectin and insulin sensitivity in observa-
tional studies; and 3) the IVs are independent of the outcome insulin
sensitivity given adiponectin levels and the confounders. Moreover, we
hypothesize that part of the effect of adiponectin on insulin sensitivity
is mediated by adiposity, which is represented by BMI and waist
circumference.
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variant as a proxy of the exposure. The large F statistics
(42.6 for rs17300539, 37.6 for rs3774261, 34.7 for rs6444175,
and 56.7 for the allele score in age-adjusted analyses) en-
sured that the SNPs chosen were strong instruments for
adiponectin levels (Table 3).
The IV-estimated effect size of adiponectin levels on
insulin sensitivity was highly signiﬁcant and consistent for
all instruments [b = 0.47 (95% CI 0.10–0.84) for rs17300539,
0.68 (0.28–1.08) for rs3774261, 0.81 (0.38–1.23) for
rs6444175, and 0.60 (0.27–0.93) for the allele score] (Table
3). These estimates reﬂect the effect of genetically inﬂu-
enced adiponectin levels on insulin sensitivity and are as-
sumed to be free from confounding. Thus, these results
indicate that the relationship between adiponectin level
and insulin sensitivity is potentially causal.
We then compared the IV analysis results with conven-
tional multiple linear regression of insulin sensitivity on
adiponectin levels. Endogeneity tests suggested that there
was no statistical difference between the IV estimate and
the observational estimate (Table 3). This was consistent
for each of the individual SNP instruments and also the
allele score, demonstrating that genetically determined
adiponectin levels affect insulin sensitivity to the same
degree as expected based on the observed association. In
our secondary analyses including individuals with type 2
diabetes, the results were similar to those from our main
analyses (Supplementary Table 2).
For some of the IVs, we still observed an association
between the IV-estimated adiponectin and insulin sensi-
tivity after adjustment for BMI and waist residual [b = 0.55
(95% CI 0.13–0.96) for rs6444175 and 0.34 (0.03–0.65) for
the allele score] (Table 3), although the effect sizes were
substantially attenuated. This suggests that at least part of
the causal beneﬁcial effect of adiponectin levels on insulin
sensitivity was mediated by lower adiposity as measured
by BMI and waist circumference. All the instruments ex-
cept for rs17300539 were strongly associated with BMI in
an age-adjusted model. However, none of them were as-
sociated with BMI after adjustment for adiponectin levels
(Supplementary Table 3).
BMI-stratiﬁed analysis (Supplementary Table 4) sug-
gested that the association between increased adiponectin
levels and higher insulin sensitivity was stronger in the
group with higher BMI, for which the observed causal
relationship between adiponectin and insulin sensitivity
also persisted. However, in the group with lower BMI, as
indicated by the wide CIs of the IV estimates and non-
signiﬁcant heterogeneity P values for most of the instru-
ments, we did not have enough power to robustly conﬁrm or
refute an association owing to limited sample size.
Estimated impact of adiponectin on insulin sensitivity.
Depending on the IV used, the age-adjusted effect estimate
TABLE 1
Characteristics of the study participants (n = 942)
Age (years) 71.0 (0.59)
BMI (kg/m2) 26.0 (3.24)
Waist circumference (cm) 94.0 (9.17)
LDL (mmol/L) 3.92 (0.88)
HDL (mmol/L) 1.30 (0.35)
Total cholesterol (mmol/L) 5.84 (0.99)
Fasting glucose (mmol/L) 5.38 (0.56)
Adiponectin (mg/L) 9.75 (7.65–12.81)
Fasting insulin (mU/L) 11.00 (7.80–14.90)
Insulin sensitivity M/I ratio
[mg/kg/min/(mU/L)]* 5.15 (3.48–6.84)
HOMA-IR 2.57 (1.82–3.62)
Free fatty acids (mmol/L) 0.48 (0.38–0.59)
Triglycerides (mmol/L) 1.23 (0.92–1.65)
Data are means (SD) or median (interquartile range). *M/I ratio was
deﬁned as total glucose disposal per kilograms body weight per min-
ute divided by mean insulin concentration under a steady state (last
60 min of the euglycemic insulin clamp).
TABLE 2
ADIPOQ SNPs available on the Metabochip and their associations with serum adiponectin
SNP or allele
score C Position Alleles* EAF Call rate HWE P
Association with adiponectin
(age adjusted)
LD group†b (95% CI) P
rs3917086 3 188007420 A/C 0.029 0.997 0.621 0.022 (20.078 to 0.122) 0.668 1
rs864265 3 188036986 T/G 0.149 1 0.015 20.055 (20.101 to 20.009) 0.020 2
rs822387 3 188038731 C/T 0.072 1 0.660 0.162 (0.099–0.224) 4.8 3 1027 3
rs17300539‡ 3 188042154 A/G 0.072 1 0.189 0.205 (0.144–0.267) 1.1 3 10210 3
rs16861209 3 188045808 A/C 0.067 0.968 0.088 0.214 (0.149–0.278) 1.5 3 10210 3
rs16861210 3 188049192 A/G 0.080 1 0.550 0.188 (0.128–0.248) 1.1 3 1029 3
rs16861194 3 188042119 G/A 0.087 1 0.855 20.051 (20.114 to 0.011) 0.106 4
rs822396 3 188049571 G/A 0.173 1 0.475 0.013 (20.032 to 0.059) 0.562 5
rs3774261‡ 3 188054253 A/G 0.375 0.999 0.950 0.109 (0.074–0.144) 1.3 3 1029 6
rs6773957 3 188056399 A/G 0.375 0.999 0.950 0.109 (0.074–0.144) 1.4 3 1029 6
rs6444175‡ 3 188062438 A/G 0.291 1 0.438 0.113 (0.076–0.151) 5.3 3 1029 6
rs3774262 3 188054508 A/G 0.085 1 0.185 0.030 (20.030 to 0.091) 0.327 7
rs9853541 3 188095161 A/G 0.378 1 0.121 0.002 (20.035 to 0.038) 0.927 8
rs11708293 3 188096021 G/A 0.043 0.999 1.000 20.043 (20.129 to 0.042) 0.322 9
rs11716002 3 188096058 G/A 0.236 1 0.105 0.011 (20.031 to 0.052) 0.616 10
rs17301514 3 188096103 A/G 0.134 0.999 1.000 0.008 (20.043 to 0.060) 0.757 11
Allele score§ 0.404 (0.299–0.509) 1.2 3 10213
SNPs were ﬁrst sorted based on physical position in the ADIPOQ gene and then aggregated by LD group. C, chromosome; EAF, effect allele
frequency; HWE, Hardy-Weinberg equilibrium. *The ﬁrst allele is the effect allele. †LD group was assigned based on pairwise r2 . 0.5 in the
HapMap2 CEU panel. ‡SNPs selected for IV analysis. §The allele score was created using genotypes for rs17300539 and rs3774261 (r2 = 0.137).
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for genetically determined adiponectin on insulin sensitivity
varied from 0.470 to 0.805. Based on these point estimates,
we estimated the relationship between percent change in
adiponectin levels and corresponding percent change in
insulin sensitivity (Supplementary Fig. 1). For example, we
calculated that a 10% increase in serum adiponectin level
would lead to an improvement of insulin sensitivity ranging
between 4.6 and 8.0%. Similarly, excluding the mediation
through obesity, the percent increase in insulin sensitivity
associated with a 10% elevation in adiponectin level was
estimated to be between 2.6 and 5.3%. However, owing to
the large CIs for the IV estimates, these numbers should be
interpreted with caution.
DISCUSSION
In a population-based cohort study of men aged 71 years
assessed with gold-standard measures of insulin sensitiv-
ity, for the ﬁrst time we provide evidence of a causal effect
of increased adiponectin levels on improved insulin sen-
sitivity in humans using a Mendelian randomization ap-
proach with ADIPOQ SNPs as instruments.
The ADIPOQ gene, which encodes for adiponectin, has
been widely investigated for variants associated with adi-
ponectin levels. The ADIPOQ SNPs available in our study
belonged to the two previously identiﬁed LD blocks (21),
and the ones selected as IVs have been repeatedly re-
ported for their association with adiponectin in individuals
of European descent (14,15,22–25) (Supplementary Table
5). This conﬁrms that the SNPs we selected are robust
instruments for adiponectin levels in European populations.
Studies of the relationship between ADIPOQ and insulin
sensitivity in candidate gene studies have been less con-
sistent (26). The 3q27 region in which the ADIPOQ gene is
located was reported for its linkage signal with seven
metabolic traits and was suggested for an association with
obesity and insulin sensitivity (27). In a genome-wide
linkage and association study of adiponectin, the two in-
strument SNPs in our study, rs6773957 and rs3774261,
were identiﬁed as top hits, but neither was signiﬁcantly
associated with fasting insulin, fasting glucose, or other
metabolic parameters (16). Richards et al. (25) also
reported no signiﬁcant associations for four other SNPs at
the ADIPOQ locus with the homeostasis model assessment
index of insulin resistance (HOMA-IR). Similarly, Warren
et al. (24) did not ﬁnd an association between seven
independent SNPs at ADIPOQ, including rs3774261, and
metabolic traits such as fasting glucose, fasting insulin,
and HOMA-IR. In a recent large study, Dastani et al. (28)
demonstrated that several individual SNPs that were sig-
niﬁcant in their genome-wide association studies of adipo-
nectin levels, including a few ADIPOQ SNPs, were
associated with type 2 diabetes and related traits. Further-
more, they found a multi-SNP genotypic risk score based on
the identiﬁed hits to be strongly associated with metabolic
traits related to insulin resistance. Therefore, even though
ADIPOQ has been established as a major determinant of
adiponectin levels, its associations with measures of insulin
sensitivity have not been consistent, which may have been
due to lack of statistical power to detect this indirect effect.
Of note, prior studies have not assessed associations of
ADIPOQ variants and insulin sensitivity measured with in-
travenous methods in a larger study sample.
The impact of ADIPOQ variants on adiposity has not
been conclusive. The SNPs rs2241766 and rs1501299 have
been associated with obesity in Swedish individuals (29).
In the Finnish Diabetes Prevention Study, a few ADIPOQ
SNPs were associated with baseline and 4-year follow-up
measurements of body weight as well as BMI (30). How-
ever, no consistent effect on BMI was demonstrated for
SNPs in the ADIPOQ locus in a previous meta-analysis of
published candidate gene studies on ADIPOQ (31). Our
observation that the ADIPOQ SNPs selected as IVs were
not associated with measures of adiposity after adjustment
for adiponectin levels indicates that the instruments do not
have a pleiotropic effect that would otherwise violate the
assumptions of Mendelian randomization. Moreover, it
indicates that differences in adiposity for carriers of dif-
ferent ADIPOQ alleles could be mediated through adipo-
nectin levels.
The role of adiposity in the relationship between adi-
ponectin and insulin sensitivity is debatable. The degree of
adiposity is associated with both adiponectin levels and
insulin sensitivity (2,3,7) and thus could be a confounder
for the adiponectin-insulin sensitivity relationship. If this is
the case, adjustment for adiposity by including BMI and
waist residuals into the regression model should not affect
the association between ADIPOQ and insulin sensitivity
level because under independent assortment ADIPOQ
genotypes should not be associated with adiposity. This
could occur if ADIPOQ SNPs cosegregate with other ge-
netic determinants of adiposity, but no such gene variants
TABLE 3




IV estimate Observational estimate Endogeneity
P†b (95% CI) P b (95% CI) P
Age adjusted 0.498 (0.420–0.576) 1.23 10233
rs17300539 42.6 0.470 (0.097–0.842) 0.014 0.878
rs3774261 37.6 0.678 (0.278–1.077) 9.13 1024 0.364
rs6444175 34.7 0.805 (0.381–1.228) 2.13 1024 0.136
Allele score* 56.7 0.600 (0.274–0.926) 3.33 1024 0.528
Age, BMI, and waist residual adjusted 0.275 (0.206–0.344) 1.33 10214
rs17300539 38.5 0.265 (20.079 to 0.609) 0.131 0.955
rs3774261 29.3 0.387 (20.007 to 0.781) 0.055 0.572
rs6444175 28.1 0.546 (0.133–0.960) 0.010 0.178
Allele score 46.7 0.340 (0.026–0.654) 0.034 0.677
Waist residual, BMI-adjusted waist circumference. †Endogeneity was assessed by Durbin-Wu-Hausman test and reﬂects whether the differ-
ence between the IV estimate and the observational estimate was statistically signiﬁcant. *The allele score was created using genotypes for
rs17300539 and rs3774261 (r2 = 0.137).
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in LD with the ADIPOQ variants are known to date. In this
study, what we observed were attenuated associations of
the SNPs and insulin sensitivity with adjustment for adi-
posity (Supplementary Table 1), which does not support
a role of adiposity as a confounder for the adiponectin–
insulin sensitivity relationship. Instead, it implies that ad-
iposity partly mediates the effect of adiponectin on insulin
sensitivity, as illustrated in Fig. 1. This is supported by
previous studies showing a positive correlation between
adiponectin levels and clamp-measured insulin sensitivity
independent of BMI (32) and that administration of
recombinant adiponectin increases insulin sensitivity in
both lipotrophic and obese mice (5). As proposed by
Kadowaki et al. (33), obesity caused by environmental risk
factors could interact with genetic factors leading to re-
duced adiponectin levels, which in turn plays a crucial
causal role in the development of insulin resistance, type 2
diabetes, and metabolic disease. Our results suggest that
this causal effect on insulin sensitivity is modulated par-
tially through adiposity, which may work by antagonizing
the secretion of proinﬂammatory cytokines, such as tumor
necrosis factor-a and interleukin-6 (34).
It is possible that at increased levels of adiposity,
adiponectin plays a more important causal role in the regu-
lation of insulin sensitivity compared with that in normal-
weight individuals. There is a possibility that an interaction
exists between adiposity and the ADIPOQ SNPs, wherein
transcription factors that may be upregulated by, for ex-
ample, inﬂammatory mediators, could have differential
binding and thus different effects. In this case, the adiposity-
adjusted IV estimates that represent causal effects not me-
diated by adiposity may be prone to less accuracy. Given the
modest sample size when stratifying on median BMI, our
study is not suitable for examining these issues, but further
studies on the interrelationship between adiposity, adipo-
nectin, and insulin sensitivity are warranted.
Cook and Semple (10) reviewed the evidence of cau-
sality in the relationship between adiponectin and insulin
resistance and concluded that existing evidence indicated
that adiponectin can improve insulin sensitivity in mice.
For instance, intraperitoneal injection of adiponectin en-
hanced insulin action by suppressing hepatic glucose
production and decreasing serum glucose levels (4). Fur-
ther evidence came from studies on rhesus monkeys
where the decrease of adiponectin levels was in parallel
with the development of insulin resistance (35). However,
hyperinsulinemia seemed to suppress adiponectin in both
mice and humans suggesting that low adiponectin levels
may also be a consequence of insulin resistance (10). Our
results using a Mendelian randomization approach support
the hypothesis that adiponectin levels are causally related
to the degree of insulin sensitivity in humans.
Adiponectin has been suggested to be a stronger marker
for insulin resistance and risk of type 2 diabetes than for
cardiovascular disease (8,36). Hypoadiponectinemia was
also more closely associated with the degree of insulin
resistance and hyperinsulinemia than with adiposity and
glycemia in several studies (3,37). In line with this, results
from our study indicate that genetically determined adi-
ponectin levels inﬂuence insulin sensitivity and that this
effect is not fully mediated by adiposity, reﬂecting that
there may be pathways between adiponectin and insulin
sensitivity that do not act through adiposity. Together with
ﬁndings that adiponectin shares genetic backgrounds with
insulin resistance–related metabolic traits (7,28), emerging
evidence is pointing toward an important role of adiponectin,
independent of adiposity, in the development of insulin re-
sistance and type 2 diabetes.
We acknowledge that our research question is novel and
that there are no previous studies with which our results
can be compared. Despite the fact that this is a single
study with a relatively modest sample size, our results are
unlikely to represent chance ﬁndings for the following
reasons: First, the ULSAM cohort is the largest single-
center population-based cohort in the world with insulin
sensitivity measured by the euglycemic insulin clamp
technique. Compared with indirect measurements and
surrogate indices, this method directly measures whole-
body glucose disposal at a given level of insulinemia under
steady-state conditions and is therefore regarded as the
gold standard for measuring insulin resistance (38). Sec-
ond, ADIPOQ is the most established gene inﬂuencing
adiponectin levels, and the SNPs chosen as IVs were ro-
bustly associated with adiponectin levels. Genetic varia-
tion in ADIPOQ affects adiponectin production and is not
known to affect insulin sensitivity in other ways. There-
fore, by focusing on ADIPOQ, concerns over potential
pleiotropic effects of the instrument could largely be
eliminated. Third, the study was undertaken in a homoge-
neous, age-standardized sample of men aged 71 years from
Uppsala in Sweden, and therefore population stratiﬁcation
that could violate assumptions of Mendelian randomiza-
tion is unlikely.
Limitations of our study include the relatively small
sample size. However, this was partially compensated by
the accurate euglycemic insulin clamp measurement of
insulin resistance that increased statistical power. Further,
as our study was based on elderly men of Northern
European descent, the generalizability to women, other
age-groups, and other ethnicities is unknown. It is of note
that a recent large cohort study of elderly adults demon-
strated a nonlinear relationship between adiponectin and
risk of incident diabetes (39). In our study, the association
between adiponectin and insulin sensitivity measured by
the euglycemic clamp was deemed to be linear, except at
very high levels of adiponectin, where there may be
a slight deviation from linearity. It is plausible that the
previously observed nonlinear relationship between adi-
ponectin levels and new-onset diabetes characterized by
leveled-off associations at high levels of adiponectin is
a result of insufﬁcient enhancement of b-cell function,
despite increased insulin sensitivity. Potential deviation
from linearity may affect the accuracy of the effect esti-
mates in a Mendelian randomization study, but a linear
model is still sound in this case to test the null hypothesis
of no effect of exposure on outcome (11).
In summary, our results indicate that genetically de-
termined adiponectin levels inﬂuence insulin sensitivity to
the same degree as the observed epidemiological associ-
ations. This suggests that the association between adipo-
nectin levels and insulin sensitivity is likely to represent
a causal relationship. Further elucidation of this relation-
ship could provide insights into the physiological roles of
adiponectin in the etiology of insulin resistance and shed
light on the therapeutic potential of adiponectin for the
metabolic syndrome and type 2 diabetes.
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Supplementary Table 1. Observed associations between instrumental variables and insulin sensitivity. 
 
Instrumental variable Beta (95% CI) P – value 
Age adjusted 
rs17300539 0.096 (0.014, 0.179) 0.022 
rs3774261 0.074 (0.028, 0.121) 1.9 × 10-3 
rs6444175 0.091 (0.041, 0.141) 3.7 × 10-4 
Allele score 0.242 (0.101, 0.384) 8.0 × 10-4 
Age, BMI and waistR adjusted 
rs17300539 0.048 (-0.019, 0.115) 0.157 
rs3774261 0.036 (-0.002, 0.073) 0.061 
rs6444175 0.053 (0.012, 0.093) 0.011 
Allele score 0.119 (0.005, 0.234) 0.042 
BMI, body mass index; waistR, waist residual, i.e. BMI-adjusted waist circumference.  
Supplementary Table 2. Secondary analyses including individuals with type 2 diabetes (N = 1,057), 
age-adjusted results. 
  Instrumental variable 
estimate 
Observational estimate  
Instrumental 
variable 








P-value Endogeneity†  P-
value 
























*The allele score was created using genotypes for rs17300539 and rs3774261 (R2 = 0.137). 
†Endogeneity was assessed by Durbin-Wu-Hausman test and reflects whether the difference between 
the IV estimate and the observational estimate was statistically significant. 
 
Supplementary Table 3.  Association between instrumental variables and body mass index (BMI).  
 
 Age adjusted Age and adiponectin adjusted 
 Beta (95% CI) P-value Beta (95% CI) P-value 
rs17300539 -0.47 (-1.00, 0.06) 0.084 0.06 (-0.46, 0.58) 0.815 
rs3774261 -0.42 (-0.72, -0.12) 0.006 -0.15 (-0.44, 0.15) 0.330 
rs6444175 -0.44 (-0.77, -0.12) 0.008 -0.15 (-0.47, 0.16) 0.337 
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Supplementary Table 4.  Comparison of instrumental variable estimated and observed association between adiponectin and insulin 
sensitivity, stratified by overweight status defined by median BMI. 
 





Beta (95% CI) P-value Beta (95% CI) P-value Endogeneity† 
P-value 
Normal weight (BMI < 25.7 kg/m2), N = 471 
rs17300539 25.4 0.459 (0.061, 0.858) 0.024 
0.228 (0.140, 0.316) 5.9 × 10-7 
0.230 
rs3774261 16.0 0.199 (-0.285, 0.684) 0.420 0.902 
rs6444175 13.2 0.476 (-0.073, 1.025) 0.090 0.354 
Allele score* 27.5 0.309 (-0.066, 0.684) 0.107 0.662 
Overweight (BMI >= 25.7 kg/m2), N = 471 
rs17300539 16.2 0.244 (-0.418, 0.907) 0.470 




rs3774261 14.9 0.746 (0.060, 1.432) 0.033 0.517 
rs6444175 15.4 0.719 (0.048, 1.390) 0.036 0.562 
Allele score 22.2 0.564 (0.006, 1.121) 0.048 0.892 
*The allele score was created using genotypes for rs17300539 and rs3774261 (R2 = 0.137). †Endogeneity was assessed by Durbin-Wu-
Hausman test and reflects whether the difference between the IV estimate and the observational estimate was statistically significant.
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Supplementary Table 5. Effect size comparison between ULSAM cohort and other studies for the 
SNPs used as instrumental variables. 
 
SNP N Effect 
allele 





A 0.205 (0.144, 0.267) 1.1 × 10-10 Age adjusted Current 
study 
0.188 (0.128, 0.247) 8.1 × 10-10 
 
Age, BMI and 
waistR adjusted 
1,919 A 0.155 (0.077, 0.233) 9.3 × 10-5 Age, sex and BMI 
adjusted 
[1] 
rs3774261 941 A 0.109 (0.074, 0.144) 1.3 × 10-9 Age adjusted Current 
study 
0.092 (0.059, 0.126) 8.0 × 10-8 
 
Age, BMI and 
waistR adjusted 
11,519 A 0.04 (no CI reported) 4.7× 10-8 Not mentioned [2] 
rs6444175 942 A 0.113 (0.076, 0.151) 5.3 × 10-9 Age adjusted Current 
study 
0.098 (0.061, 0.134) 1.5 × 10-7 
 
Age, BMI and 
waistR adjusted 
14,733 G -0.08 (-0.1, -0.07) 1.2 × 10-21 Age, sex and BMI 
adjusted 
[3] 
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Supplementary Figure 1. Instrumental variable estimated percent change in insulin sensitivity with 
varying percent change in adiponectin levels.The instrumental variable point estimates were used to 
calculate the change in insulin sensitivity when adiponectin changes by a certain percentage. The black 
lines are based on age adjusted results: rs17300539, black long dash; rs3774261, black dash; rs6444175, 
black solid; allele score, black short dash with dot. Grey lines are the results further adjusted for 
adiposity.  
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Novelty statement 
 
- The relation between selenium intake and risk of type 2 diabetes is controversial.  
- Our results from a longitudinal cohort study indicate no substantial association of 
selenium status with incidence of diabetes and various physiological measures of glucose 
and insulin metabolism, including an euglycemic clamp test.  
- Our study adds to the currently lacking evidence from prospective cohort studies and 





Aims: The relation between selenium status and risk of type 2 diabetes is controversial. We 
aimed to evaluate associations of serum selenium, a marker of dietary selenium, with measures 
of glucose metabolism and risk of diabetes. 
Methods: We used data from a population-based, longitudinal cohort of 1,925 Swedish men 
who were 50 years old and did not have diabetes at baseline in the 1970s. At baseline, an 
intravenous glucose tolerance test (IVGTT) was performed and at a follow-up examination after 
20 years, an oral glucose tolerance test (OGTT) and a hyperinsulinemic euglycemic clamp for 
the assessment of insulin sensitivity were conducted.  
Results: At baseline, the mean (SD) selenium concentration was 75.6 (14.3) ug/L. During 20 
years of follow-up, 88 incident cases of diabetes occurred in 1,024 participants with follow-up 
data. Baseline serum selenium levels were not associated with risk of diabetes (odds ratio = 1.06; 
95% CI: 0.83 to 1.38). Higher selenium levels were associated with lower early insulin response 
(standardized beta [β] = -0.08; 95% confidence interval [CI]: -0.14 to -0.03) at baseline after 
adjusting for potential confounders, but not with any other measures of beta cell function or 
insulin sensitivity at baseline or follow-up. The association with early insulin response was non-
significant after taking multiple testing into account. 
Conclusions: Our results do not support a role of dietary selenium in the development of 




Selenium (Se) is an essential trace mineral and a key component of several selenoproteins in the 
antioxidant defense system. For example, glutathione peroxidase (GPx), a class of enzymes that 
protect against oxidative stress, contains selenium as selenocysteine in the catalytic site [1]. 
Selenium has been suggested to have insulin-mimetic and anti-diabetic properties [2, 3], but 
results from existing studies on its association with risk of type 2 diabetes mellitus (T2DM) are 
inconclusive [3]. In cross-sectional studies, higher selenium status has been associated with both 
a lower and a higher prevalence of T2DM [4], while most randomized clinical trials (RCTs) did 
not support a benefit of selenium supplementation for risk of T2DM and glucose control [4]. 
Selenium supplementation in clinical trials is generally given in high doses and effects may thus 
not reflect effects of usual variation in dietary selenium intakes. To date, little evidence is 
available from prospective cohort studies of selenium status in relation to glucose tolerance and 
risk of diabetes. Plasma selenium levels were not clearly associated with the development of 
dysglycemia in French adults [5], but toenail selenium levels were inversely associated with risk 
of T2DM in U.S. health professionals [6].  
The selenium content of foods varies greatly depending on soil conditions and as a result, 
selenium intakes calculated using food composition databases are inaccurate [7]. In contrast, 
serum selenium is generally considered to be a reliable biomarker for selenium status [8]. The 
correlation between serum selenium and selenium intake has been shown to be reasonably high 
[9]. Little evidence exists for the association of circulating selenium and incidence of T2DM, and 
there is a lack of studies studying selenium status in relation to detailed measures of insulin 
processing, secretion and sensitivity. 
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Hence, the objective of the present study was to investigate prospectively the relationship 
between baseline selenium concentration as a surrogate of selenium status and: 1) physiological 
measures of glucose and insulin metabolism; and 2) incidence of T2DM during almost 30 years 
of follow-up in an older Swedish population.  
Patients and Methods 
Study sample 
The Uppsala Longitudinal Study of Adult Men (ULSAM) was initiated between September 1970 
and September 1973 with an invitation of all 50-year-old men living in Uppsala County, Sweden. 
There are five follow-ups to date, at 60, 70, 77, 82 and 88 years of age. The present analysis uses 
data from the baseline at age 50 years and the first three follow-up investigations. 
Of the 2,322 participants (81.7 % of 2,841 invited) at the age 50 years examination, 393 
individuals were excluded for the following reasons: serum selenium data not available (n = 
274), presence of diabetes at baseline (n = 115) or missing glucose measurements (n = 8). 
Diabetes was ascertained by elevated fasting blood glucose (≥ 6.1 mmol/L, which equals plasma 
glucose ≥ 7.0 mmol/L) or use of anti-diabetic medicine. In total, 1,925 individuals without 
diabetes formed the baseline study sample of this analysis. After 20 years of follow-up, 1,681 
available participants (422 died and 219 moved out of Uppsala County) were invited to 
participate in the study at age 70 years, and 1,221 attended (72.6 % of eligible individuals). 
Among them, 1,026 had baseline serum selenium and 936 individuals without diabetes were 
included for the analyses on glucose metabolic measures. We chose the age 70 years follow-up 
as the main study point because it included a comprehensive examination of glucose and insulin 
metabolism, such as an euglycemic clamp to evaluate insulin sensitivity. We also used data from 
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the age 60 years (n = 1,860, 87.3 % of eligible individuals) and the age 77 years examination (n 
= 839, 60 % of eligible individuals) for sensitivity analyses. Detailed information on the 
ULSAM cohort can be found on the Internet (http://www.pubcare.uu.se/ULSAM/). 
The study was approved by the Ethics Committee of Uppsala University, and all participants 
provided written informed consent.  
Measurements at baseline (50 years old) 
Selenium was determined in serum using the graphite-furnace atomic absorption spectrometric 
method [10]. Samples were diluted (1+9) with a solution containing nickel (to reduce the 
volatility of selenium) and nitric oxide (to keep samples free of precipitates), and measured by a 
standard additions method. 
An intravenous glucose tolerance test (IVGTT) was performed where blood glucose and serum 
insulin levels were measured between 0 and 60 min after the intravenous glucose load. 
Proinsulin concentrations were analyzed using the two-site immunometric assay technique [11]. 
Glucose tolerance was evaluated by the K-value calculated as K= (ln2×100)/T1/2 where T1/2 is the 
time in minutes required for the concentration to be reduced by half its value. Early serum 
insulin response was represented by the insulin peak and expressed as the mean value of the 
serum insulin concentrations determined at 4, 6 and 8 minutes. The insulin index was defined as 
the ratio between peak serum insulin response and fasting serum insulin concentration. Based on 
fasting glucose and insulin concentrations, the homeostasis model assessment index for insulin 
resistance (HOMA-IR) and  beta cell function (HOMA-B) were calculated [12].  
Information about cigarette smoking status was based on data from a standardized interview. 
Current smokers were further classified according to the quantity of cigarettes smoked (<10 or 
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>=10 cigarettes per day) based on information from the questionnaire. Leisure time physical 
activity was recorded in the questionnaire in four levels: sedentary, moderate, regular and 
athletic. Education level was also assessed on the questionnaire and was re-grouped into three 
categories: 7 years or 8 years was defined as low education; 12 years as medium education; and 
≥3 years of college or completion of university graduate exam as high education.     
Measurements at 20-year follow-up (70 years old) 
Participants at the age 70 years examination underwent a 75-gram oral glucose tolerance test 
(OGTT) with measurement of plasma glucose and immunoreactive insulin. The intra-individual 
coefficient of variation (CV) for fasting plasma glucose was 3.2 %. The insulinogenic index, 
calculated as [(insulin at 30 min) – (insulin at 0 min)]/ [(glucose at 30 min) – (glucose at 0 min)], 
was used as a measure of glucose-stimulated insulin secretion indicative of  beta cell function 
[13]. Proinsulin levels were measured by the two-site immunometric assay technique [11]. The 
hyperinsulinemic euglycemic clamp was performed as the gold-standard to estimate insulin 
sensitivity according to a previously documented procedure [14] with slightly higher insulin 
infusion rate (56 instead of 40 mU min-1 (m2)-1) to better suppress hepatic glucose production. 
The M/I ratio was calculated where glucose disposal (M) per minute was divided by the steady-
state mean insulin concentration (I) and accounted for body weight. Details about these 
measurements have also been described previously [15].  
Diabetes ascertainment 
T2DM at follow-up was defined by elevated fasting glucose levels and/or use of anti-diabetic 
medicine. Elevated glucose levels were assessed as fasting blood glucose ≥ 6.1 mmol/L at the 
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age 60 years examination (equals ≥7.0 mmol/L of plasma glucose) and fasting plasma glucose 
≥7.0 mmol/L at age 77 years.  
Statistical analysis 
Selenium levels were analyzed both as a categorical variable in tertiles and as a continuous 
variable (presenting betas per 1-SD increment). Continuous outcome variables were natural log-
transformed to improve normality of the distribution and also presented as changes in SD-units. 
Observations beyond ±4 SD from the mean on the log-transformed scale were defined as outliers 
and truncated (n =15 for OGTT plasma glucose at age 70 years and n ≤ 3 per measurement for 
the rest). Differences in baseline sample characteristics by selenium categories were tested by 
Kruskal-Wallis equality-of-populations rank test for continuous variable and Person’s chi-square 
test for categorical variables. The relationships between selenium and glucose metabolism 
measures at baseline and after 20 years of follow-up were examined by linear regression 
analysis. Logistic regression analysis was used to test the association between baseline selenium 
levels and risk of T2DM at follow-up. For these regression analyses, two sets of models were 
used: model 1 adjusted for age at baseline; model 2 further adjusted for potential confounders 
including body mass index (BMI), cigarette smoking, leisure time physical activity, and 
education level. P-values for trend were calculated by assigning the median value to each 
selenium tertile category and modeling it as a continuous variable. In a sensitivity analysis, we 
evaluated the association of baseline selenium levels and incident diabetes risk using the follow-
up data at age 60 years and age 77 years, and compared the estimates with those from the age 70 
years follow-up. Analyses were performed using Stata/IC (version 12.1, StataCorp, College 
Station, TX). Two-tailed P-values < 0.05 were regarded significant. Multiple testing was 




Baseline characteristics for the 1,925 participants at the age 50 years examination are presented 
in Table 1 by tertiles of serum selenium levels. The mean (SD) concentration of serum selenium 
in our study population was 75.6 (14.3) μg/L and the range was 24 − 132.8 μg/L. Individuals 
with higher selenium levels had a higher BMI, more leisure time physical activity, were better 
educated and less likely to be heavy cigarette smokers. There were no differences in levels of 
glucose or insulin metabolism measures across selenium tertiles in univariable analyses (Table 
1).    
At baseline, serum selenium was not significantly associated with fasting glucose levels or 
glucose tolerance represented by the K-value from the IVGTT (Table 2). Higher serum selenium 
levels were associated with a lower insulin peak during the IVGTT indicating lower early insulin 
response. This association persisted after adjustment for potential confounders (selenium as 
continuous variable, standardized β = -0.08; 95% CI: -0.14 to -0.03, P for trend = 0.026), but not 
after taking multiple testing into account and may thus represent a chance finding. Selenium was 
not substantially associated with HOMA measures of insulin resistance or insulin secretion, and 
it was not cross-sectionally associated with baseline T2DM either. 
At follow-up after 20 years (at age 70 years), we observed no clear associations with any 
glucometabolic traits. Among 1,024 individuals with baseline selenium levels and follow-up 
data, 88 developed diabetes during the 20-year follow-up period. Selenium levels were not 
substantially associated with a higher risk of T2DM during follow-up in either age-adjusted or 
multivariable models (Table 3). Analysis with selenium as a continuous variable also revealed no 
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association of baseline selenium levels with incident risk of T2DM (odds ratio = 1.06 [95% CI: 
0.83 to 1.38], model 2).  
In sensitivity analyses, 53 individuals free of diabetes at baseline developed diabetes by the age 
60 years follow-up. A total of 91 incident diabetes cases were identified in the age 77 years 
examination after 27 years of follow-up since baseline at age 50 years. The odds ratio estimates 
based on continuous selenium levels (Table 3) were similar to those observed at age 70 years 
with no evidence for an association of selenium levels with incident diabetes.  
Discussion 
We examined relations between serum selenium levels and measures of glucose and insulin 
metabolism, as well as risk of T2DM after 20 years of follow-up in 1,925 participants from the 
ULSAM cohort. There was no clear association of selenium status on various measures of 
insulin sensitivity or beta cell function. The only association with a nominally significant trend 
between selenium levels and the insulin peak in IVGTT at baseline was likely to be a chance 
finding due to the multiple tests that we performed. Selenium levels were also not associated 
with risk of developing T2DM.  
Prior data on selenium on glucose metabolism and risk of T2DM are inconsistent. Most studies  
of a direct association between selenium status and T2DM risk were based on cross-sectional 
studies [4]. In contrast, we did not observe a cross-sectional association between baseline 
selenium status and T2DM prevalence at age 50 years. It is to be noted that the nature of the 
association cannot be determined in such studies; it is unclear whether high selenium interferes 
with insulin signaling and increases the risk of T2DM, or whether disturbed glucose metabolism 
leads to changes in selenium levels. In a French elderly cohort of similar design and baseline 
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selenium levels to our study, a non-significant association between plasma selenium and risk of 
developing dysglycemia was reported in men (Hazard ratio [HR] = 0.50, 95% CI: 0.24 to 1.04) 
but not in women (HR = 1.13, 95% CI: 0.55-2.32) when the high tertile was compared with the 
low tertile [5]. A recent prospective analysis in cohorts of U.S. health professionals  suggested a 
lower risk of T2DM across increasing quintiles of toenail selenium concentrations (P for trend = 
0.01) [6].  
As recently reviewed by Rayman and Stranges [4], several RCTs have examined the relationship 
between selenium and risk of T2DM or glucose homeostasis. For example, in the Selenium and 
Vitamin E Cancer Prevention Trial (SELECT), 8,752 men in the selenium group took 200 μg of 
selenomethionine per day. By the 7-year planned interim analysis, no significant difference in 
the risk of T2DM as a secondary end point was detected between the selenium group and the 
placebo group [16] and the same conclusion was reached with an extended follow-up of more 
than two years [17]. In a post-hoc analysis of the Nutritional Prevention of Cancer (NPC) trial, 
selenium supplementation (200 μg/day as selenium yeast) was associated with higher incidence 
of T2DM (HR = 1.55, 95% CI: 1.03-2.33). In a stratified analysis by baseline selenium tertiles, 
this HR increased with increasing selenium category and was highly significant in the top tertile 
[18]. Although concern has been raised for an increased risk of insulin resistance and T2DM 
with selenium oversupply [19], possibly due to an interference of selenium compounds on 
insulin signaling cascade [20], a recent systematic review on existing RCTs did not show an 
overall effect of selenium supplementation on major cardiovascular disease or T2DM [21]. 
Comparison and interpretation of the findings for the effects of selenium in different studies is 
not straightforward. Firstly, baseline selenium levels are greatly different across populations, due 
to factors such as soil selenium content, dietary patterns, selenium supplements used and 
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genetics [7, 22]. For example, dietary selenium intakes are considerably lower in Europe than in 
USA and Canada [22]. In Sweden, the estimated intake is 31 to 38 μg per day [7] while in USA 
the daily intake ranges from 60 to 220 μg [22]. Serum or plasma selenium concentrations also 
vary substantially by country [22]. In our cohort, serum selenium averaged 76 μg /L. In contrast, 
participants in the lowest tertile of the NPC trial had an average plasma selenium level of 106 
μg/L at baseline [18], and in the SELECT trial the median baseline serum selenium level was 
135 μg/L [16]. GPx activities have been estimated to be at a maximum at a plasma selenium 
concentration around 90 μg/L [23], by which standard most participants in the NPC and 
SELECT trials already achieved maximal selenoenzyme functions at baseline, whereas most of 
the ULSAM participants did not.  
Secondly, selenium supplementation in the clinical trials used high doses and the resulting 
circulating selenium levels were substantially higher than would result from dietary intake only. 
This is even more pronounced if the baseline levels were already different. For example, in 
SELECT, serum selenium increased gradually to 251.6 μg/L at the last visit, more than three 
times the average level in ULSAM. Selenium is a trace element with a relatively narrow range 
between deficiency and toxicity [24, 25]. Protective effects of selenium on diabetes and glucose 
metabolism, if these exist, may only be found at optimal levels that enhance selenoprotein 
activities. A loss of benefit or even adverse effects could occur outside the optimal range. A 
previous study reported a higher risk of cardiovascular disease mortality with both deficient and 
high levels of serum selenium, as compared with normal levels [26]. In mice, both maximal and 
deficient expression of selenoproteins dysregulated glucose homeostasis and promoted T2DM-
like phenotypes [27]. A similar U-shape association may also help explain the inconsistent 
findings for selenium and risk of T2DM in human studies [28].  
13 
 
The strengths of our study include the homogeneous population, long follow-up time, and 
detailed measurement of glucose metabolism. In particular, insulin sensitivity was assessed by 
the euglycemic clamp which directly measures whole body glucose disposal at a given level of 
insulinemia under steady-state conditions and is regarded to be the gold standard method for 
measuring insulin sensitivity in vivo. However, several limitations are also worth mentioning. 
Most importantly, dietary intake, such as total caloric intake, saturated fats and alcohol 
consumption, were not assessed at baseline, so we cannot rule out the possibility of confounding 
by unmeasured dietary factors or other unmeasured or imperfectly measured confounders. 
Secondly, the modest number of incident diabetic cases could have restricted the statistical 
power of our study for this outcome. Thirdly, our population only consisted of older Swedish 
men. Therefore, our results may not be generalizable to populations with higher selenium levels 
or to younger individuals, women and other ethnicities. Lastly, serum selenium levels for most of 
the participants in our study are not high enough for selenoprotein P activities, which is 
optimized at higher selenium concentration (110 − 125 μg/L) than GPx [29]. As selenoprotein P 
potentially adversely influences insulin sensitivity [30], this may explain the lack of association 
in our study.  
In conclusion, overall findings from the present study do not support a substantial association of 
selenium status with insulin sensitivity, insulin secretion, or risk of T2DM. Taken together with 
prior studies including RCTs, the body of evidence argues against a role for selenium 
supplementation as a broad approach for the prevention of diabetes. However, the question 
whether selenium supplementation can be effective for the prevention of diabetes in specific 
subgroups of the population and if so, at what levels of selenium intake is still not completely 
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Table 1. Baseline characteristics of the study population at age 50 yearsa according to serum selenium concentrations. 
 All Low Se tertile Middle Se tertile High Se tertile P-value 
N 1,925 670 620 635  
Selenium, μg/L 75.6 (14.3) 61.4 (6.8) 75.1 (3.1) 91.1 (10.2) 
Age, years 49.7 (49.1-50.2) 49.6 (49.0-50.2) 49.7 (49.2-50.2) 49.7 (49.1-50.1) 0.044 
BMI, kg/m2 25.0 (3.2) 24.6 (3.3) 25.0 (3.1) 25.3 (3.1) <0.001 
Cigarette smoking      
Never smoker 826 (42.9) 275 (41.0) 273 (44.0) 278 (43.8) 
<0.001 
Ex-smoker 415 (21.6) 113 (16.9) 141 (22.7) 161 (25.4) 
Current smoker (<10/day) 207 (10.8) 77 (11.5) 65 (10.5) 65 (10.2) 
Current smoker (>=10/day) 477 (24.8) 205 (30.6) 141 (22.8) 131 (20.6) 
Leisure time physical activity      
Sedentary 271 (14.8) 115 (18.0) 76 (13.1) 80 (13.2) 
0.039 
Moderate 660 (36.1) 228 (35.6) 220 (37.8) 212 (34.9) 
Regular 804 (43.9) 273 (42.7) 256 (44.0) 275 (45.2) 
Athletic 95 (5.2) 24 (3.8) 30 (5.2) 41 (6.7) 
Educationb      
Low 976 (67.6) 399 (79.8) 311 (67.6) 266 (55.0) 
<0.001 Medium 234 (16.2) 66 (13.2) 79 (17.2) 89 (18.4) 
High 234 (16.2) 35 (7.0) 70 (15.2) 129 (26.7) 
Fasting blood glucose, mmol/l 4.8 (4.5-5.2) 4.8 (4.5-5.1) 4.8 (4.6-5.2) 4.9 (4.6-5.3) 0.244 
Fasting serum insulin, µU/ml 11.0 (8.2-15.3) 10.6 (7.8-15.0) 11.2 (8.3-15.5) 11.2 (8.1-15.3) 0.782 
Proinsulin, pmol/l 2.2 (1.4-3.7) 2.2 (1.4-3.6) 2.3 (1.4-3.5) 2.3 (1.4-3.7) 0.930 
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Proinsulin-insulin ratio 0.06 (0.04-0.09) 0.06 (0.04-0.10) 0.05 (0.03-0.09) 0.06 (0.04-0.09) 0.180 
IVGTT K-value 1.6 (1.2-2.0) 1.6 (1.2-2.0) 1.6 (1.2-2.1) 1.6 (1.3-2.1) 0.578 
IVGTT insulin peak, µU/ml 54.7 (38.0-80.2) 55.7 (40.7-82.3) 55.3 (37.7-78.0) 52.2 (36.7-80.2) 0.308 
IVGTT insulin index 4.9 (3.4-7.0) 5.1 (3.6-7.1) 4.8 (3.3-6.9) 4.8 (3.3-7.0) 0.288 
HOMA-IR 2.7 (1.9-3.8) 2.6 (1.9-3.8) 2.8 (2.0-3.9) 2.7 (1.9-3.8) 0.486 
HOMA-B 111.2 (81.1-157.4) 112.2 (81.9-163.2) 109.1 (79.8-158.0) 111.4 (82.7-151.3) 0.791 
BMI, Body mass index; IVGTT, Intravenous glucose tolerance test; HOMA-IR, Homeostatic model assessment-insulin resistance; HOMA-B, 
Homeostatic model assessment-Beta cell function. Mean (SD) is presented for age and BMI. Median (IQR) is used for all the other continuous 








N Model Low Se 
tertile 




At baseline (age 50 years) 
Fasting blood glucose 1,925 1 ref 0.07 (-0.04, 0.18) 0.10 (-0.01, 0.21) 0.02 (-0.03, 0.06) 0.076 
 2 ref 0.06 (-0.05, 0.17) 0.10 (-0.01, 0.21) 0.02 (-0.03, 0.06) 0.066 
Proinsulin-insulin ratio 1,226 1 ref -0.15 (-0.28, -0.01) -0.12 (-0.26, 0.01) -0.04 (-0.10, 0.01) 0.075 
 2 ref -0.14 (-0.28, -0.00) -0.12 (-0.26, 0.02) -0.04 (-0.09, 0.02) 0.102 
IVGTT K-value 1,431 1 ref -0.01 (-0.13, 0.12) 0.06 (-0.06, 0.19) 0.03 (-0.03, 0.08) 0.314 
 2 ref -0.01 (-0.14, 0.11) 0.05 (-0.08, 0.18) 0.02 (-0.04, 0.07) 0.437 
IVGTT insulin peak 1,352 1 ref -0.05 (-0.18, 0.08) -0.10 (-0.23, 0.03) -0.06 (-0.12, -0.01) 0.118 
 2 ref -0.08 (-0.21, 0.05) -0.15 (-0.28, -0.02) -0.08 (-0.14, -0.03) 0.026 
IVGTT insulin index 1,351 1 ref -0.05 (-0.18, 0.08) -0.08 (-0.21, 0.05) -0.05 (-0.10, 0.01) 0.219 
 2 ref -0.03 (-0.16, 0.10) -0.06 (-0.20, 0.07) -0.04 (-0.10, 0.02) 0.364 
HOMA-IR 1,475 1 ref 0.03 (-0.10, 0.15) 0.01 (-0.12, 0.13) -0.02 (-0.07, 0.04) 0.902 
 2 ref -0.01 (-0.13, 0.10) -0.05 (-0.17, 0.07) -0.04 (-0.09, 0.01) 0.409 
HOMA-B 1,474 1 ref -0.05 (-0.17, 0.08) -0.05 (-0.17, 0.08) -0.01 (-0.06, 0.04) 0.469 
 2 ref -0.09 (-0.21, 0.03) -0.12 (-0.24, 0.00) -0.04 (-0.09, 0.01) 0.058 
At 20-year follow-up (age 70 years) 
Fasting plasma glucose 936 1 ref -0.01 (-0.17, 0.14) 0.08 (-0.08, 0.24) 0.04 (-0.03, 0.10) 0.315 
 2 ref -0.02 (-0.18, 0.14) 0.06 (-0.10, 0.22) 0.03 (-0.04, 0.10) 0.447 
Proinsulin-insulin ratio 899 1 ref 0.12 (-0.04, 0.28) -0.05 (-0.22, 0.11) -0.03 (-0.10, 0.04) 0.460 
 2 ref 0.12 (-0.04, 0.28) -0.05 (-0.22, 0.12) -0.02 (-0.10, 0.05) 0.519 
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Clamp M/I ratio 892 1 ref 0.12 (-0.04, 0.28) 0.03 (-0.13, 0.19) 0.02 (-0.05, 0.09) 0.757 
 2 ref 0.13 (-0.02, 0.29) 0.03 (-0.12, 0.19) 0.03 (-0.04, 0.09) 0.746 
Insulinogenic index 886 1 ref -0.07 (-0.23, 0.10) 0.00 (-0.16, 0.17) -0.00 (-0.07, 0.08) 0.920 
 2 ref -0.05 (-0.22, 0.11) 0.04 (-0.13, 0.20) 0.01 (-0.07, 0.08) 0.636 
HOMA-IR 927 1 ref -0.14 (-0.29, 0.02) -0.04 (-0.19, 0.11) -0.02 (-0.09, 0.05) 0.664 
  2 ref -0.15 (-0.30, -0.00) -0.05 (-0.20, 0.10) -0.02 (-0.09, 0.05) 0.572 
HOMA-B 927 1 ref -0.12 (-0.28, 0.03) -0.11 (-0.26, 0.05) -0.05 (-0.12, 0.02) 0.183 
  2 ref -0.13 (-0.28, 0.02) -0.10 (-0.26, 0.05) -0.04 (-0.11, 0.03) 0.209 
IVGTT, Intravenous glucose tolerance test; HOMA-IR, Homeostatic model assessment-insulin resistance; HOMA-B, Homeostatic model 
assessment-Beta cell function. Linear regression was performed and results are beta (95% CI). For categorical selenium, the coefficients represent 
SD difference on the natural log scale in the outcome variable as compared with the low tertile (reference). For continuous selenium variables, the 
regression coefficients represent SD change in the outcome variable per SD change in selenium levels on the natural log scale. Model 1: adjusted 




Table 3. Association of baseline serum selenium (at age 50 years) with diabetes risk during follow-up at age 60 years, age 70 years and age 77 
years.  
Study  N Low Se 
tertile 
Middle Se tertile High Se tertile Continuous Se 






Diabetes (yes/no) 53/1,486 15/501 15/489 23/496   
Model 1 1,539 1 0.99 (0.48, 2.05) 1.51 (0.78, 2.92) 1.15 (0.87, 1.52) 0.201 




Diabetes (yes/no) 88/936 24/302 33/314 31/320   
Model 1 1,024 1 1.31 (0.76, 2.27) 1.21 (0.69, 2.10) 1.04 (0.82, 1.31) 0.544 
Model 2 1,024 1 1.31 (0.73, 2.36) 1.25 (0.68, 2.27) 1.06 (0.83, 1.38) 0.497 
Age 77 
years exam 
Diabetes (yes/no) 91/565 27/179 34/182 30/204   
Model 1 656 1 1.23 (0.71, 2.14) 0.97 (0.55, 1.70) 0.97 (0.76, 1.25) 0.876 
Model 2 656 1 1.16 (0.65, 2.08) 0.97 (0.54, 1.75) 0.96 (0.74, 1.25) 0.880 
Logistic regression was used and results as OR (95% CI). The low Se tertile is the reference category. Model 1: adjusted for age; Model 2: 
adjusted for age at baseline, BMI, cigarette smoking, leisure time physical activity, and education at the baseline examination. 
 
